Effects of Serine/Threonine Protein Phosphatases on Ion ... - CiteSeerX

PHYSIOLOGICAL REVIEWS Vol. 80, No. 1, January 2000 Printed in U.S.A.

Effects of Serine/Threonine Protein Phosphatases on Ion Channels in Excitable Membranes STEFAN HERZIG AND JOACHIM NEUMANN Institut fu¨r Pharmakologie, Universita¨t Ko¨ln, Ko¨ln; and Institut fu¨r Pharmakologie und Toxikologie, Universita¨t Mu¨nster, Mu¨nster, Germany

I. Introduction II. Structure and Nomenclature of Serine/Threonine Protein Phosphatases A. Biochemical classification of protein phosphatases B. Primary structure of the catalytic subunits of protein phosphatase and subcellular localization III. Modulators of Protein Phosphatase Activity A. Protein inhibitors B. Nonprotein inhibitors C. Activators IV. Methodological Considerations V. Effects of Phosphatases on Ion Channel Electrophysiology A. Voltage-dependent Ca21 channels B. Voltage-dependent Na1 channels C. K1 channels D. Ligand-gated cation channels E. Anion channels VI. Summary and Perspectives

173 174 174 174 180 180 181 185 185 188 188 190 190 194 195 196

Herzig, Stefan, and Joachim Neumann. Effects of Serine/Threonine Protein Phosphatases on Ion Channels in Excitable Membranes. Physiol. Rev. 80: 173–210, 2000.–This review deals with the influence of serine/threoninespecific protein phosphatases on the function of ion channels in the plasma membrane of excitable tissues. Particular focus is given to developments of the past decade. Most of the electrophysiological experiments have been performed with protein phosphatase inhibitors. Therefore, a synopsis is required incorporating issues from biochemistry, pharmacology, and electrophysiology. First, we summarize the structural and biochemical properties of protein phosphatase (types 1, 2A, 2B, 2C, and 3–7) catalytic subunits and their regulatory subunits. Then the available pharmacological tools (protein inhibitors, nonprotein inhibitors, and activators) are introduced. The use of these inhibitors is discussed based on their biochemical selectivity and a number of methodological caveats. The next section reviews the effects of these tools on various classes of ion channels (i.e., voltage-gated Ca21 and Na1 channels, various K1 channels, ligand-gated channels, and anion channels). We delineate in which cases a direct interaction between a protein phosphatase and a given channel has been proven and where a more complex regulation is likely involved. Finally, we present ideas for future research and possible pathophysiological implications.

Tu ne quaesieris, scire nefas, quem mihi, quem tibi finem di dederint, Leuconoe, nec Babylonios temptaris numeros. Ut melius, quidquid erit, pati! Seu pluris hiemes seu tribuit Iuppiter ultimam, quae nunc oppositis debilitat pumicibus mare Tyrrhenum. Sapias, vina liques, et spatio brevi spem longam reseces. Dum loquimur, fugerit invida aetas: carpe diem quam minimum credula postero.

Q. Horatius Flaccus: Carmen 1.11.

0031-9333/00 $15.00 Copyright © 2000 the American Physiological Society

I. INTRODUCTION Nearly all aspects of cell function involve phosphorylation of the amino acids serine/threonine. It has been estimated that one-third of cellular proteins are reversibly phosphorylated (95). Phosphorylation can regulate proteins that induce very short-term or very long-term effects like ion channels and transcription factors. Specifically, cell division, cell differentiation, neuronal activity, muscle

173

174

STEFAN HERZIG AND JOACHIM NEUMANN

contraction, and metabolic functions are regulated by phosphorylation. Here, we are mostly concerned with phosphatases in mammalian cells that possess excitable membranes. At present, it seems that many important dephosphorylation reactions in these cells are catalyzed by a limited number of catalytic subunit isoforms. However, the important concept emerges that the substrate specifity and function of phosphatases are mainly regulated by ancillary proteins. Therefore, we address their putative function where required. The past decade witnessed rapid progress on the physiological role of phosphatases. The advent and widespread experimental use of new inhibitors as pharmacological tools hastened this process. Ion channels are ideal candidates for studying the dynamics of phosphorylation and dephosphorylation of proteins, because their molecular properties can be measured on-line in single-channel experiments. Based on these considerations, we try to address the structural and biochemical properties of phosphatases and their regulatory subunits first. The tools available for physiological experiments are then described, and a paragraph is devoted to methodological problems regarding the use of such compounds. The present electrophysiological knowledge about regulation of ion channels is also summarized. We are aware of the vast amount of data in this field but have chosen to restrict our presentation to those types or families of ion channels studied in more detail. Emphasis is placed on experiments where the molecular target of the phosphatase is probably the channel itself, or where a more complex but interesting signaling cascade is involved. It should be stated here that electrophysiological experiments will usually fail to prove the exact molecular nature of the dephosphorylated protein or even the exact amino acid. Up to now, most studies have employed native cells. Space limitations necessitate us to focus the present review along several dimensions. Preference is given to cite more recent work, mainly covering the 1990s (until 4/99). For in depth discussion of earlier literature, excellent reviews are available (375). The role of phosphatases in cell division is covered by another review in this journal (319). This review is concerned with serine/threoninespecific phosphatases. However, additional phosphatases (mitogen-activated protein kinase phosphatases) exist that dephosphorylate both threonine and tyrosine residues within the same substrate protein (432). Tyrosine phosphatases, which may also be relevant for ion channel regulation, are also not covered here. Even within the remaining area of ion channel regulation by serine/threonine phosphatases, we have to skip a considerable number of valuable papers. We apologize for any omission that will have to be considered a regrettable flaw.

Volume 80

II. STRUCTURE AND NOMENCLATURE OF SERINE/THREONINE PROTEIN PHOSPHATASES A. Biochemical Classification of Protein Phosphatases Philipp Cohen (77, 79) suggested to divide phosphatases solely on an enzymatic basis into protein phosphatase (PP) 1 and PP2. This classification holds true for mammalian phosphatases that are the subject matter here. In contrast, bacterial phosphatases do not neatly follow this scheme (81). Mammalian type 2 PP were subdivided into PP2A, PP2B, and PP2C (77). Type 1 PP are characterized by their inhibition by protein inhibitors 1 and 2. Type 1 PP dephosphorylates preferentially the b-subunit of phosphorylase kinase. Type 2 PP are not inhibited by inhibitors 1 and 2 (of PP1) and dephosphorylate mainly the a-subunit of phosphorylase kinase. PP2B is characterized by its requirement for Ca21 and calmodulin, whereas PP2C requires Mg21 for activity (375). Both PP1 and PP2A do not require divalent cations for their enzymatic activity. More recently, new serine/threonine phosphatases have been cloned and sequenced (78). New mammalian phosphatases are PP4 (or PPX), PP5, PP6 (or Sit4), and PP7 (see sects. IIB, 5–9). In contrast to the other PP, PP7, when expressed in vitro, is inactive against the widely used substrate phosphorylase a (it is unknown whether this is also true in vivo); however, phosphorylated histone can be used as substrate. PP7 is dependent on Mg21 but not calmodulin and is activated by Ca21 (208). B. Primary Structure of the Catalytic Subunits of Protein Phosphatase and Subcellular Localization The catalytic subunits of phosphatases that dephosphorylate serine and threonine are encoded by the PPP and PPM gene families (78). These families are defined by distinct amino acid sequences and crystal structures. The PPP family includes the prototypical types 1, 2A, and 2B phosphatases. It also comprises novel phosphatases like PP4, PP5, and PP6 (78). The PPM family includes Mg21dependent phosphatases like PP2C. Hence, PP2C stands quite apart (375). This view is also supported by the fact that most inhibitors of PP1 and PP2A affect PP2B at high concentrations, but not PP2C (see sects. IIB4 and IIIB). An overview of the various catalytic subunits for the PP in this review is given in Table 1. In contrast to the monomeric PP2C, the PP1, PP2A, and PP2B are multimeric forms. The multimeric forms consist of the catalytic subunit and one or two accessory proteins. These accessory

1. Composition of some mammalian serine/threonine phosphatases

proteins can confer substrate specificity, can regulate enzyme activity, and can control the subcellular localization of the holoenzyme (127).

TABLE

PPase

Catalytic Subunit

1a (19, 31, 364), 1d (364), 1g1 (364), 1g2 (364)

1

2A

Ca (15, 84), Cb (15, 85)

2B

CNAa1 (164, 245), CNAa2 (245), CNAb1 (261), CNAb2 (154), CNAb3 (154), CNAg (320) Ca1 (302, 404), Ca2 (302, 404), Ca3 (302, 404), Cb1 (408, 437), Cb2 (408, 437) PP3 (203) PP4 (44) PP5 (58) PP6 (130) PP7 (208)

2C

3 4 5 6 7

Regulatory or Accessory Subunit

IPP1 (4, 206, 207), IPP1 (206, 207, 198), 1 2 DARPP-32 (178, 444), RGL (394, 405), GL (104), GM (94), NIPP1 (423), RIPP (32), L5 (192), HSP (71), RBGP (112), p53BP2 (176), PSF (192), CPI17 (125, 126), sds22 (100), PPP1R5 (105) Aa (177, 430), Ab (177), Ba (308), Bb (308), Bg (469), B9a1 (407), B9a2 (407), B9b (83), B9g (83), B9d (83), B0 (RP72) (319), RP130 (319), B56a (309), B56b (309), IPP2A (280), 1 IPP2A (279) 2 CNBa1 (419), CNBa2 (52), CNBb1 (419), CNBb2 (52); Cain (266), AKAP79 (75)

1. PP1

PPase, protein phosphatase. For details, see text. Reference numbers are given in parentheses.

TABLE

Tissue

A) CATALYTIC SUBUNITS. Cloning revealed that the catalytic subunit of type 1 phosphatases is differentiated into types 1a, 1d, and 1g derived from three different genes (364). Protein phosphatase 1a codes for a protein of 330 amino acids (e.g., in rat and rabbit, Refs. 19, 31, 364). The catalytic subunit of PP1d is comprised of 327 amino acids (rat, Ref. 364). The catalytic subunit of PP1g has two splice variants called PP1g1 and PP1g2 that code for 323 and 337 amino acids, respectively (364). Sequences are highly conserved between species. For instance, human PP1g1 is 93% nucleotide sequence similar and identical in protein sequence to the rat homolog (334). Table 2 includes the tissue expression of the catalytic subunits of PP1. However, even within one organ, the cellular or subcellular distribution of PP is not necessarily uniform. For example, in rat salivary glands, only some cell types reacted with antibodies specific for PP1g1 (380). In the heart, where PP1a, PP1d, and PP1g1 are immunologically detectable in whole tissue homogenates, the myofibrillar fractions contain mainly PP1a (70). This should be considered when comparing biochemical or (electro)physiological data from whole tissues and cells. B) ACCESSORY OR REGULATORY SUBUNITS. There are proteins that associate in equimolar concentrations with PP1 catalytic subunits leading to dimers (for brevity, unless stated otherwise, in the remainder PP1 stands for the

2. Tissue distribution of protein phosphatases catalytic subunits 1a

11 (378) Heart 1 (86) Liver 1 (86, 364) Intestine 1 (378) Kidney 1 (378) Spleen 1 (378) Adrenal 1 gland (378) Lung 11 (378) Skeletal 1 muscle (86) Testis 11 (378) Retina Brain

175

PHOSPHATASES AND ION CHANNELS

January 2000

1g1 111 (364, 378) 1 (86, 364) 1 (86, 364) 1 (378) 1 (364, 378) 11 (378) 11 (378) 11 (378) 1 (86) 1 (378)

1d

1g2

2A

111 (378) 1 (378) 2 (378), 1 (364) 111 (378) 1 (378) 1 (378) 1 (378) 111 (378) 2 (378) 11 (378)

2 (377)

1a, b

2 (377) 2 (377) 2 (377) 2 (377)

1a, b (392) 1a, b (392) 1a, b (392) 1a, b (392) 1a, b (392) 1a, b (392) 1a, b (392)

111 (364, 377)

2B CNAa

2B CNAb

111 (245, 320) 1 (245) 1 (245)

111 (261, 320) 1 (261) 1 (261)

1 (245) 1 (245)

1 (261)

1 (245) 11 (245) 2 (245)

11 (261) 11 (261) 2 (245)

2B CNAg 2 (320)

2 (320) 111 (320)

2Ca

2Cb1

2Cb2

3

1 (408) 1 (408) 1 (408) 1 (408) 1 (408)

1 (408) 1 (408) 1 (408) 1 (408) 1 (408)

1 (408) 1 (408) 2 (408) 2 (408) 2 (408)

1 (203)

1 (408) 1 (408) 1 (408)

1 (408) 1 (408) 1 (408)

2 (408) 2 (408) 2 (408)

2, Below detection limit. See text for details. Reference numbers are given in parentheses.

4

5

6

7

1 (44) 1 (44) 11 (44) 1 (44) 1 (44)

1 (58) 11 (58) 1 (58)

11 (24) 111 (24) 1 (24) 1 (24) 1 (24) 1 (24)

2 (208) 2 (208) 2 (208)

1 (44) 1 (44) 111 (44)

1 (58)

1 (24) 111 (24) 1 (24)

2 (208) 2 (208)

2 (208)

1 (208)

176


TABLE

Volume 80

3. Tissue distribution of accessory proteins for PP1

Tissue

DARPP-32

Brain Heart Liver Intestine

111 (178)

Kidney Spleen Adrenal gland Lung Skeletal muscle Retina

1 (313)

I1

I2

1 (294) 1 (294) 1 (294)*

GL

1 (294, 354) 1 (294, 354)

PPP1R5

NIPP1

CPI17

1 (105) 1 (105) 1 (105) 1 (105)

11 (423) 111 (423) 11 (423)

11 (126) 2 (126)

2 (104) 2 (104) 111 (104) 2 (104)

2 (405) 11 (405) 2 (405)

2 (104) 2 (104) 2 (104)

2 (405)

1 (105) 1 (105)

1 (423)

2 (104) 2 (104)

2 (405) 111 (405)

1 (105)

11 (423) 111 (423)

11 (313)

1 (179) 2 111 (294)

RGL

11 (294, 354)

bladder 111 (126)# 2 (126)

2 (126)

GM

1 (338) 2 (338) 1 (338)

2 (338)

1 (105)

2, Below detection limit. See text for details. * Species dependent. #111 in aorta (126). Reference numbers are given in parentheses.

catalytic subunit of PP1). These accessory protein can change (that is, inhibit or augment) the activity, substrate selectivity, or subcellular localization of the catalytic subunit. They are discussed below and in section IIIA. Their tissue distribution and their functional effects are summarized in Tables 3 and 4, respectively. Many regulatory proteins of type 1 PP contain a common sequence. It was noted that the motif R (or K), V (or I), X (variable amino acid), and F is common to all PP1-binding proteins, e.g., RGL, GL, M110, p53BP, inhibitor 1, DARPP-32, and NIPP1 (see below). The different regulatory subunits are mutually exclusive (114, 232). The first regulators to be identified were I1 and I2 (206, 207). A) I1, I2, and DARPP-32. I2 (inhibitor 2 of PP1) forms a complex with the catalytic subunit of PP1 to generate

4. Effect of accessory/regulatory subunits on PP1 activity

TABLE

Subunit

Inhibitor-1 (206, 207) DARPP-32 (178) Inhibitor-2 (206, 207) NIPP-1 (33) RIPP-1 (32) CPI17 (125) p53BP2 (176) sds22 (100) PPP1R5 (104, 105) GL (104, 105) PSF (192) L5 (193) GM (68) RGL

Stimulation

Inhibition: Ki, nM

2 1 3 0.2 20 2 1 25,000 100 100 1,000 Phosphorylase a Phosphorylated myosin Insulin (399)

Epinephrine (295)

Inhibition is quantified by inhibition constant (Ki) values. Stimulation is mentioned for appropriate substrates or pharmacological stimuli. See text for further details.

the ATP-Mg-dependent PP (95, 354). I2 inhibits PP1. I1 (inhibitor 1 of PP1) and DARPP-32 only inhibit PP1 after their phosphorylation by the cAMP-dependent protein kinase or cGMP-dependent protein kinase (181). Table 3 presents their tissue distribution. These inhibitors are discussed further in section IIIA because they are very useful tools for electrophysiological experimentation. B) RGL. Another regulatory subunit is the G subunit (also called RGL). It was detected as the protein that attached PP1 to glycogen in rabbit skeletal muscle (394). It could also bind the catalytic subunit of PP1 to the sarcoplasmic reticulum (SR). It could be phosphorylated by protein kinase A (PKA), and this phosphorylation was accompanied by the release of PP1 from the SR preparation or the glycogen particles (215). RGL is comprised of 1,109 amino acids (405). It is highly expressed in skeletal muscle (see Table 3 for tissue distribution). The G subunit increases the activity of PP1 toward its substrates like phosphorylase a or glycogen synthase (95). Phosphorylation of the G subunit by PKA on amino acids serine-48 (site 1) and serine-67 (site 2) after treatment of intact skeletal muscle preparations with epinephrine reduced the affinity of G subunit for PP1 (94, 295, 324). The G subunit remains attached to glycogen under these conditions, but PP1 dissociates from the glycogen particle (213). Dissociated PP1 is less active toward glycogen synthase and phosphorylase a (214). In this way, epinephrine can decrease phosphatase activity, and this leads to inactivation of glycogen synthase (213). Insulin has the opposite functional effect (in skeletal muscle) via a somewhat similar mechanism. Insulin stimulates mitogen-activated protein kinase-activated protein (MAPKAP) kinase-1. This kinase phosphorylates site 1 on the G subunit. This phosphorylation increases PP1 activity against glycogen synthase. Thus site-specific phosphorylation of RGL and subsequently altered phosphatase activity can explain both the stimulatory effect of insulin and

January 2000


the inhibitory effect of epinephrine on glycogen synthesis in skeletal muscle (399). C) GL. There is a specific protein that mediates the binding of PP1 to glycogen in the liver, called GL. GL is comprised of 284 amino acids. In contrast to RGL, GL is not phosphorylated significantly by PKA. GL inhibited dephosphorylation of phosphorylase a by PP1. It is only present in liver (see Table 3). D) GM. A protein that attached PP1 to myosin was called M subunit or GM (68). GM stimulated the activity of the catalytic subunit of PP1 toward phosphorylated native myosin but not toward phosphorylase a, indicating that it conveys substrate specificity. PP1 attached to GM is only present in myofilaments and cannot be purified from cytosol (68). Two proteins were identified and termed M130/ M133 based on their apparent molecular weight. Fittingly, two clones were isolated coding for 963 and 1,004 amino acids. They differ in the 41 intervening additional amino acids in the higher molecular weight form and are probably coded by distinct genes (63, 379). Differences in function are at present unknown (217, 218). Immunologically, the M130 was detectable in many chicken tissues including aorta, stomach, and heart but absent in liver and skeletal muscle (338, see Table 3). The M130 subunit in strips from rabbit portal veins is phosphorylated by an unknown endogenous kinase, and at the same time smooth muscle phosphatase activity is attenuated (218, 416). Hence, the function of GM might be regulated by phosphorylation. E) NIPP1. Nuclear proteins (isolated from bovine thymus nuclei) called NIPP1a (18 kDa) and NIPP1b (16 kDa) bind to and inactivate PP1 (33, 227, 229; see Table 4). This inhibition is accompanied by phosphorylation and reversed by PP2A or inhibitors of PKA or casein kinase II (422). These heat-stable proteins are proteolyzed fragments of a precursor protein (39 – 41 kDa) that has been cloned and sequenced and called NIPP-1. Its cDNA predicts 351 residues, and it is ubiquitously expressed (see Table 3). There is evidence for receptor-mediated hepatic phosphorylation of NIPP1 in intact animals (227). F) Others. A ribosomal protein called RIPP, ribosomal inhibitor of PP1, of 23 kDa was isolated from rat liver ribosomes. This protein preferentially bound and inhibited PP1 in a noncompetitive manner (32). RIPP might play a role in the regulation of protein synthesis. On the other hand, PP1 activity is stimulated by another ribosomal protein from rat liver called L5 (193). A cytosolic protein that belongs to the heat shock protein family binds to PP1g2, an isoform of PP1 enriched in testis. The functional role of this association is unknown (71). PP1 can bind to the retinoblastoma gene product. This may contribute to the function of PP1 in cell division (112). However, binding has not yet been shown in vivo. With the use of the yeast two-hybrid system it is was revealed that PP1g binds to p53BP2. The latter is a protein

177

that binds to the p53 protein that acts as a tumor repressor. p53BP2 also inhibits potently PP1 activity against phosphorylase a (176). PP1 also binds to a splicing factor. The factor was identified as polypyrimidine tract-binding protein-associated splicing factor (PSF). PP1 was inhibited by recombinant PSF (see Table 4). It is conceivable that the inhibitory action of PSF is potentiated by phosphorylation of PSF. The interaction may play a role in the physiological regulation of splicing in the spliceosome (192). In porcine aorta, PP1 could be inhibited by a protein of ;20 kDa. The inhibition was proportional to its phosphorylation by an unknown endogenous kinase or exogenous protein kinase C (PKC). The IC50 was within the physiological concentration of the inhibitory protein of 20 kDa and might thus be functionally relevant (125). This protein has been sequenced and was called CPI17 (C-kinase activated PP inhibitor; apparent molecular mass 17 kDa; Ref. 126). It is expressed in smooth muscle like aorta or bladder but not in skeletal muscle or nonmuscle tissue (Table 3; Ref. 126). A new 36-kDa protein was identified that binds and inhibits PP1 activity. It was termed PPP1R5 (105). This protein is related to GL, but it is, in contrast to GL, ubiquitously expressed (Table 3; Ref. 105). The inhibitory or stimulatory actions of the accessory subunits of PP1 are compared in Table 4. C) DIRECT ALTERATION OF PP1 ACTIVITY. A more direct way to modulate phosphatase 1 activity is by posttranslational modification of their catalytic subunits. Phosphorylation and methylation have been reported. All mammalian PP1 share a -TPPR- sequence (364), which is a recognition site for phosphorylation by cyclin-dependent protein kinases. Indeed, PP1a and PP1g1 are phosphorylated on threonine-320 and threonine-311, respectively, by cell cycle-dependent protein kinases (cyclin-dependent protein kinases), and this phosphorylation inhibits their phosphorylase phosphatase activity (103). The phosphorylation led to the incorporation of 0.5 mol phosphate/mol protein within 30 min. At this time point, phosphatase activity decreased to 50% of the initial value (103). This phosphorylation was first observed in vitro but later also in a cell cycle-dependent manner in intact cells and was accompanied by changes in cell cycle-dependent phosphatase activity in cytosol and nucleus (264). 2. PP2A A) CATALYTIC SUBUNIT. The catalytic subunits of PP2A (see also Tables 1 and 2 for synopsis) exist in two isoforms called PP2Aa and PP2Ab. They have been cloned from many species (15, 84, 85, 161, 182, 248, 249, 392, 393). Rat liver PP2Aa cDNA codes for a 309-amino acid protein. PP2Ab was different from PP2Aa in 8 amino acids, but the cDNA coded also for 309 amino acids and is coded by a different gene. The expression on protein and mRNA is higher for PP2a than PP2b. For instance, in porcine heart,

178


TABLE

Tissue

Volume 80

5. B subunits of PP2A: tissue distribution Ba

Brain 111 (469) Heart 11 (469) Liver 1 (469) Intestine Kidney Spleen Lung Skeletal muscle Testis 111 (469)

Bb

Bg

B9a 5 B56g (309)

B9b

B9g

B9d

B0 5 PR 130

B0 5 PR 72

B56a

B56b

111 (469) 1 (469) 1 (469) 111 (469) 1 (469) 1 (469) 1 (469) 1 (469)

111 (469) 2 (469) 2 (469) 2 (469)

111 (83, 407) 11 (83, 407) 1 (83, 407)

1 (83) 111 (83) 1 (83)

111 (83) 1 (83) 1 (83)

111 (83) 1 (83) 1 (83)

11 (183) 11 (183) 1 (183)

2 (183) 111 (183) 2 (183)

1 (309) 111 (309) 1 (309)

111 (309) 1 (309) 1 (309)

1 (83, 407) 1 (83) 11 (83, 407) 11 (83, 407)

1 (83) 1 (83) 1 (83) 1 (83)

1 (83) 1 (83) 1 (83) 1 (83)

1 (83) 1 (83) 111 (83) 1 (83)

1 (183)

2 (183)

1 (309)

1 (309)

11 (183) 11 (183)

2 (183) 111 (183)

1 (309) 111 (309)

1 (309) 1 (309)

111 (83)

1 (83)

111 (83)

111 (469)

2 (469) 1 (469)

1 (83)

See text for details. Reference numbers are given in parentheses.

the ratio is 8:1 (392). PP2A is apparently mainly cytosolic. However, some PP2A was also detectable in the nucleus (418). B) ACCESSORY/REGULATORY SUBUNITS. Several subunits of PP2A are known. Trimeric PP2A is formed by the A (structural component, also called PR65), B (phosphatase regulatory subunit, PR), and C (catalytic subunit) subunits. It is controversial whether the native enzyme is a trimer. Dimers (formed of equimolar A and C) might be native forms or isolation artifacts (438). A) A subunit. Two isoforms of the A subunits of PP2A have been cloned (177, 430). These A subunits were also called putative regulatory subunits and have an apparent molecular mass of ;65 kDa. This gave rise to the alternative nomenclature of PR65 for the A subunit (177). The Aa and Ab forms encode proteins of 589 and 602 amino acids, respectively. The effect of the A subunit on PP2A activity is substrate dependent. Recombinant Aa inhibited the activity (using phosphorylase a or myosin light chains as substrate) of the C subunit from the bovine heart with high potency (IC50 5 0.1 nM) (235). In contrast, in rabbit reticulocytes, the A subunit could stimulate the enzymatic activity of the C subunit when using eukaryotic elongation initiation factor 2 as substrate (61). B) B subunit. Three major variants of the B subunit have been termed B (52 kDa, also called B/PR55), B9 (53 kDa, also called B9/PR54), and B99 (72 kDa and a splice variant of 130 kDa). For overview and tissue distribution, see Tables 1 and 5. The binding of the B subunits is mutually exclusive. Three isoforms called a (447 amino acids), b (443 amino acids), and g of the B subunits have been cloned (174, 308, 469). The B9 subunit (PR 53) is further divided into a, b, g, and d. B9a can be alternatively spliced to generate B9a1 and B9a2, coding for proteins of 514 and 475 amino acids, respectively. Four variants (probably splice variants) of the B9g isoform can be further distinguished. The B99 subunit is comprised of two isoforms of 72 kDa (PR 72) and 130 kDa (PR 130) (319). PR 72 and PR 130 isoforms contain 529 and 1,150 amino acids, respectively. Like for the A subunit, the effect of the

B subunit on the enzymatic acitivity of PP2A is substrate dependent. Reconstituted dimers of A and C subunits were inhibited by the B subunit purified from bovine heart with an IC50 of 0.59 nM (235). In contrast, the B subunit (PR55) stimulated the dephosphorylation of cdk1-phosphorylated histone H (3). C) DIRECT REGULATION OF PP2A ACTIVITY. Covalent modification of the catalytic subunit can increase or decrease the activity of PP2A as discussed above for PP1. The COOH-terminal leucine (. . .TPDYFL) of the catalytic subunit of PP2A can be reversibly methylated by specific enzymes (273, 275). This leads to a modest increase in PP activity (129, 275, 449). This methylation is stimulated by cAMP and inhibited by okadaic acid (136). Agonist-induced reversible methylation of PP2A has been noted in intact cells (259) and is cell cycle dependent (418). In contrast, tyrosine phosphorylation reduces PP2A activity. The COOH-terminal tyrosine-307 is probably phosphorylated (. . .TPDYFL). This phosphorylation is catalyzed by tyrosine kinases like Src or Lck (55). In addition, an autophosphorylation-activated protein kinase phosphorylates a threonine residue on PP2A and inhibits the activity of PP2A (165, 166). This may lead to enhanced phosphorylation and thus stimulation of mitogen-activated protein (MAP) kinase and MAP kinase kinase (306, 395). In contrast, casein kinase 2a binds to autophosphorylated PP2A, leading to an increase in phosphatase activity against MEK 1 (184). 3. PP2B PP2B, alternatively called calcineurin, is a Ca21/calmodulin-dependent protein phosphatase. The enzyme consists of two subunits, the catalytic A subunit (see Table 1) of ;60 kDa (CNA) and the regulatory B subunit (CNB) of ;19 kDa. Calcineurin is present in nearly all mammalian cells studied. However, it is most highly expressed in the brain (see Table 2 for tissue distribution). A) CATALYTIC SUBUNIT (A SUBUNIT). Cloning from rat brain indicated a length of 521 amino acids for the A subunit.

January 2000


There are three mammalian genes for the A subunit, giving rise to the CNAa, CNAb, and CNAg isoforms. CNAa and CNAb are highly expressed in brain, whereas CNAg is testis specific. Differential splicing of CNAa generates two transcripts (a1 and a2). The CNAb gene is alternatively spliced to three transcripts CNAb1, CNAb2, and CNAb3. CNAa1 and CNAb2 are highly expressed in neuronal tissue, whereas CNAg is specific for the testis (419). The catalytic subunit (A subunit) of PP2B shows autoinhibition that is relieved by interaction with the B subunit. PP2B is quite different from PP1 and PP2A. It is the only PP clearly regulated by a second messenger, namely, Ca21. The inhibition of B on A is relieved if B binds Ca21. This explains why the enzyme is dependent on Ca21 for activity. Using proteolysis of the autoinhibitory COOH terminus of the A subunits generates a Ca21independent isoform. This can be used experimentally to understand the function of PP2B. B) REGULATORY SUBUNIT (B SUBUNIT). The B subunit was sequenced at the protein level and found to comprise 168 amino acids. It shows sequence similarity to calmodulin. Like calmodulin, it binds 4 mol Ca21/mol (5). Two different B subunit genes are known that are called CNBa and CNBb. CNBa gives rise to one isoform expressed in many tissues named CNBa1 (170 amino acids) and, by means of a different promotor, leads to another testis-specific isoform called CNBa2 (216 amino acids). Similarly, CNBb (179 amino acids) is only expressed in the testis (52, 419). The substrate specificity of PP2B is quite high. Wellinvestigated substrates include a subunit of phosphorylase kinase, inhibitor 1 (of PP1), DARPP-32, the type II regulatory subunit of the cAMP-dependent protein kinase, and the site 2 of the glycogen binding subunit of PP1 (RGL; Ref. 213). Data with inhibitors for PP2B (see also sects. IIIB, 7 and 8) indicate that the activity of the PP2B is substrate dependent. Although these inhibitors decreased the activity toward a 19-amino acid peptide, they caused a stimulation of activity toward p-nitrophenylphosphate (287). PP2B might play a role in signal transduction especially in the brain, where its expression is very high. C) ACCESSORY PROTEINS. A) AKAP 79. A protein kinase A anchoring protein (AKAP 79) was able to bind PP2B. AKAP 79 inhibited in a noncompetitive manner PP2B activity with an IC50 of ;4 mM. It did not inhibit PP1 or PP2A. The interaction was studied in bovine brain (75). B) Cain. Another protein called calcineurin inhibitor (cain) was more recently studied (266). Cloning predicted a sequence of 2,182 amino acids. The IC50 was ;0.4 – 0.5 mM. Hence, cain is more potent than AKAP 79. Cain was highly expressed on RNA and protein level in brain, kidney, and testis. It was least detectable in heart, spleen, lung, liver, and skeletal muscle. It is mainly cytosolic. It was speculated that cain may target inactivated PP2B to specific intracellular regions where its release would pro-

179

vide Ca21-regulated phosphatase activity to specific signaling pathways (266). 4. PP2C PP2C is monomeric. In mammalian cells, PP2Ca and PP2Cb are known (404, 437). PP2Ca is comprised of 382 amino acids. Several isoforms of PP2Ca, namely, PP2Ca1, PP2Ca2, and PP2Ca3, have been reported (302). PP2Ca1 is the most abundant isoform. Alternative splicing seems to generate the isoforms PP2Cb1 and PP2Cb2. They were cloned from a mouse library and show differences in COOH termini and the 39-untranslated region. PP2Cb1 is expressed in all mouse tissues studied, whereas PP2Cb2 is confined to heart and brain where they might subserve special functions (408). PP2Cb1 and PP2Cb2 code for 390 and 389 amino acids, respectively. Tissue distribution is included in Table 2. PP2C was originally assumed to be exclusively cytosolic (375). More recent work identified PP2C also in the nucleus of mammalian cells (87). 5. PP3 A PP3 has been suggested to exist (203). It was described as a particulate protein in the bovine brain that was inhibited by okadaic acid but stimulated by inhibitor 2 and inositol phosphates (471). Because there has not been any recent report on PP3, it seems likely that this enzyme may have been artifactual. 6. PP4 PP4, also called PPX (44), is expressed highly in testis; however, it was also detectable in all other tissues investigated (see Table 2). Its structure, like that of PP6, is reminiscent of the paradigmatic PP2A. PP4 is comprised of 307 amino acids (rabbit); PP4 is mainly localized in the nucleus, although smaller amounts are also present in the cytosol (44). Regulatory subunits of PP4 are thought to exist but have not been clearly identified (78). 7. PP5 PP5 is ubiquitously expressed in human tissues (see Table 2). The calculated molecular mass of the protein is ;58 kDa (the 59-end of the sequence was incomplete in the inital report, Ref. 58). PP5 contains an autoinhibitory domain. Polyunsaturated fatty acids can relieve this inhibition (57). PP5 was detectable mainly in the nucleus, although some immunoreactivity was also present in the cytosol (56, 58, 67). PP5 interacts with the atrial natriuretic peptide receptor and was isolated in complex with a glucocorticoid receptor (56). These associations might indicate some kind of regulatory interaction.

180


8. PP6 PP6 is structurally related to PP2A. PP6 (303) has so far been identified in all mammalian tissues examined (see Table 2). Sit 4, the Saccharomyces homolog of PP6, has regulatory subunits (130). Therefore, regulatory subunits of PP6 are thought to exist but have not been clearly identified (78). 9. PP7 PP7 is comprised of 653 amino acids. With a comparison of RNA from various human tissues, PP7 was only detectable in the retina and not, for instance, in the heart (see Table 2). III. MODULATORS OF PROTEIN PHOSPHATASE ACTIVITY In contrast to some tyrosine phosphatases, serine/ threonine phosphatases are probably not located transmembranic but subplasmalemmal. This is no problem when using cell-free extracts. In more intact systems, inhibitors or activators have to pass the membrane. This is easiest if the compounds are freely permeable. Otherwise, the membrane has to be broken. This can be done mechanically (injection through pipette), electrically (gene pulser), chemically (transfection reagents), or by viral gene transfer. Hence, if information is available on cell permeability, it will be provided for the compounds listed in this section.

Volume 80

low degree of order in the protein. I1 binds to and inhibits PP1 only after being phosphorylated on threonine-35 by cAMP-dependent protein kinase or cGMP-dependent protein kinase (181). It is very selective for PP1. For instance, phosphorylated recombinant human I1 inhibited PP1 and PP2A with IC50 values of 1.1 and 21,000 nM, respectively (119). Phosphorylation of I1 occurs in vivo in skeletal muscle, heart, and cardiomyocytes after b-adrenergic stimulation (76, 168, 329). In vitro-phosphorylated I1 has been used as a tool to study in permeabilized preparations whether a process involves PP1. For instance, I1 phosphorylated by cGMP-dependent protein kinase induced force generation in permeabilized smooth muscle cells (413). As expected, mutagenesis of threonine-35 to alanine yielded a mutant I1 that could not be phosphorylated by I1 and that did not inhibit PP1. Mutation of threonine-35 to aspartic acid, which is intended to mimic phosphorylation, led to a mutant form of I1 that inhibited both PP1 and PP2A with IC50 values of 24 and 25 mM, respectively (119). Immobilized I1 binds ;10 times better to PP1 than to PP2A, independent of its phosphorylation state. Amino acids 9 –12 KIQF are conserved in rat, rabbit, and human, and they seem to be crucial for binding and inhibition of PP1 (114). If this sequence is deleted, phosphorylation of I1 is unable to inhibit PP1 activity (119). Interestingly, I1 is present in the liver of rabbits, guinea pigs, and sheep but absent from mouse and rat liver (210, 294). I1 is present, for example, in skeletal muscle, heart, kidney, uterus, and adipose tissue (117, 294). I1 is a cytosolic protein. 2. DARPP-32

A. Protein Inhibitors All these inhibitors are comprised of amino acids and are thus not expected to pass cell membranes easily. 1. Inhibitor 1 PP1 Inhibitors 1 and 2 of PP1 were identified by Huang and Glinsmann (206, 207). They share unusual physical properties. Both are heat stable and are not precipitated by 1% trichloroacetic acid, in contrast to most other proteins. The sequence of I1 has been reported first by direct protein sequencing from rabbit skeletal muscle and then from a rat skeletal muscle library and a human brain library by cloning and results in a predicted protein of 171 amino acids (4, 117, 119). The NH2-terminal region is highly conserved. Only in the COOH termini were differences between rabbit, rat, and human noted (119). I1 from rabbit skeletal muscle and human brain has a calculated molecular mass of 18.7 and 19.2 kDa, respectively (4, 119). The apparent molecular mass is ;26 kDa on SDS-PAGE. This discrepancy has been explained by a

DARPP-32 is similar to I1 in function but derived from a different gene, and it is mainly expressed in the brain (178). It has been sequenced on protein and cDNA level from bovine brain (262, 444) and rat brain (115). DARPP-32 from bovine brain has a predicted molecular mass of 22.6 kDa and, like I1, a higher apparent molecular mass of 32 kDa on SDS-PAGE. The same threonine residue on DARPP-32 is phosphorylated by cAMP-dependent protein kinase but also by cGMP-dependent protein kinase. Phosphorylation of DARPP-32 changes its IC50 for PP1 from 1 mM to 2 nM (96, 97), underscoring its high selectivity. Under unphysiological conditions (mM Mn21 in the assay), I1 and DARPP-32 are dephosphorylated and inactivated by PP1. Both I1 and DARPP-32 are dephosphorylated by PP2A and even better by PP2B (98, 178, 180). The dephosphorylation by PP2B is dependent on the presence of Ca21. Hence, it was suggested that this might be a way for Ca21 levels to control protein phosphorylation (214). DARPP-32 is a cytosolic protein. Thiophosphorylated I1 or DARPP-32 is not (easily) dephosphorylated and has been successfully used to

January 2000


study the physiological role of PP1-mediated phosphorylation in muscle contraction. 3. Inhibitor 2 PP1 I2 from rabbit skeletal muscle is comprised of 204 amino acid and has a calculated molecular mass of 22.9 kDa (198). Similarly to I1, its apparent molecular mass on SDS-PAGE is larger and amounts to ;31 kDa. It is unrelated in sequence to I1. Its tissue distribution has been studied (294, 354). It binds to and inhibits PP1 regardless of phosphorylation. Therefore, it has been used to study the effect of PP1 in intact cells. It forms complexes with PP1 and is therefore discussed in depth above. A caveat is noteworthy. I2 inhibits the free catalytic subunit of PP1 in the nanomolar range. However, the glycogen-associated PP1 is poorly inhibited, and the smooth muscle myosinassociated PP is not inhibited at all (7, 213, 214). However, it is known that glycogen-associated PP and the myosinassociated PP contain the catalytic subunit of PP1 (95). Hence, inability to block a process by addition of I2 does not prove that a PP1 is not involved but requires additional experimentation. The binding site for I2 is probably close to that of okadaic acid (460). Mutational analysis suggests that I2 inhibits via interaction with the amino acid tyrosine-272 on PP1 because its IC50 is changed from 13 to 180 ng/ml in the mutant Y272K (458). 4. Inhibitor 1 PP2 Inhibitor 1 PP2 has been isolated from bovine kidney. It is thermostable and not inactivated by 1% trichloroacetic acid. Its apparent molecular mass was 30 kDa. (277). Later, it was identified as putative class II human histocompatibility leukocyte-associated protein (PHAP) I (279). PHAP I had been cloned and sequenced before by another group (421). It seems to inhibit the catalytic subunit directly (279). It is present in the nucleus but more abundant in the cytosol (421). The tissue distribution has not been rigorously tested. However, its transcript was also detectable in Northern blots from rat heart and skeletal muscle (J. Neumann and H. Lu¨ss, unpublished observations). It is not known whether its activity is regulated by a posttranslational modification like I1 of PP1 (277). 5. Inhibitor 2 PP2 This inhibitor has been isolated from bovine kidney. It is also thermostable and not inactivated by 1% trichloroacetic acid. Its apparent molecular mass was initially reported as 20 kDa (277). Protein sequencing revealed that the protein had been described before as SET (278, 426, 427), PHAP II (421), and template activating factor-1b (322). SET has a predicted molecular mass of 32,100 Da

181

and an observed molecular mass of ;39 kDa and is largely located in the nucleus (138). Thus proteolysis should account for the lower molecular mass reported initally. Ubiquitous expression of SET was reported (2). Interestingly, SET was phosphorylated on serine in intact cells. Whether this alters phosphatase inhibitory function remains to be established (2). These inhibitors might be useful tools to study the physiological function of PP2A. It has been speculated that I1 and I2 of PP2A might be involved in signal transduction. Specifically, they were suggested to mediate the effects of insulin on PP2A (277). 6. Simian virus 40 small tumor antigen Simian virus 40 (SV40) is a member of the papova family of small DNA tumor viruses. Its lytic cycle takes place in permissive monkey cells. SV40 infection leads to the production of proteins that are immunogenic and that were called tumor antigens. One such antigen is the SV40 small tumor antigen. It can inhibit PP2A activity with an IC50 of 10 –15 nM. This has been reported for substrates such as myosin light chains, phosphorylated by myosin light-chain kinase (453). As mentioned above, PP2A can occur as a monomeric, dimeric, or trimeric species: C (catalytic subunit), AC, or ABC. SV40 inhibits PP2A activation after forming a complex with the AC species (453). This occurs with brain PP2A or in CV-1 cells that all contain the Ba form of the the B subunit of PP2A. Here, SV40 small tumor antigen displaces the B subunit from the PP2A holoenzyme (386, 453). In cells the interaction of small tumor antigen with PP2A leads to deinhibition and thus activation of MAP kinase and MEK which induces cell proliferation (386). SV40 small tumor antigen can conceivably be used in cell extracts to quantify the amount of PP2A activity. The protein is not expected to pass through intact cell membranes. However, it can be injected into cells or alternatively might be delivered to cells as their coding DNA by various means of transfection including virus vectors (386, 387). B. Nonprotein Inhibitors 1. Okadaic acid and derivatives The history of okadaic acid (OA) is paradigmatic (80). Okadaic acid is a polyether compound with a C-38 structure, isolated from the black sponge Halichondria okadai named in honor of Yaichiro Okada (146). Shibata et al. (376) noted that OA increased tone in smooth muscle preparations. Erroneously, this was interpreted as opening of Ca21 channels and activation of a Ca21-dependent kinase and phosphorylation of regulatory proteins. Moreover, OA was studied as a skin tumor promoter in mice (396). However, Takai et al. (400) were the first to

182


report that OA is a potent phosphatase inhibitor in smooth muscle preparations (34). Okadaic acid inhibited PP1, PP2A, and PP2B with IC50 values of 272, 1.6, and 3,600 nM, respectively (35). PP2C, phosphotyrosyl phosphatase, acid phosphatase, and alkaline phosphatase were not inhibited by up to 10 mM OA. Inhibition was noncompetitive, mixed competitive, and reversible (35). Hescheler et al. (190) noted that OA inhibited PP activity in skeletal muscle preparations and increased currents through cardiac L-type Ca21 channels. It is currently thought that tumor promotion by OA and related compounds like calyculin A and microcystin LR is due to inhibition of PP1 and PP2A (for review, see Ref. 146). The OA binding site of PP is not the substrate binding site because OA inhibits PP1 and PP2A noncompetitively (35). However, a caveat is warranted. Okadaic acid in concentrations ,2 nM inhibits also PP4, PP5, and PP6 that are present in mammalian cells (78). At least 16 derivatives of OA are known, and potent inhibitors include, in addition to OA, dinophysistoxin-1 and acanthifolicin (146). Dinophysistoxin-1 was first isolated from the hepatopancreas of the mussel Mytilus edulis. It caused shellfish poisoning in Japan. Its name is derived from its source in the dinoflagellate Dinophysis fortii (146). Chemically, it is 35-methylokadaic acid (199). Acanthifolicin is an episulfide derivative of okadaic acid. It occurs naturally in the sponge Pandaros acanthifolium. Treatment of acantifolicin with diazomethane led to acanthifolicin-methyl ester (146). Of importance, some derivatives are inactive and can be used as negative controls. These include OA methyl ester, nor-okadaon, acanthifolicin methyl ester. Interestingly, chemical degradation products of OA, namely, OA spiroketal I and II, were still able to inhibit type PP2A, indicating that it may be possible to design simpler but still active OA derivatives (146). Okadaic acid increases the phosphorylation state of a number of proteins. Some have been identified; these include vimentin and the 27-kDa heat shock protein (human fibroblasts, Refs. 170, 454). Okadaic acid increased the phosphorylation state of the epidermal growth factor receptor (185), histone H3 (300), a progesterone receptor (92), the a-subunit of the inhibitory nucleotide binding protein Gi-2 (46), and cardiac regulatory proteins (326). In the nuclei, OA caused sustained activation of gene expression as well as hyperphosphorylation of suppressor gene products (145, 170). Okadaic acid induced apoptotic death (39). In other systems, OA inhibited heat-induced apoptosis (25). Nuclear effects of OA include transcription of c-fos and c-jun, the classical early response genes (243). NFkB was induced and dissociated from IkB (410). Okadaic acid reduced the expression of the myogenic determination gene MyoD1 (242). Okadaic acid activated the 70-kDa heat shock protein promoter (53). The permeation of OA through cells seems to be rather poor. It has

Volume 80

been estimated that OA penetrates the cell membrane 100-fold less readily compared with calyculin A (128). Peroral application of radioactive OA led only to 1% absorption. Intraperitoneal application of radioactive OA indicated that OA is excreted through hepatobiliary circulation (146). However, OA freely permeated through the lipid membrane of multilayer vesicles in a liquidcrystalline state, indicating that OA gains access to receptors in the cytosol (325). Okadaic acid (458, 460) binds probably to YRCG (amino acids 267–270) or the vicinity. Mutational analysis suggests that OA inhibits via interaction with amino acid tyrosine-272 on PP1 because its IC50 is changed from 200 to 50,000 nM in the mutant Y272S (458). 2. Cantharidin and analogs Cantharidin, cantharidic acid, palasonin, and endothall are structural analogs (268). Cantharidin (CA) is the vesicant in blister beetles (beetle in Greek is kanuaro§) and present in Spanish flies, palasonin is an anthelmintic in seeds of a medicinal tree, and endothall is a synthetic herbicide. The toxic action of cantharidin is thought to be due to phosphatase inhibition. Initially CA was reported to bind to PP2A in mouse liver (281). However, CA inhibits PP1 and PP2A with IC50 values of ;500 and 40 nM (200, 282, 330). Palasonin and cantharidic acid exhibited similar inhibitory activity (282). Endothall inhibited both PP1 and PP2A with IC50 values of ;5,000 and 1,000 nM (282). Neither compound inhibited PP2B (.30,000 nM) or PP2C (.1 mM). All compounds are herbicides. However, endothall is more potent, possibly due to the expression of other PP in plant or to permeability differences (282). Cantharidin is a terpenoid. It is cell membrane permeable. It caused phosphorylation of regulatory proteins in rhabdomyocytes and leiomyocytes (251, 330). This phosphorylation was accompanied by contraction of papillary muscles and coronary arterial preparations (250, 286, 330). It is less potent and selective than okadaic acid but is inexpensive. Mutational analysis indicates that OA and CA might act on different amino acids on PP1 (460). In mutational analysis of amino acids 274 –277 of PP1, no change in the IC50 for cantharidic acid was noted, in contrast to OA, which was much more active when GEFT was changed to the mutant YRCG (460). It has been claimed that CA and endothall are not readily permeable through cell membranes but are taken up by hepatocytes (122, 124). However, others reported that endothall is membrane permeable. Okadaic acid displaced cantharidin from PP2A (281). 3. Calyculin A Calyculin A (CyA) was isolated from another marine sponge, Discodermia calyx. It is an octamethylpolyhy-

January 2000


droxylated C-28 fatty acid linked to two g-amino acids and esterified with phosphate. How it is phosphorylated and dephosphorylated and whether this changes its activity has apparently not been reported. It is cell membrane permeable. Calyculin A induced muscle fiber contraction (226) and contraction of cardiac preparations (327). In addition to CyA, seven other related compounds were isolated termed alphabetically calyculin B to H (146). They have different substitutions with cyano groups and methyl groups. There is an inactive acetonide derivative that might be a useful negative control. Like OA, CyA increased phosphorylation of vimentin, phospholamban, the inhibitory subunit of troponin, and C protein (54, 327, 327a). Calyculin A is equally potent against PP1 and PP2A (146, 225), with IC50 values from 1 to 14 nM. Okadaic acid and CyA seem to compete for the same inhibitory site on PP2A (401). Mutational analysis suggests that CyA inhibits the enzyme via interaction with amino acid tyrosine272 on PP1, because its IC50 is changed from 0.5 to 3000 nM in the mutant Y272K (458). 4. Microcystins Whereas OA and CyA are fatty acid derivatives, microcystin and nodularin are peptide toxins. Microcystins are of toxicological relevance. They cause death in cattle and humans exposed to water contaminated by certain algae. These include colonical and filamentous algae and cyanobacteriae like Microcystis aeruginosa (48, 49, 146). Algae and prokaryotes seem not to contain PP1 or PP2A; hence, they can survive these toxins in contrast to other phyla. Microcystins are cyclic heptapeptides containing five constant (some of which are unique) and two variable amino acids. The variable amino acids in microcystins are given in the one-letter code. Hence, their short-hand notation is microcystin-LR, -YR, and -RR. More than 40 additional microcystins have been identified (146). Microcystin-LR inhibits PP1 and PP2A with IC50 values of 0.1 nM each (298) or 1.7 and 0.04 nM, respectively (202). It inhibits PP2B with an IC50 of 0.2 mM and does not inhibit PP2C up to 4 mM (298). Okadaic acid prevents the interaction of microcystin with PP2A, implying a similar site of action. Moreover, binding of inhibitor 2 to PP1 prevented the binding of microcystin-LR to PP1. It is important to keep in mind that the newer mammalian PP4 and PP5 are also inhibited by ,2 nM microcystin. Hence, it is possible that some effects thought to result from PP1 or PP2A inhibition actually result from PP4 or PP5 inhibition (44, 58, 303). Moreover, inhibition of PP6 by microcystin has not been tested, and other phosphatases will likely be cloned in the future. Microcystin is the most potent (and toxic) PP inhibitor. As expected for a peptide, cell permeation is a problem. In fibroblasts, microcystin-LR did not increase phosphorylation. However, it led to hyper-

183

phosphorylation in hepatocytes (123). This is consistent with the clinical observation that intoxications with microcystin-contaminated water led to hepatic necrosis and subsequent death, as shown recently by an epidemic caused by microcystin-contaminated dialysis fluid (230). Peroral microcystin is taken up with a bile acid transport system across the ileum into hepatocytes (123). When radioactive microcystin was given intravenously to mice, label was detected mainly in liver but also in kidney, gut, and lung. No label was found in spleen and heart. Hence, no transport system for microcystin seems to exist in cardiomyocytes or splenocytes (357). Interestingly, these investigators clearly demonstrated that hepatic radioactive label persisted after single administration and that the label was covalently bound to a protein that they did not identify further but that is expected to be a PP. Permeability problems can be overcome by permeabilizing preparations with, e.g., a-toxin or b-escin. With the use of this approach, microcystin increased the tone in isolated preparations from guinea pig femoral artery, guinea pig ileum, rabbit femoral artery, and rabbit portal veins (158). The three-dimensional structure of microcystin-LR bound to PP1 has been determined (18, 155). The modified amino acid N-methyl-dehydroalanine (Mdha) in microcystin was bound to cysteine-273 in PP1 (155). In a two-step mechanism, microcystin-LR first binds to and inactivates PP1 or PP2 within minutes. Thereafter, a covalent modification of Mdha in microcystin was formed (within hours) with PP1 or PP2A (82). Mutation of cysteine-273 in PP1 to alanine impeded covalent binding of microcystin to PP1. However, this mutation does not reduce the potency of microcystin, OA, nodularin, tautomycin, and inhibitor 2 to inhibit PP1 activity. This strongly implies a two-step mechanism and indicates that binding to PP1 and inhibition of activity are distinct processes (360). Likewise, another laboratory also identified cysteine-273 in PP1g1 as the amino acid that is covalently bound to microcystin. However, in their hands, mutation of cysteine-273 to alanine increased the IC50 of microcystin on PP1 from 0.2 to 4.0 nM. They argued that this opposite finding could be due to different dilutions of the PP1 between laboratories (299). It was extrapolated that microcystin should covalently bind to cysteine-266 in PP2A (360). Mutational analysis suggested that microcystin and other toxins like OA, nodularin, and CyA competed for the same inhibitory site on PP1 near amino acids 273–276 (460). Mutational analysis suggests that microcystin inhibits via interaction with amino acid tyrosine-272 on PP1 because its IC50 is changed from 0.3 to 14 nM in the mutant Y272K (458). 5. Nodularin Nodularin was isolated from the toxic water cyanobacterium Nodularia spumigenia (49). It is a cyclic pentapeptide. Like microcystin, it is toxic to the liver. It

184


does not penetrate into fibroblasts, but it is active in hepatocytes, like microcystins (146). Nodularin R and its derivative called motuporin (nodularin V) potently inhibit PP1 as well as PP2A with IC50 values of 1.6 and 0.03 nM, respectively (201). Hence, it inhibits PP1 and PP2A ;10 times more potently than OA. It is ;70-fold selective for PP2A. It inhibits PP2B with an IC50 of 8.7 mM but does not affect PP2C (201). Hence, the IC50 values are comparable to those of microcystin-LR. In contrast to microcystins, nodularin R or V does not covalently bind to PP1 or PP2A (82). Mutational analysis suggests that nodularin inhibits PP activity via interaction with amino acid tyrosine-272 on PP1 because its IC50 is changed from 0.5 to 150 nM in the mutant Y272S (458). The three-dimensional solution structure of nodularin closely resembles that of microcycstin-LR (13). 6. Tautomycin Tautomycin was isolated from Streptomyces spiroverticillatus as an antibiotic because it is toxic to yeast and fungi. Its structure as a polyketide resembles somewhat that of OA (205, 296). It inhibits PP1 and PP2A with IC50 values of 0.7 and 0.65 nM, respectively (146), or 0.16 and 0.4 nM, respectively (296). Others reported IC50 values of 0.4 and 34 nM for PP1 and PP2A, respectively (401). The latter results might be interpreted as selectivity for PP1. However, p-nitrophenylphosphate was used as substrate, whereas other laboratories that reported more potent inhibition of PP2A used the more conventional and perhaps more relevant substrate phosphorylase a. Tautomycin does not inhibit PP2C, and its IC50 for PP2B is 100 mM. Okadaic acid prevents the interaction of tautomycin with the catalytic subunit of PP2A. Unlike microcystin, tautomycin led to hyperphosphorylation in all cell types tested, like keratinocytes and K562 cells (146). Hence, it is apparently cell membrane permeable. Mutational analysis suggests that tautomycin inhibits via interaction with amino acid tyrosine-272 on PP1 because its IC50 is changed from 1.1 to 2,600 nM in the mutant Y272K (458). Like CyA, it can be used in comparison with OA. This might indicate whether a physiological effect is mediated by PP1 or PP2. 7. Ciclosporin Ciclosporin, or cyclosporin A (a cyclic undecapeptide), and FK-506 (a macrocyclic lactone) inhibit PP2B (342). This inhibition is not direct. First ciclosporin and FK-506 bind to cyclophilin and a FK-506-binding protein (FKBP), respectively. Thereafter, they interact with the latch region of the CNB subunit of PP2B (74, 314). Then inhibition of CNA, the catalytic subunit, occurs. The three-dimensional structure of the calcineurin-FK-506 and FKBP complex supports this notion (162, 247). Rapamy-

Volume 80

cin, an immunosuppressant fungal metabolite, also binds to FKBP but does not inhibit PP2B because it cannot interact with CNB for steric reasons (162). In contrast, it targets to a rapamycin-associated protein (FRAP) that leads to inactivation of some specialized protein kinases like p70s6k (6, 346). Work with ciclosporin is complicated by the fact that it requires special solvents like Tween and ethanol mixtures that tend to be cell toxic. However, it is cell membrane permeant. 8. Cypermethrin Type 2 pyrethroids like cypermethrin are used as insecticides because they modulate ion channel activity, but they have also been reported to inhibit PP2B in nanomolar concentrations (118) independent of mediator proteins like cyclophilin (see sect. IIIB7). However, subsequently others reported that up to 1 mM cypermethrin did not affect PP2B, PP1, or PP2A (297). 9. Apomorphine Somewhat surprisingly, apomorphine and SKF-38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1H-3-benzazepine) inhibited PP2A1 (trimeric ABC) from rat brain with IC50 values of 1 and 50 mM, respectively. In contrast, apocodeine was inactive. It has apparently not been reported whether PP2A from other tissues or other PP are inhibited by apomorphine (238). Apomorphine is cell membrane permeant. 10. Fostriecin The antitumor antibiotic fostriecin (CI-920) is a type II DNA topoisomerase-directed anticancer drug, like doxorubicin or etoposide (41). Other phosphatase inhibitors are tumor promotors (see above). Phase I clinical trials of fostriecin are being conducted in the United States. It is a naturally occurring compound from Streptomyces pulveraceous subspecies fostreus, an actinomycete found in a Brazilian soil sample. It is a water-soluble polyene lacton with a phosphate ester. Fostriecin inhibited both PP1 and PP2A with IC50 values of 4 mM and 40 nM, respectively, but it did not inhibit tyrosine phosphatases (356). Fostriecin led to histone phosphorylation and vimentin phosphorylation in baby hamster kidney cells (88, 167). Fostriecin is very polar, and hence, it must be actively transported into cells. The mechanism is poorly understood but may involve the reduced folate carrier (88). It is has been suggested that the PP inhibition at least contributes to its efficacy against solid tumors in humans. 11. Heparin Heparin inhibits and binds to PP1 but not PP2A (120, 121, 153), The compound can actually stimulate PP2A

January 2000


(see below). This property has led to a procedure to separate these phosphatases using a heparin-based affinity column chromatography. Spermine inhibits both PP1 and PP2A with similar potency (375). It was speculated that polycationic compounds might mimic the action of some unknown intracellular factor. Their use as tools to study PP function is hampered by their lack of membrane permeability. 12. Thyrsiferyl 23-acetate This compound is, like OA, a polyether fatty acid and contains a squalene carbon skeleton. It was isolated from the red alga L. obtusa. It is unique because it is a selective inhibitor of PP2A. Up to 1 mM it does not inhibit PP1, PP2B, PP2C, or tyrosine phosphatase activity. Its IC50 for PP2A is ;4 mM. Hence, it is several orders of magnitude less potent than OA or CyA. However, it can be used in cell extracts to distinguish between type 2A and other phosphatases. It is expected to be cell membrane permeant (307). The potency of inhibitors is usually 10 –100 times less in intact tissue or cells than in enzymatic inhibition assays (54). This has been explained by reduced uptake into cells, their preferential localization within the lipid phase, or by the high intracellular concentrations of the targeted phosphatases (76, 122; see also sect. IV). C. Activators 1. 2,3-Butanedione monoxime 2,3-Butanedione monoxime (BDM) was initially described as a chemical phosphatase. However, it was demonstrated that BDM does not directly dephosphorylate substrates like phosphorylase a. Instead, BDM activates the phosphatase holoenzyme of PP1 and/or PP2A (468). A caveat is in order. BDM is probably a poor tool because it is no specific phosphatase activator but exhibits various effects on additional proteins. Indeed, there are numerous examples where BDM directly blocks ion channels but does not cause dephosphorylation (9, 116, 367, 384, 457). 2. Sphingosine derivatives Ceramide can stimulate the activity of trimeric PP2A. However, the activity of the dimer (CA) or the free catalytic subunit (C) cannot be stimulated by ceramide (101). Ceramide might be an important second messenger for cell membrane-located receptors (20, 252). 3. Other activators PP2A is activated by polylysine, protamine, polybrene, and histone H1 (120, 343). Histone H1 is only

185

present in the nucleus and might thus be a physiological stimulator of PP2A that is detectable in the nucleus in small amounts (see above). Protamine did not stimulate the activity of the purified catalytic subunit of PP2A, but the PP2A1 (trimeric ABC) was stimulated. Protamine could also stimulate the dimeric form of PP2A reconstituted with recombinant SV40 tumor small antigen (234). Protamine can stimulate or inhibit PP2A, depending on the substrate studied. Protamine stimulated and inhibited trimeric PP2A when myosin light chain or histone-1 were used as substrates, respectively (234). In constrast, heparin can stimulate trimeric PP2A independently of the substrate under study (234). The activation probably does not result from dissociation of trimeric PP (64). However, the subtype of B subunit is important. Heparin did not displace Ba/PR55a from the trimeric form (the main bovine brain isoform) but did displace Bb/PR55b. In both cases, the PP2A activity was enhanced. This implies that dissociation is not necessary for stimulation of phosphatase activity by heparin (234). Heparin, protamine, and polylysine are not present within the cytosol of mammalian cells. However, they may mimic the effect of an endogenous activator. Arachidonic acid inhibits PP1 but activates PP2A (159) and PP5 (57). IV. METHODOLOGICAL CONSIDERATIONS The vast majority of studies cited below, which address the role of protein phosphatases in the regulation of ion channels, make use of phosphatase inhibitors in more or less intact biological systems, i.e., cells, tissue slices, isolated organs, or channels in isolated membrane patches or bilayers. It is important to point out the limitations of those results for a proper assessment of the present state of knowledge. A number of caveats apply to the above-mentioned approach, and these will be briefly outlined in this chapter. Table 6 compiles a selection of frequently used phosphatase inhibitors, together with their subtype selectivity as known from the cited biochemical studies. It may serve as a guideline for choosing the appropriate tools to investigate selected phosphatases, but “cookbook” advice is strongly discouraged. The so-called selectivity (i.e., difference between inhibition constants against various molecular targets) applies to the comparison between phosphatase isoforms. Effects on other proteins may have to be taken into account. For example, fluoride ions (forming aluminum fluoridate in the absence of chelators in any physiological solution) are known to affect G proteins, and orthovanadate is a wellknown inhibitor of Na1-K1-ATPase. Such risk may be reduced when using high-affinity agents such as the microcystins or okadaic acid derivatives, but not all potential candidates (protein kinases, nucleotide-binding pro-

186


TABLE

Volume 80

6. Biochemical inhibition constants of phosphatase inhibitors PP1

PP2A

Okadaic acid Microcystin LR

270 0.04–1

2 0.04–1

Calyculin A Cantharidin

1–14 500

1–14 40

Nodularin Tautomycin

1.6 0.2–0.7, 4

0.03 0.4, 0.7, 34

Ciclosporin Cypermethrin Apomorphine Fostriecin

100

Heparin Thyrsiferyl acetate I1 PP1 I1 PP2A I2 PP1 I2 PP2A DARPP-32

PP2B

PP2C

3600

NI: 10,000

NI: 30,000 8,700 100,000

NI: 1,000,000 NI NI

PP3

5 0.3

PP4

PP5

0.2 0.008

1.4–10 15

PP6

2 2

PP7

Reference No.

NI: 1,000 NI: 100

35, 44, 58, 208, 303 58, 200, 208, 298, 303 146, 208, 225 200, 208, 282, 330

NI: 100 NI: 20,000

201 146, 296, 401 342 118 238 356, 431

1 1,000 130–4,000 ;10 mg/ml 4,000 1–5 NI 3–7 NI 1–2

3–40

NI: 10,000

NI NI: 1,000,000 21,000 4

NI: 1,000,000

NI: 1,000,000

NI

NI

4–8 NI

NI

NI

153 307 119, 139, 206, 207 278 139, 206, 207, 341 277, 278 96, 178

NI, no inhibition of phosphatase activity (at the concentration indicated); empty space, not measured; numbers, IC50 values in nM.

teins, ATPases, or unknown) for unspecific action have been thoroughly studied. A way to minimize this problem would be to undertake the appropriate control experiments. Several examples can be given. It is reasonable to use a second or third compound from a different chemical class, but with a similar selectivity profile, as a positive control, e.g., results with OA suggesting a role for PP2A can be substantiated using cantharidin or protein inhibitors of PP2A if possible. Data with CyA can be complemented with nanomolar OA (PP2A), or with PP1 inhibitor 2. Protein preparations of inhibitor 2 of PP1 should still be active after heat inactivation of possible contaminants. PP2B inhibition can be achieved with ciclosporin, and PP2B activity should be negligible when intracellular Ca21 is strongly buffered with EGTA or 1,2-bis(2-aminophenoxy)ethaneN,N,N9,N9-tetraacetic acid (BAPTA). Negative controls are possible if inactive derivatives are available, as with OA (i.e., norokadaone, okadaic acid methyl ester). Studies with peptide inhibitors should be accompanied by inactive peptides of the same physicochemical properties, e.g., by using a scrambled sequence. A second point of concern relates to the comparison between biochemical inhibition constants and functional effects and their concentration dependency. First, little is known about the extent and time course of intracellular accumulation of those compounds that penetrate cell membranes. There may be considerable differences among drugs (see, for example, Ref. 128). Even if the cellular content would be known, the free concentration might be much lower than expected due to accumulation

in subcellular compartments or binding to membrane or to specific targets. Accordingly, biochemical inhibition constants are often far lower than concentrations necessary for functional effects (see, for example, Refs. 326, 327, 330). Another point is of importance here. When measuring the phosphorylation state of a protein or, even more indirectly, the activity of an ion channel, a steady state is observed, which may vastly differ from the (pseudo)equilibrium conditions of an enzyme activity assay. The fraction of phosphoprotein here is a result of the balance between underlying protein kinase and phosphatase activities, as illustrated by a simple model calculation. Assume a phosphoprotein phosphorylated at one site by one protein kinase, and dephosphorylated by one or two different protein phosphatases. The steady-state phosphoprotein level PrP (fraction of 1) is then defined by the law of mass action as

PrP 5

1 @~K 1 3 PP1 1 K 2 3 PP2!/PK# 1 1

(1)

where PP1 and PP2 are the total activity of two phosphatases, PK is the total kinase activity (all used in arbitrary units), and K1 and K2 are the remaining fractions of phosphatase activity in the presence of a selective inhibitor I, also following simple mass action

K1 5 1 2

I K D1 1 I

(2)

January 2000


187

FIG. 1. Model calculation (Eqs. 1 and 2) for effect of a protein phosphatase (PPase) inhibitor on phosphoprotein level. A and B: 1-kinase, 1-phosphatase model. C and D: 1-kinase, 2-phosphatase model (see text). Note difference between inhibition constants of model (log 0, and 3) and fits (arrows).

where KD1 is the true inhibition constant of PP1 against I (and analogous for KD2 and PP2). A quantitative problem arises even in the simple case where only one phosphatase is involved (PP2 5 0) (see Fig. 1, A and B). Data were calculated (thin, noisy lines) and fitted (solid lines, using 1- or 2-site models of a Langmuir isotherm, Eq. 2). KD1 was 1 nM (log 5 0), and the kinase activity was always set to PK 5 1. The difference between the calculations in Figure 1, A and B, resides in the counteracting phosphatase activity (A: PP1 5 0.5, B: PP1 5 10). In both cases, the apparent half-inhibitory concentration (arrow) is higher than predicted (log 5 0). This shift amounts to more than 10-fold in case B. The apparent inhibitory concentration approximates the true value I when PK .. PP1. However, then phosphoprotein levels at baseline are close to 1, and a phosphatase inhibitor would have nearly no absolute effect. The problem is even more serious if a subtype-selective inhibitor is used to assess the relative proportion of two different phosphatases in dephosphorylating a common substrate. In Figure 1, C and D, a second phosphatase is included in the model, and a pronounced subtype selectivity was chosen (KD1 5 1 nM, log 5 0, and KD2 5 1 mM, log 5 3). The half-inhibitory constants are right-shifted as above, but the proportions of the two components also depend on the relationship between kinase activity and total phosphatase activity; PK was set 1, and PP1 and PP2 were equieffective (C: PP1 5 PP2 5 0.25, D: PP1 5 PP2 5 10). The fraction attributed to the more sensitive PP1 is seriously underestimated, especially in Figure 1D, where baseline PrP level is low. Thus, in cases where two phosphatases act in an intact cellular system, their relative contribution cannot be easily estimated from inhibitor experiments. These aspects can account in part for the

fact that functional inhibition constants are much higher than expected based on in vitro data (Table 6). Different phosphatases can operate sequentially under physiological conditions, e.g., PP2B dephosphorylates inhibitor 1 of PP1 (see sects. IIA2 and IIB3). To check whether a phosphatase acts at the channel itself, and not somewhere upstream a signaling pathway, measurements of channels in bilayers or inside-out patches are often performed. However, it has to be taken into consideration that endogenous enzymes may coexist (and even copurify) with the channels, as known not only for protein kinases (see Ref. 89), but also for PP2B (371). Examples suggesting close association between phosphatases and channels are given below. Another point of interest is that biochemical data (as in Table 6) usually relate to skeletal muscle phosphatase preparations, with model phosphoprotein substrates such as phosphorylase a (see above). It is not clear whether these inhibition constants depend on the substrate, although this problem refers more likely to the high-molecular-weight protein inihibitors with (allo) steric mechanisms of inhibition, rather than active-site inhibitors such as the microcystins or OA (see above). Tissue or species variations of inhibition constants for a given catalytic subunit have only scarcely been addressed but can profoundly hamper interpretation of data (186). It is therefore recommended, at least for results that are hard to interpret, to check the biochemical activity of a phosphatase inhibitor by purifying and using the same source of enzyme as present in the functional experiments. Finally, the effects of phosphatase inhibitors and interpretation of their concentration-response curve critically depend on proper preparation and storage of stock solution or choice of solvent (16). Rather than relying on manufacturers information, solutions should be checked

188


using a well-defined and robust assay, e.g., an isolated phosphatase enzyme assay. V. EFFECTS OF PHOSPHATASES ON ION CHANNEL ELECTROPHYSIOLOGY A. Voltage-Dependent Ca21 Channels 1. L-type Ca21 channels Similar to the paradigm of cAMP-dependent phosphorylation, cardiac L-type channels served as a classical model system to study regulation of voltage-dependent ion channels by protein phosphatases and their inhibitors. PP1 and PP2A reduced the isoproterenol-stimulated whole cell current in guinea pig myocytes (189). In rat heart cells (109), PP2A, but not PP1, reduced the current also under basal conditions. Inhibitor 2 of PP1 and OA at micromolar concentrations elevated baseline current density and potentiated the stimulatory response to isoproterenol in the guinea pig (189, 190). At the single-channel level, OA (5 mM) slowed channel rundown after patch excision (339). Wang et al. (435) measured cardiac channels in lipid bilayers. Here, OA (0.1 mM) dramatically increased channel activity, suggesting that endogenous phosphatases are still associated with the channels after reconstitution in the bilayer system. Neumann and coworkers (326, 327, 330) published a series of papers on the phosphatase inhibitors OA, CyA, and CA, respectively. All compounds increased single-channel activity and enhanced the phosphorylation of other, regulatory proteins like phospholamban, troponin inhibitor, and myosin light chains in myocytes. Contractile force of multicellular preparations was also increased. Notably, the concentrations eliciting these functional effects were consistently higher than those required for inhibition of cardiac phosphatases in vitro. Incomplete cellular penetration and the more complex situation of an intact phosphorylation-dephosphorylation system (see sect. IV) may account for this discrepancy. In expression systems using cardiac a1Csubunits, several investigators failed to detect significant PKA-mediated increase of the Ca21 current (344, 383, 470). On the other had, PP1 reduced the current (383) in the Xenopus model. Forskolin as well as OA elevated the currents when previously inhibited by the PKA inhibitor H-89 (344). Furthermore, prepulse-induced facilitation could be enhanced by PKA and by OA in some (51, 372, 373) but not all studies (236). Gao et al. (152) were the first to report robust cAMP-dependent modulation in an expression system. Their data suggest that for appropriate PKA-dependent stimulation and phosphorylation of a1C-subunits, the protein kinase has to be anchored in the membrane by proteins like AKAP 79, both in the expres-

Volume 80

sion system and in native cardiac cells. The results, including site-directed mutagenesis of Ser-1928 to abolish cAMP-dependent regulation, await confirmation by other groups. There is still no firm evidence that the cardiac a1C-subunit itself serves as the substrate for regulatory phosphorylation and dephosphorylation, although this has been shown directly for neuronal and skeletal muscle L-type channels (175, 461). Although L-type channels from heart are consistently stimulated by inhibitors of PP1 and PP2A (see above and Refs. 173, 253), the situation can be more complex. In intestinal smooth muscle cells, CyA was reported to stimulate (420) or depress (436) Ca21 currents, and the direction of the effects of OA differed between intracellular dialysis and bath application (270). Later, Obara and Yabu (335) noted a biphasic response of whole cell currents to increasing concentrations of both OA and CyA. They concluded that PP2A inhibition reduces and PP1 inhibition stimulates the channels in these cells. In vascular smooth muscle cells, OA antagonized the current reduction exerted by PKC inhibitors (336). When studied at the singlechannel level, preferential inhibition of PP1 using tautomycin (1–100 nM) led to a reduction in the channel availability, i.e., the probability that a voltage step will elicit channel openings and lead to an active sweep (163). On the other hand, preferential inhibition of PP2A (by 1 mM OA) increased open probability within active sweeps by promoting long openings (mode 2), and PP2A reduced open probability. Although these studies differ in the assignment regarding phosphatase subtype to function, they show that qualitatively different effects are mediated by PP2A and PP1 in smooth muscle L-type channels. This could indicate the presence of distinct regulatory phosphorylation sites with differential sensitivity toward phosphatases, as shown biochemically for skeletal muscle Ca21 channels (267). In rabbit heart, Ono and Fozzard (340) noted two types of effects of OA at the single L-type channel level. Here, both availability and open probability (open times) were raised as expected (see above), but in different concentration ranges of OA (availability being more sensitive, suggesting PP2A to be involved). Allen and Chapman (8) used BDM to assess the effect of dephosphorylation on single cardiac L-type channels. Open probability was reduced by the proposed “chemical phosphatase,” mainly due to lengthening of long closures. In addition, availability was reduced, and kinetic analysis of the slow gating process revealed that the oxime reduced the lifetime of the available state (as expected for increased dephosphorylation), but also increased the lifetime of the unavailable state. The use of BDM as a tool is complicated, however, because of nonspecific inhibitory effects unrelated to channel phosphorylation (9). Wiechen et al. (443) compared the effects of OA, its inactive derivative norokadaone, and CyA (1 mM each) on single

January 2000


channels in guinea pig cardiomyocytes. Availability was stimulated by OA and by CyA, and a more complex analysis of slow gating was compatible with a selective drug effect on the dephosphorylation rate. Okadaic acid, but not CyA, increased open probability, mode 2 gating, and prepulse-facilitated mode 2. They concluded that in these cells, like in vascular smooth muscle, PP2A controls open probability and modal gating, whereas PP1 governs availability (see also Ref. 187). In summary, several lines of evidence indicate differential modulation of L-type channels by PP1 and PP2A, although the exact single-channel mechanism may differ between species, tissues, and channel isoforms. Relatively little is known about the effects of PP2B on cardiac L-type channels, although this phosphatase is abundant in heart and capable of dephosphorylating various sarcolemmal substrates (301). Inhibition of PP2B by peptide inhibitors (140) or by ciclosporin (186) had little or no stimulatory effect, respectively. One has to consider, however, that whole cell studies are inherently associated with some level of intracellular Ca21 buffering, which may affect basal PP2B activity. Indeed, a liposomal preparation of PP2B was reported to affect action potentials in embryonic chick ventricle (417), but this effect has not yet been confirmed at the Ca21 current level. In GH3 cells, neuronal L-type channel inactivation was unaffected by ciclosporin and FK-506 (424), thus not supporting the “calcineurin hypothesis” (50) originally raised for neuronal Ca21 channels (see also Ref. 144). In smooth muscle cells, however, both PP2B and ciclosporin strongly affect channel activity, and PP2B seems to be one mediator of the inhibitory action of Ca21 on these channels by reducing open probability as well as availability (370). L-type Ca21 current in pinealocytes, carried by the a1D-pore subunit, is decreased by various protein phosphatase inhibitors (66). Conversely, secretory function of pancreatic b-cells can be enhanced by OA (11), but the moderate increase found for L-type currents can only partially explain this effect, possibly more at threshold potentials for current activation (171). Okadaic acid may even decrease Ca21 current (365) and insulin secretion in isolated islets (365) or RINm5f cells (12). Interestingly, activation of PP2B can mediate the inhibitory effects of somatostatin, galanin, and an a2-agonist on insulin secretion. This effect is independent of changes of the Ca21 current and can be blocked by deltamethrin and a PP2B inhibitory peptide, but not by OA. Modulation of protein phosphatase activity as a physiological mechanism of Ca21 channel regulation has been addressed in a number of studies. Herzig et al. (187) have analyzed by a discrete-time Markov analysis the slow gating process governing availability. The prolongation by isoproterenol (337) of the lifetime of the available state, thought to represent phosphorylated channels, can be

189

prevented by OA, supporting the concept that PKA stimulation can indirectly inhibit PP1 by phosphorylation of inhibitor 1 (329). A very similar model has been proposed for the regulation of neuronal L-type, but also N- and P-type, channels by D1 receptor-induced PKA activation with subsequent phosphorylation of DARPP-32 and inhibition of PP1 (397). Muscarinic receptor-mediated reduction of PKA-stimulated cardiac L-type currents, in addition to the well-known cAMP-dependent mechanism (188), may partly be due to phosphatase stimulation (186) in guinea pig ventricular myocytes, but not in frog heart cells (233). The proposed mechanism resembles the signal transduction cascade (Gi/o-induced PP2A stimulation) described below for some K1 channels (258, 442), but the details of possible intermediate steps are unknown. Inositol hexakisphosphate and related mediators have been proposed to serve as second messengers to increase Ca21 currents and insulin secretion via protein phosphatase inhibition (271). Finally, the peptide chromastatin lowers Ca21 entry, presumably through L-type channels, into chromaffin cells via PP2A stimulation (151), and an A2 adenosine receptor agonists exerts a similar effect via phosphatase stimulation (305). There may also be developmental changes of protein phosphatases, e.g., in the heart, where a decreased sensitivity of the adult versus newborn heart cells to various phosphatase inhibitors was found (157, 289). 2. Non-L-type Ca21 channels In central and peripheral neurons, whole cell Ca21 current represents a mixture of low- and high-voltageactivated currents. The latter can be dissected pharmacologically into L type (dihydropyridine sensitive, encoded by a1C- or a1D-subunits), N type (v-conotoxin GVIA sensitive, encoded by a1B-subunits), P or Q type (sensitive to v-agatoxin IVA or v-conotoxin MVIIC, respectively, encoded by a1A-subunits), and R type (toxin resistant, probably encoded by a1E-subunits). With the notable exception of two studies in sympathetic neurons (42, 440), addition of phosphatase inhibitors led to an increase in neuronal Ca21 channel amplitude and/or a reduced extent of inactivation. Dolphin (106) demonstrated that cAMPdependent stimulation of currents in rat dorsal root ganglia is mimicked by an active fragment of inhibitor 1 of PP1, suggesting that endogenous PP1 dephosphorylates a regulatory PKA site. Unfortunately, many studies employed OA in concentrations too high to discriminate between PP1 and PP2A inhibition. This holds true for snail neurons, where a PKC-mediated stimulation of currents by serotonin was amplified by 500 nM OA (191), and, in another study, the rate of inactivation was reduced by dialysis with either 50 mM OA or a peptide inhibitor of CaM kinase II (451). Both kinases were apparently not

190


involved in the action of the muscarinic agonist carbachol (156), as intracellular injection of OA and of microcystinLR, but not bath application of 50 mM ciclosporin, mimicked and occluded the stimulation exerted by carbachol. In a mammalian neuronal cell line, OA (100 nM) prevented part of the inhibitory action of a dopamine D2 agonist on N-type currents (45). This part (the late or sustained component) of inhibiton was not voltage dependent and likely reflects regulation of a PKA site, whereas the okadaic acid-insensitive part (on the rate of activation) represents voltage-dependent regulation by direct G protein interaction of the channels. Synaptosomes from rat hippocampus were studied with fura 2 Ca21 imaging (23). Here, preincubation with 100 nM OA markedly potentiated the stimulation by a PKC activator, suggesting a strong basal PP1 and/or PP2A activity in this system. In cultured rat cortical neurons, Thomas et al. (411) demonstrated that postsynaptic excitatory currents are increased in amplitude by 1 mM CyA (in the bath) or microcystin (10 mM in the pipette). This effect was not mimicked by PP2B inhibitors (10 mM ciclosporin or 2 mM FK-506). These compounds had been shown earlier by the same group (425) to increase the frequency but not amplitude of postsynaptic currents, which seems to indicate a presynaptic mechanism involving PP2B. There is strong evidence for a role of PP2B in the control of neuronal Ca21 channels. Immunoreactivity of this phosphatase is colocalized with Ca21 channel b-subunits in dorsal root ganglia (291). PP2B interferes with G protein inhibition of N-type channels in sympathetic neurons (467), where the response to a2-adrenergic or somatostatin receptor stimulation is inhibited by an autoinhibitory PP2B fragment or by ciclosporin, but not by OA. High-voltage-activated currents in lactotrophs from rat pituitary were stimulated by PKC activation, and ciclosporin mimicked this effect in the absence of a PKC inhibitor (137). In rat cortical synaptosomes, ciclosporin and FK-506 increased Ca21 influx and glutamate release (374), in line with the electrophysiological results of Victor et al. (425). In the NG 108 –15 cell line, overexpression of PP2B reduced N-type currents, and this reduction could be overcome by FK-506 (292). Calcium-dependent dephosphorylation of neuronal channels may also be involved in several other studies using OA (59, 256, 315, 466), where channel stimulation was mimicked by calmodulin antagonists or impeded by Ca21, respectively. Because the OA concentrations used here were in the micromolar range, it is impossible to tell whether a PP2B has been nonselectively inhibited here by the toxin or whether PP1 was involved indirectly (e.g., through PP2B-mediated dephosphorylation of endogenous PP1 inhibitors). In summary, both PP1/2A and PP2B mechanisms control neuronal high-voltage-activated Ca21 currents. In most cases, current is raised directly or made resistant

Volume 80

against inhibitory modulation by inhibition of these phosphatases. The work reviewed, however, does not sufficiently address the exact molecular substrate for phosphorylation. Given the prominent role for N-type and P/Q-type channels in neurotransmitter release, it is important to further investigate this question in reductionistic systems (single-channel recording, reconstituted channels, and expression systems allowing for site-directed mutagenesis and biochemical measurements). B. Voltage-Dependent Na1 Channels Voltage-dependent Na1 channels are phosphorylated by PKA and PKC. The functional consequences seem to be different among the respective channel subtypes from brain, heart, and skeletal mucle (26, 347, 385). The role of protein phosphatases has been studied in more detail for rat brain Na1 channels. Here, PP2B and PP2A are active, but with different selectivities for the various serine residues phosphorylated by PKA (321). These results are in line with the presence of five different soluble Na1 channel dephosphorylating enzymes in rat brain, which have been pharmacologically and immunologically identified as either 2A-like or 2B-like (62). There may be an exception in striatal neurons, where Na1 currents are reduced by the PP1-specific inhibitor phosphorylated DARPP-32 (366). Interestingly, a convergence of PKC- and PKAmediated phosphorylation (280) of Na1 channels could be due to an inhibition of dephosphorylation of PKA sites by PP2A or PP2B in the presence of PKC (254). C. K1 Channels 1. Inward rectifier K1 channels Inward rectifier channels may be activated or inhibited by phosphorylation, depending on the particular type and system under study. In nucleus basalis neurons, substance P leads to a PKC-mediated suppression of currents, an effect which can be potentiated and rendered irreversible by 100 nM OA (402). This suggests a dephosphorylation of the PKC site by PP2A or PP1. In the pituitary GH3 cell line, thyrotropin inhibits inward rectifiers by a Ca21-dependent mechanism, and this effect can be reverted by the catalytic subunit of PP2A, but not of PP1 (21). The cardiac ventricular inward rectifier current is inhibited by stimulation of b-adrenergic stimulation, an effect mimicked by forskolin, cAMP derivatives, or the catalytic subunit of PKA (257). This inhibition can be reversed by muscarinic stimulation using acetylcholine. The muscarinic effect can be abolished by 1 mM OA, both at the whole cell level and in the single-channel configuration (258). Importantly,

January 2000


the effect of the phosphatase inhibitor was still obtained when channels were studied in the inside-out configuration [with guanosine 59-O-(3-thiotriphosphate) or Gia used to antagonize PKA-induced inhibition]. This suggests a pathway leading from muscarinic receptors via pertussis toxin-sensitive G proteins to a protein phosphatase that is closely associated with the channel and dephosphorylates a PKA site. Unfortunately, the concentration of OA (1 mM) does not allow one to conclude whether PP2A or PP1 is involved, but the authors checked the phosphatase specificity of their approach using the inactive derivative norokadaone. b-Adrenergic regulation is very different for the cardiac acetylcholine-gated K1 channel, which also shows some extent of inward rectification. Here, the directly G protein-mediated activation due to muscarinic receptors is inhibited by b-adrenergic stimulation or PKA (239), suggesting that the phosphorylated channel has a lower open-state probability. Alkaline phosphatase reverts this effect. Dephosphorylation also seems to account for spontaneous desensitization of the activated native (241) and recombinant (GIRK1/GIRK4 heteromultimeric) channels (244). The endogenously present phosphatase seems to be located in the cytosol (241), requires Ca21, and is inhibited by 3 mM orthovanadate, but not by OA (241). This is somewhat puzzling because PP2B would be a good candidate for Ca21-dependent dephosphorylation, but this enzyme is relatively insensitive to orthovanadate (375). In guard cells from plants, a PP2B is likely responsible for dephosphorylation and inhibition of inward rectifiers (290). In contrast, dephosphorylation (of a site phosphorylated by unknown kinases) and inhibition of inward rectifier currents in guinea pig chromaffin cells is probably catalyzed by PP2A or PP1, because the effect is blocked by micromolar CyA or OA concentrations (223, 224). Rundown of recombinant Kir 2.1 channels is also prevented by inhibition of PP2A and PP1 by microcystin, but this effect is linked to a PKA site in the Xenopus expression system used (361). In view of the functional and structural diversity of inward rectifiers, it is not astonishing that a common pattern of phosphorylation- or dephosphorylation-linked events does not emerge from the literature. 2. Transient outward K1 channels Only a few studies have addressed the role of dephosphorylation with respect to transient outward currents. Recombinant neuronal channels have been postulated (196) to be dephosphorylated by PP2B, which resulted in reduction of currents. As shown in a later study, the rate of inactivation was markedly accelerated by PP2B and slowed by calmodulin kinase II (358). In rat heart, BDM was used to infer a role of phosphatases in the control of

191

cardiac transient outward currents. Indeed, the BDMinduced reduction of current was reversed by cAMPdependent stimulation (448), but a nonspecific effect of BDM was not excluded, and the subtype of the putative endogenous phosphatase is not known. FK-506 reduced Ito in rat cardiomyocytes, but this effect appears unrelated to PP2B inhibition (108). In pituitary GH4C1 cells, a subpopulation of slowly inactivating channels was characterized at the single-channel level, which was depressed by a membrane-permeant cAMP derivative. Recovery was observed after somatostatin (72), which stimulates Ca21dependent K1 channels in these cells via PP2A activation (442), but it remains to be elucidated whether this mechanism is also involved in the control of transient inward currents. 3. Delayed rectifier K1 channels In the classical studies on cardiac Ca21 currents, Hescheler and co-workers (189, 190) also noted some role of phosphatases on the cardiac delayed rectifier current, iK. Although OA (5 mM, bath applied) amplified the increase of this current after isoproterenol (190), cell dialysis with PP1 by itself did not affect the current but prevented isoproterenol-induced stimulation (189). In frog cardiac myocytes, intracellular dialysis with micromolar OA or microcystin concentrations reduced a slowly activating delayed rectifier current (140), an effect opposite to that of isoproterenol and similar to that of ATP depletion. The authors concluded that delayed rectifier currents are regulated by at least two phosphorylation sites, one which has to be phosphorylated for channel activity, and another that mediates inhibition by phosphatase inhibitors. The apparent discrepancy between the studies may be due to species differences or to the heterogeneity of iK (362). Unfortunately, none of these experiments reveals which phosphatase subtype mediates channel dephosphorylation under physiological conditions. Duchatelle-Gourdon et al. (110) suggested a role of a Mg21-stimulated (i.e., PP2C) phosphatase to revert catecholamine stimulation of cardiac delayed rectifiers, but direct biochemical or pharmacological evidence was not given. Regrettably, no specific tools are available to inhibit PP2C. In an attempt to characterize phosphatase regulation of an expressed delayed rectifier potasssium channel, Lopatin and Nichols (288) studied effects of BDM on Kv2.1 channels expressed in Xenopus oocytes. Unfortunately, they found reversible inhibition by the drug, regardless of the phosphorylation conditions, and had to conclude that direct block rather than chemical phosphatase activity was the most likely mechanism. Kang et al. (237) investigated in detail the mechanism of angiotensin II-induced increase in delayed rectifier current of rat hy-

192


pothalamic neurons. This effect was pertussis toxin sensitive and inhibited by nanomolar OA. Involvement of PP2A was further substantiated by the effect of antibodies directed against PP2A, which blocked the angiotensin II effect. This is yet another example of a signaling chain leading from receptors via PTX-sensitive G proteins to PP2A (212). 4. ATP-dependent K1 channels In rabbit heart cells, ATP-dependent K1 currents are modulated by PKC phosphorylation (284, 285). This effect is stabilized by nanomolar OA and reverted or prevented by addition of PP2A to inside-out patches. This finding suggests that the PKC site involved is dephosphorylated by a PP2A located in close vicinity of the channel. The direction of PKC effects apparently depends on the ambient ATP concentration. At low ATP, where channels are basally active, PKC inhibits the current, whereas at higher ATP, where channels usually are silent, PKC activates the current. This is consistent with a less steep ATP concentration dependence of phosphorylated channels (284). These data (at low ATP concentrations) are somewhat in contrast to those of Kwak et al. (263) obtained in rat cardiomyocytes. They demonstrated that 100 nM OA slowed spontaneous rundown of channel activity, whereas orthovanadate accelerated the decrease in current observed in inside-out patches in the absence of ATP. The opposite effects were exerted by PP2A and a tyrosine phosphatase, and exact nature of the serine/threonine kinase involved was not investigated. In the absence of PKC activity, a PKA site might thus be responsible for long-term stability of channel activity. Along similar lines, in smooth muscle cells of the gallbladder, glibenclamidesensitive currents are enhanced by PKA activation, and this effect is stabilized by 5 mM OA (457). In this preparation, an increase of channel activity (under physiological conditions) is caused by PKA phosphorylation, and the dephosphorylation may be catalyzed by PP2A or PP1. In renal tubule cells, the ATP-dependent K1 currents run down after excision of the patches in low-ATP solution. Rundown is blocked by Mg21 withdrawal, orthovanadate, and 1 mM OA (260). Because PP2A, but not Ca21, PP1, or PP2B reduced channel activity, the authors concluded that rundown is caused by a membrane-associated PP2A. Interestingly, McNicholas et al. (310), using the ROMK1 (195) channel expressed in Xenopus oocytes, reproduced the prevention of rundown by Mg21 withdrawal and orthovanadate, but 1 mM OA or CyA was not equally effective in their hands. They concluded that rundown is mediated by a Mg21-dependent dephosphorylation (by PP2C?) of a PKA site. However, it seems conceivable that the differences between their results and those of Kubokawa et al. (260) are due to lack of a native channel-

Volume 80

associated 2A phosphatase in the expression system. Alternatively, the rundown was so rapid (.50% in 30 s) that the time of exposure to the organic phosphatase inhibitor may have been insufficient for steady-state effects. The interpretation of the orthovanadate effects is certainly even more difficult, due to the indiscriminate character of its effects (for instance, inhibition of protein kinases, Na1-K1-ATPases, or tyrosine phosphatases; Ref. 263). 5. Ca21-activated K1 channels There are a considerable number of studies on dephosphorylation of Ca21-activated K1 channels, probably due to their vast abundance and important physiological role for regulation of the activity of neuronal, endocrine, and smooth muscle function. No unifying picture can be drawn based on this information. This is not so much related to the gross structural heterogeneity of these channels, classically signified by their conductance (small-conductance SKCa channels, intermediate-conductance IKCa channels, and large-conductance, “maxi” or “big” BKCa channels). Rather, the latter group of BKCa channels has been examined in the majority of studies, with results differing between tissues or cell types, protein kinases, and phosphatase subtypes. This may of course be related to the respective regulatory scenario of the cell and/or the particular channel isoform (one of the many possible splice variants), but this idea has yet to be confirmed at the level of an in vitro expression system. Up to now, most experiments have been done with native channels, and kinase regulation is not easily reconstituted in channel expression systems (464). As a starting point, the study of Reinhart et al. (352) is worthwhile of detailed consideration. They found that BKCa channels prepared from rat brain and reconstituted in lipid bilayers showed two different biophysical and regulatory phenotypes: so-called type 1 channels (fast gating, high sensitivity to charybdotoxin, activated by low Ca21) are stimulated by PKA in the majority of cases, and this effect was reversed by PP2A, but not by PP1. Type 2 channels (slower open and closed times, less sensitve to charybdotoxin and Ca21) are downregulated by PKA, an effect also specifically reverted by PP2A. The same group (73) showed that these type 2 channels can also be stimulated by phosphorylation, mediated by an endogenous kinase present in the bilayer system, because Mg21 plus ATP and adenosine 59-O-(3-thiotriphosphate) were sufficient to cause stimulation. This ATP effect could be reverted by PP1 (10 – 40 nM), but not PP2A (60 nM), also suggesting a different site involved compared with the site that mediates suppression of channel activity. In another study, exogenous PKC could mimic and thiophosphorylated inhibitor 1 of PP1 could stabilize this type of upregulation (353). The conclusions from these systematic ex-

January 2000


periments are manyfold. 1) Within the same experimental system, different channel subtypes reveal qualitatively distinct responses (stimulation vs. inhibition of type 1 vs. type 2 channels by PKA). 2) The same type (here, the so-called type 2 BKCa channels) is bidirectionally modulated by PKA and PKC, and 3) the backward reactions are also catalyzed in a phosphatase subtype-specific manner (PP2A vs. PP1). Finally, both kinases and phosphatases must exist in close association with the channel molecule, because their influences are still present after channel reconstitution in the bilayer. Based on kinetic studies of BKCa channels in excised patches from the pituitary, Bielefeldt and Jackson (36) argued that a kinase (involved here in maintaining channel activity) is in very close asssociation with the channel (“intramolecular model”), more so than the corresponding phosphatase (diffusionlimited “intermolecular model”). It is therefore tempting to speculate that slow, spontaneous oscillations in the open probability of BKCa channels, already described by Reinhart et al. (352), and termed “Wanderlust” kinetics by Silberberg et al. (382) may reflect phosphorylation-dephosphorylation reactions catalyzed by endogenous, channel-associated enzymes. In the papers mentioned subsequently, dephosphorylation of Ca21-activated K1 channels (or associated regulatory proteins) leads to an increase in activity. In the rat pituitary tumor cell line GH4C1, Armstrong’s group (441) showed that atrial natriuretic peptide stimulates BKCa channels through an elevation of cGMP, stimulation of cGMP-dependent protein kinase (PKG), and activation of a phosphatase sensitive to 10 nM OA (PP2A). This final mechanism resembles, but the initial cascade differs from the effect of somatostatin in the same cells (442). Somatostatin does not induce a rise in cGMP, and it requires a pertussis toxin-sensitive G protein, but ultimately also leads to a channel stimulation inhibited by OA. Later studies provided evidence that the signaling cascade initiated by the activation of somatostatin receptor leads to accumulation of lipoxygenase metabolites of arachidonic acid (111). A biochemical link between eicosanoids and the activation of PP2A (159) has already been mentioned, and stimulation of this phosphatase may be of broader physiological importance. Zhou et al. (463) demonstrated that BKCa channels from bovine tracheal smooth muscle are stimulated by PP2A in excised patches and that an indirect stimulation exerted by an active fragment of PKG is blocked by the appropriate concentrations of phosphatase inhibitors. Interestingly, a similar type of regulation was shown in the same paper for intermediate-conductance KCa channels in Chinese hamster ovary cells expressing recombinant PKG Ia. In both cases, PP1 was ineffective at equimolar concentrations (350–700 nM), and PP2A was detected in the membranes by Western blot analysis. Activation of PKG, PP2A, and finally BKCa channels was again proposed as the common pathway of cGMP-dependent regulation in these

193

systems. Similar mechanisms may operate in some neurons. In hippocampal neurons, secreted b-amyloid precursor protein causes hyperpolarization via BKCa channels (148). The authors proposed that cGMP, PKG, and a protein phosphatase (sensitive to 10 nM OA) are involved. BKCa channels in a clonal pituitary cell line have similar sensitivity toward OA. Interestingly, PP2A regulation here seems to get targeted to the channel by glucocorticoid treatment (412). Holm et al. (197) investigated BKCa channels at the whole cell level in mouse cortical neurons. Neurotrophin-3 and nerve growth factor activated the current, and this effect was blocked by 30 nM OA, which leaves some uncertainty about the phosphatase subtype involved. The nature of the upstream mechanisms also remained somewhat unclear but likely involved a tyrosine kinase and a phospholipase C. In summary, stimulation of BKCa channels by dephosphorylation through PP2A seems to be a common mechanism to reduce cellular excitability, present in various tissues and initiated by a number of signaling cascades, most notably by cGMP and PKG. On the other hand, protein dephosphorylation may also reduce BKCa channel activity, as already mentioned above. A number of such examples come from studies in above smooth muscle cells. Archer et al. (14), using rat pulmonary artery, showed that nitric oxide increased whole cell BKCa currents. Based on pharmacological evidence (inhibition by methylene blue, mimicking by Spguanosine 39,59-cyclic monophosphothioate and by 2 mM OA), they proposed that this effect is mediated by phosphorylation of the channels. Along similar lines, Stockand and Sansom (389) and Sansom et al. (363) described a cGMP-dependent stimulation of BKCa channels from human mesangial smooth muscle cells (see Ref. 390 for review). The effect was exerted by PKG and by cellpermeant cGMP derivatives. The activation was biphasic, and the second declining phase of activity was abolished by low concentrations of OA and cantharidin, but not by CyA. Conversely, PP2A but not PP1 inhibited channel activity in excised patches. These results are most easily explained by a PKG site that must be phosphorylated to support channel activity. This site also seems to be specifically dephosphorylated by PP2A. Note that arachidonic acid activates BKCa channels in this system, but in a manner independent of phosphorylation (391). Phosphorylation and stimulation by PKA and cAMP derivatives have been addressed by Schubert et al. (369) in myocytes from rat tail artery. Astonishingly, the presence of 1 mM OA in the whole cell pipette did not modify the response to iloprost, a prostacyclin analog shown to act via PKA activation. It is feasible that longer incubation times or larger pipette diameters would have been required to achieve sufficient intracellular dialysis of the phosphatase inhibitor. In gastrointestinal smooth muscle cells, phosphatase inhibitors led to an increase in channel activity

194


(47, 272). These effects were observed in excised patches (47), where PKA also had stimulatory effects. The phosphatase subtype could not be identified unequivocally, since CyA appeared to have a lower potency and/or efficacy than OA. In neuroendocrine and neuronal cells, there are some examples (36, 228, 274) of BKCa channel stimulation by phosphorylation and inhibition by phosphatases, but in none of these studies have the respective enzyme isoforms been precisely identified. FK-506 increases single-channel activity in cultured hippocampal neurons, but again (see sect. VC2), this effect is unrelated to PP2B inhibition (409). In collecting duct cells of the rat nephron (194), both small- and intermediate-conductance KCa channels are activated by phosphorylation, evidently via PKG. The phosphatase inhibitors CyA (10 nM) and OA (1 mM) were tested and effective at concentrations that do not firmly discriminate between PP2A and PP1. In summary, native Ca21-activated K1 channels, notably BKCa channels, display a variety of regulatory pathways, including phosphorylation by PKG and PKA and dephosphorylation by PP2A and PP1. These enzymes are, both functionally and anatomically, in tight association with the channels, and a number of physiologically important regulatory mechanisms converge at this target. However, it is desirable to address the diversity of the responses in various systems at the molecular level. In particular, information about the particular sites of phosphorylation would be required from future biochemical studies or from electrophysiological studies after sitedirected mutagenesis of the cloned channels. D. Ligand-Gated Cation Channels 1. N-methyl-D-aspartate receptor channels Glutamate receptors of the NMDA type are nonselective cation channels critical for neuronal excitability and particularly for Ca21-dependent modulation of synaptic plasticity. They are regulated by phosphorylation and dephosphorylation. Evidence for a more direct interaction between protein phosphatases and these channels can be derived from single-channel studies. In cultured hippocampal neurons, both exogenous PP1 and PP2A depressed open probability, and CyA and OA exerted opposing effects (434). Calyculin A (20 nM) also increased the whole cell current, with effects on kinetics depending on the glycine concentrations. In the mouse nucleus accumbens, DARPP-32 is essential for the dopamine-induced phosphorylation of a NMDA receptor subunit (131). These findings hint that endogenous PP1 or PP2A regulate channel phosphorylation, activity, and kinetics. There is ample literature, on the other hand, on NMDA receptor regulation by PP2B. Lieberman and Mody (283) tested the effect of 10 mM OA on single-channel currents

Volume 80

of neurons from dentate gyrus. The phosphatase inhibitor increased open times and open probability. These effects were mimicked by FK-506 but not by lower concentrations of OA. Stimulation of channels by phosphatase inhibition depended on Ca21 instead of Ba21 as the charge carrier. Calcineurin by itself had an inhibitory effect. At the whole cell level, inhibitors of both PP1/2A and PP2B prevented either long-term rundown (311) or short-term desensitization/inactivation (414) or had no effects at all on these phenomena (276, 359, 429). This leaves some uncertainty on the important question whether or under which conditions Ca21 entering through the channel are regulating the channel itself by activating Ca21-dependent phosphatases. This question may crucially depend on the type of neuron studied, since PP2B expression and PP2B inhibitor effects are both absent in hippocampal interneurons (381). Convincing data favoring the idea that PP2B mediates NMDA receptor desensitization were obtained by measurements of excitatory postsynaptic currents (EPSC) in hippocampal cell cultures. Here, desensitization of NMDA receptors was gauged by the change in EPSC amplitude after a train of repetitive agonist applications in the absence or presence of an NMDA receptor blocker. Strong Ca21 chelation as well as various PP2B inhibitors, but not CyA, completely abolished desensitization (415). The kinase involved in this system is a tonically active PKA, which can be modulated by b-adrenoceptor activation (349), providing a physiological pathway between noradrenergic input and synaptic strength at a glutamatergic synapse. Phosphatases may also participate in physiological long-term changes in NMDA receptor function such as long-term depression (447) or long-term potentiation (37), but the signaling pathway as well as the phosphatase subtype involved are not known. In summary, for a better understanding of the multitude of functional data, it would be important to define the susceptibility of the phosphorylation sites of the cloned NMDA receptor subunits toward protein phosphatases. 2. Other nonselective cation channels As described for NMDA and AMPA (446) receptors, various other ligand-gated cation currents are stimulated by phosphatase inhibitors. Examples include 5-HT3 receptors (38), capsaicin receptors (102), and P2x3 purine receptors (246), all of which apparently desensitize (i.e., current decreased in the continuous presence of agonist) via PP2B activity. In contrast, P4 purine receptors are less active in the presence of PP1/2A or PP2B inhibitors (345). Okadaic acid induced phosphorylation of the recombinant nicotinic acetylcholine receptor d-subunit, but the functional consequences have not yet been studied (255). Cyclic nucleotide-gated nonselective cation channels may be regulated by protein phosphatases, as demon-

January 2000


strated for the cGMP-gated channel in the retina (160). Here, an endogenous phosphatase seems to sensitize the channel toward cGMP, an effect mimicked by exogenous PP1 but counteracted by PP2A. The hyperpolarization-activated nonselective cation current if in heart tissues is regulated by (de)phosphorylation, as shown by an increase in current amplitude after application of CyA. In sinus node cells, this effect can be clearly discriminated from the well-known direct regulation by cAMP: here, the CyA response was not accompanied by a shift in the activation curve along the voltage axis (1), although such a shift was reported earlier (455) for ventricular myocytes. A hyperpolarization-induced cation current in peripheral neurons, which is also regulated by cAMP, does not respond to conditions altering protein kinase or phosphatase activity (221). Other nonselective cation currents have been reportedly stimulated by OA (43, 403), by microcystin-LR (445), or by low Mg21 and vanadate (222, 223), suggesting regulation by PP1/2A or, perhaps, PP2C, respectively. In summary, phosphorylation sites coupled to increased channel activity and agonist sensitivity apparently exist in a vast number of nonselective cation channels. Physiological regulation pathways involving the phosphatases encountered here remain to be resolved, except for the obvious role of Ca21-dependent PP2B activity in some cases. E. Anion Channels 1. Cystic fibrosis transmembrane conductance regulator channels The cystic fibrosis transmembrane conductance regulator (CFTR) gene encodes a cAMP-dependent Cl2 channel present in heart, epithelia, and other tissues. Its regulation has been recently reviewed in detail (150). The channel is activated by PKA and phosphorylated on at least nine different consensus sites (142, 149). However, other kinases like type II PKG (142) and certain PKC isoforms (30) have also been shown to phosphorylate and activate the channel. PP2A, but not PP1 or PP2B, inactivated and dephosphorylated the channel (30). Exogenous PP2A and PP2C exerted different kinetic effects on single CFTR channels expressed in baby hamster kidney cells (293). Even at nanomolar concentrations (350), OA accelerated activation (323) and slowed down or prevented inactivation when conditions were chosen to minimize de novo phosphorylation (216, 348). PP2B inhibitors increased CFTR currents when stably expressed in fibroblasts, but not the currents endogenous to two epithelial cell lines (135), suggesting that this mechanism has no physiological significance. A role of another phosphatase has early been postu-

195

lated by Hwang et al. (216); in the presence of high OA concentrations, only part of the cAMP-dependent current was preserved. A proposed candidate would be alkaline phosphatase, since blockers like levamisole, bromotetramisole (but see Ref. 269), or methylxanthines can activate CFTR currents (27–29, 219). Notably, an antibody against alkaline phosphatase increased channel activity (27), and the enzyme as well as its inhibitors affected 32P incorporation into CFTR protein (28). However, it has been argued that the effect of alkaline phosphatase was nonspecific, because channel activity was restored upon application of fresh ATP solution (30), and this enzyme should not have access to the phosphorylation sites in intact cells (150). Genistein, a known inhibitor of tyrosine kinases, stimulated CFTR currents (65, 141, 351, 452), and it increases the sensitivity of the channel toward PKA-dependent activation (204). The mechanism involved in these effects is controversial. Reduced tyrosine phosphorylation would be expected to increase PP2A activity (55). Indeed, genistein has been proposed to inhibit a phosphatase distinct from PP2A (65, 351), possibly PP2C (452). However, the results of French et al. (141) and Wang et al. (433) argue against a dephosphorylation mechanism (150). Importantly, the pattern of activation by CyA and genistein differs at the single-channel level (452), and the two compounds act in an additive manner (351). The report of Zhou et al. (462) demonstrates stimulation of cardiac CFTR currents by the Cl2 channel blocker anthracene-9-carboxylate via phosphatase inhibition. Their data suggest that yet another unknown phosphatase, pharmacologically distinct from PP2A, PP2C, or alkaline phosphatase, might be of some physiological importance for CFTR regulation. Of note, in addition to appropriate substrate specificity, intimate colocalization of phosphatases with their substrate may be an important determinant of physiological function (e.g., Refs. 27, 134). 2. GABAA receptor Cl2 channels GABAA channel currents are downregulated by PKA, and an endogenous PKA phosphorylates these channels (406). It is likely, however, that another protein kinase (e.g., tyrosine kinase, Ref. 211) is responsible for phosphorylation of a site associated with increased channel activity. Several groups have shown that Ca21 entering through activation of NMDA channels diminishes GABAA currents. A likely mechanism is Ca21-dependent activation of PP2B, since the pathway was blocked by nanomolar fenvalerate (211), cypermethrin (388), or delthametrin (10, 355), by calcineurin inhibitory peptide (60), and by Ca21 buffering with BAPTA (60, 317). The latter authors also found an effect of micromolar microcystin-LR or OA concentrations but could not exclude indirect mecha-

196


nisms (317). An additional pathway of such inhibitory cross-talk between NMDA receptors and GABAA channels may be the nitric oxide system (355). 3. Other Cl2 channels Okadaic acid has been shown to activate a variety of Cl channels, including a 50-pS channel from shark rectal gland epithelia (265), a Ca21-activated Cl2 channel from osteoclasts (147), and a PKA-activated channel from Necturus gallbladder epithelia (132, 133). In the latter case, low concentrations of OA were sufficient, and PP2A, but not PP1, had an opposite effect on channel activity after reconstitution in bilayers (133). On the contrary, Cl2 conductance in skeletal muscle was slightly diminished by 0.5 mM OA, and a stimulatory response to insulin-like growth factor I was blocked by the phosphatase inhibitor (90) and mimicked by a ceramide (91), suggesting a role of PP2A (see sect. IIIC2). In a renal cell line, the open probability and, remarkably, the single-channel conductance of an outwardly rectifying Cl2 channel were increased by insulin. These effects were mimicked by PP2B and by a tyrosine phosphatase, and they were blocked by ciclosporin, but not by OA. The authors (304) propose that insulin action in this case should be mediated by calmodulin-dependent activation of PP2B, which in turn would be able to dephosphorylate a regulatory tyrosine residue. An outwardly rectifying Cl2 channel from a human intestinal cell line is stimulated by calmodulin-dependent protein kinase II. This activation is spontaneously reverted by an OA- and microcystin-sensitive phosphatase. Interestingly, inositol 3,4,5,6-tetrakisphosphate exerted inhibitory effects, which depended on uninhibited phosphatase activity, but were not mediated directly by phosphatases, suggesting a complex regulatory scheme (450). A voltage-dependent Cl2 channel present in the same cells was increased in activity by low osmolarity. This regulation was abolished by OA (1 mM) or CyA (50 nM) (143). Hypotonicity induced a Cl2 current in chick cardiac myocytes under whole cell but not perforated-patch recording conditions (172). It became insensitive to osmotic challenge even under whole cell dialysis when intracellular cAMP was raised or endogenous phosphatases were blocked by 100 nM OA. Okadaic acid and 20 nM CyA also rendered expressed CLC-3 channels insensitive to hypotonicity (107). When a critical serine residue (position 51) was mutated to alanine, the channel was tonically active, not further stimulated by hypotonicity, and no longer inhibited by PKC stimulation (107). These results indicate a direct relationship between volume regulation by this Cl2 channel and its (de)phosphorylation. 2

Volume 80

VI. SUMMARY AND PERSPECTIVES As exemplified in the preceding sections, ion channel regulation by phosphatases takes place through numerous more or less complex pathways, as scetched in Figure 2. Some limitations of studies leading to this picture are obvious. If, for instance, 10 mM OA is applied in intact cells and an altered current through an ion channel is noted, this does not really prove direct modulation of the channel protein by phosphatase type 1 or 2. First, other phosphatases are also blocked by OA (see Table 6), and these might thus be involved (see Fig. 1). Moreover, it is conceivable that a protein kinase is stimulated, a kinase that is activated by phosphorylation, thus the effect of a change of kinase activity on channel function is actually measured. Thus a naive direct correlation of phosphatase inhibition and channel function by channel phosphorylation might lead to wrong conclusions. This indicates that an integrated approach based on biochemical, biophysical, and physiological methods will be important for progress in the field. Clearly, first all channels mentioned above as putatively regulated by phosphatases have to be identified unambiguously. As mentioned in section I, the efforts should continue to express cloned channel proteins in vitro to use highly controlled systems to study their biophysical function. This approach has its pitfalls. Crucial posttranslational modifications might be missed in the expression system. Expression systems possess their own signal transduction machinery, which may fail to work at the expressed target protein, or lead to regulatory effects that have no physiological significance. Because expression systems have become very popular, some of the very recent studies illustrate these problems. Ideally, the phosphorylation site of the channel protein should be identified by direct sequencing on the protein level. Here, the problem might arise that the physiological kinase is unknown. Hence, an unphysiological phosphorylation site might be identifed. Alternatively, putative phosphorylation sites can be identified from the predicted protein sequence. Then it would be possible to use site-directed mutagenesis to remove these phosphorylation sites and look whether the channel activity is now altered. One could also consider a biophysical approach. It would be possible to measure the protein-protein interaction of channels and phosphatases in bilayers. Ultimately, and possibly in the near future, a three-dimensional picture from cocrystallization of a channel and a phosphatase should yield clear-cut answers where they actually interact. However, the same interactions are likely but not necessarily realized in the intact cell. Information can be gained by dialysis or injection of phosphatases or antibodies into intact cells, studying alteration in channel activity. This approach has already

January 2000


197

FIG. 2. General scheme for multistep regulation of channel phosphorylation by phosphatases and protein kinases. Several steps of control or amplification are available in intact cells. Second messengers can directly activate a protein kinase or inhibit (directly or via stimulating an inhibitory protein in vicinity) phosphatase activity and thereby increase phosphorylation state of a channel. On the other hand, second messengers themselves, or acting through kinases, or additional regulatory proteins can modulate phosphatase activity, ultimately affecting phosphorylation state of a channel protein. Cross-talk of upstream regulatory events (see text) can severely hamper interpretation of electrophysiological data. Examples for regulatory networks of this kind are specified throughout cited literature.

been used in the past. This method can be complicated if the site of injection, or appropriate targeting, is crucial for the function of the protein. Moreover, sufficient amounts of the protein of interest might not be readily available. Alternatively, expression vectors, namely, adenovirus constructs, could be useful to transfer the channel or phosphatase of interest into cells. These versatile methods would be helpful to establish by mutational analysis which parts of phosphatases are actually crucial for their function. However, most phosphatases do not function alone but in concert with their regulatory or targeting protein. It might be important to cotransfect these auxiliary proteins to get meaningful results. Regrettably, in expression systems is it is difficult to control the amount of overexpressed protein. On the basis of transfection of isolated cells, there will be the development of trangenic mice that overexpress phosphatases, channels, regulators, and the combi-

nation thereof. Indeed, recently, PP1 (332) and PP2B (316) have been overexpressed. Both transgenic models show altered physiological function. Soon, data will become available whether channels are altered in these transgenic lines. In addition, several groups are currently working on knock-out mice for phosphatases or their regulators. Even here a word of caution is warranted. Some knockouts are likely to be lethal, for instance, of PP2Aa. Moreover, it is expected from precedence that overexpression and knockout leads to compensatory changes of other regulatory proteins (69). Hence, the results may be difficult to interpret. One possible route that will be used is the conditional, or tissue-specific, overexpression and knockout of phosphatases in animals. In addition to their importance in fostering our understanding of nature, research on phosphatases and their action on channels is likely to have additional benefits in medicine. There is a growing body of evidence that phos-

198


phatase are altered in, for example, cardiovascular disease. Pathological states like hypertrophy (40), cardiac failure (328), and postischemic contractile dysfunction (17, 209) have been accompanied by alterations in phosphorylation of proteins and/or phosphatase function (22, 169), including channel regulation by phosphatases (368). As mentioned above, overexpression of phosphatases can lead to cardiac hypertrophy, strengthening the connection (316, 332). In addition to these pathophysiological changes, phosphatases, in part by altering channel activity, can change the contractility of muscle (heart or vasculature, Refs. 250, 251, 286). Hence, phosphatases might be candidate targets for drug therapy (398; but see also Refs. 99, 312, 459). It is conceivable that some of the many functions regulated by phosphorylation in humans might be favorably altered by application of phosphatase activators and inhibitors or by directly altering cellular protein phosphatase expression, using gene therapy. Research of the authors on protein phosphatases and ion channels is supported by the Deutsche Forschungsgemeinschaft. Address for reprint requests and other correspondence: S. Herzig, Institut fu¨r Pharmakologie, Universita¨t Ko¨ln, Gleueler Strabe 24, D-50931 Ko¨ln, Germany (E-mail: [email protected]).

REFERENCES 1. ACILLI, E. A., G. REDAELLI, AND D. DIFRANCESCO. Differential control of the hyperpolarization-activated (if) current by cAMP gating and phosphatase inhibition in rabbit SA node myocytes. J. Physiol. (Lond.) 500: 643– 641, 1997. 2. ADACHI, Y., G. N. PAVLAKIS, AND T. D. COPELAND. Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia. FEBS Lett. 340: 231–235, 1994. 3. AGOSTINI, P., R. DERUS, S. SARNO, J. GORIS, AND W. MERLEVEDE. Specificity of the polycation-stimulated (type-2A) and ATP, Mg-dependent (type-1) protein phosphatases toward substrates phosphorylated by P34cdc2 kinase. Eur. J. Biochem. 205: 241–248, 1992. 4. AITKEN, A., T. BILHAM, AND P. COHEN. Complete primary structure of protein phosphatase inhibitor-1 from rabbit skeletal muscle. Eur. J. Biochem. 126: 235–246, 1982. 5. AITKEN, A., C. B. KLEE, AND P. COHEN. The structure of the B subunit of calcineurin. Eur. J. Biochem. 139: 663– 671, 1984. 6. ALBERTS, A. S., A. M. THORBURN, S. SHENOLIKAR, M. C. MUMBY, AND J. R. FERAMISCO. Regulation of cell cycle progression and nuclear affinity of the retinoblastoma protein by protein phosphatases. Proc. Natl. Acad. Sci. USA 90: 388 –392, 1993. 7. ALESSI, D. R., A. J. STREET, P. COHEN, AND P. T. W. COHEN. Inhibitor-2 functions like a chaperone to fold three expressed isoforms of mammalian protein phosphatase-1 into a conformation with the specificity and regulatory properties of the native enzyme. Eur. J. Biochem. 213: 1055–1066, 1993. 8. ALLEN, T. J., AND R. A. CHAPMAN. The effect of a chemical phosphatase on single calcium channels and the inactivation of whole-cell calcium current from isolated guinea-pig ventricular myocytes. Pflu¨gers Arch. 430: 68 – 80, 1995. 9. ALLEN, T. J., G. MIKALA, X. WU, AND A. C. DOLPHIN. Effects of 2,3-butanedione monoxime (BDM) on calcium channels expressed in Xenopus oocytes. J. Physiol. (Lond.) 508: 1–14, 1998.

Volume 80

10. AMICO, C., A. CUPELLO, C. FOSSATI, AND M. ROBELLO. Involvement of phosphatase activities in the run-down of GABAA receptor function in rat cerebellar granule cells in culture. Neuroscience 84: 529 –535, 1998. 11. A¨MMA¨LA¨, C., L. ELIASSON, K. BOKVIST, P. O. BERGGREN, R. E. HONKANEN, A. SJOHOLM, AND P. RORSMAN. Activation of protein kinases and inhibition of protein phosphatases play a central role in the regulation of exocytosis in mouse pancreatic beta cells. Proc. Natl. Acad. Sci. USA 91: 4343– 4347, 1994. 12. AMMON, H. P., R. O. HEURICH, H. A. KOLB, F. LANG, R. SCHAICH, G. DREWS, AND T. LEIERS. The phosphatase inhibitor okadaic acid blocks KCl-depolarization-induced rise of cytosolic calcium of rat insulinoma cells (RINm5F). Naunyn-Schmiedeberg’s Arch. Pharmacol. 354: 95–101, 1996. 13. ANNILA, A., J. LEHTIMA¨KI, K. MATILLA, J. E. ERIKSSON, K. SIVONEN, T. T. RANTALA, AND T. DRAKENBERG. Solution structure of nodularin. J. Biol. Chem. 271: 16695–16702, 1996. 14. ARCHER, S. L., J. M. HUANG, V. HAMPL, D. P. NELSON, P. J. SHULTZ, AND E. K. WEIR. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA 91: 7583–7587, 1994. 15. ARINO, J., C. W. WOON, D. L. BRAUTIGAN, T. B. MILLER, AND G. L. JOHNSON. Human liver phosphatase 2A: cDNA and amino acid sequences of two catalytic subunit isotypes. Proc. Natl. Acad. Sci. USA 85: 4252– 4256, 1988. 16. ARMSTRONG, D. L. Environmental toxins reveal ion channel regulation by protein phosphatases. Neuroreport 6: 62–71, 1995. 17. ARMSTRONG, S. C., D. B. HOOVER, M. H. DELACEY, AND C. E. GANOTE. Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes. J. Mol. Cell. Cardiol. 28: 1479 –1492, 1996. 18. BAGU, J. R., B. D. SYKES, M. M. CRAIG, AND C. F. HOLMES. A molecular basis for different interactions of marine toxins with protein phosphatase-1. Molecular models for bound motuporin, microcystin, okadaic acid, and calyculin A. J. Biol. Chem. 272: 5087–5097, 1997. 19. BAI, G., Z. ZHANG, J. AMIN, S. A. DEANS-ZIRATTU, AND E. Y. C. LEE. Molecular cloning of a cDNA for the catalytic subunit of rabbit muscle phosphorylase phosphatase. FASEB J. 2: 3010 –3016, 1988. 20. BARBER, S. A., G. DETORE, R. MCNALLY, AND S. N. VOGEL. Stimulation of the ceramide pathway partially mimics lipopolysaccharide-induced responses in murine peritoneal macrophages. J. Biol. Chem. 64: 3397–3400, 1996. 21. BARROS, F., G. MIESKES, D. DEL CAMINO, AND P. DE LA PENA. Protein phosphatase 2A reverses inhibition of inward rectifying K1 currents by thyrotropin-releasing hormone in GH3 pituitary cells. FEBS Lett. 336: 433– 439, 1993. 22. BARTEL, S., B. STEIN, T. ESCHENHAGEN, U. MENDE, J. NEUMANN, W. SCHMITZ, E. G. KRAUSE, P. KARCZEWSKI, AND H. SCHOLZ. Impaired phosphorylation of phospholamban, troponin I and C-protein in the failing human heart. Mol. Cell. Biochem. 157: 171–179, 1996. 23. BARTSCHAT, D. K., AND T. E. RHODES. Protein kinase C modulates calcium channels in isolated presynaptic nerve terminals of rat hippocampus. J. Neurochem. 64: 2064 –2072, 1995. 24. BASTIANS, H., AND H. PONSTINGL. The novel human serine/threonine phosphatase 6 is a functional homologue of budding yeast Sit4P and fission yeast ppe1, which are involved in cell cycle regulation. J. Cell Sci. 109: 2865–2874, 1996. 25. BAXTER, G. D., AND M. F. LAVIN. Specific protein dephosphorylation in apoptosis induced by ionizing radiation and heat shock in human lymphoid tumor lines. J. Immunol. 148: 1949 –1954, 1996. 26. BENDAHHOU, S., T. R. CUMMINS, J. F. POTTS, J. TONG, AND W. S. AGNEW. Serine-1321-independent regulation of the m1 adult skeletal muscle Na1 channel by protein kinase C. Proc. Natl. Acad. Sci. USA 92: 12003–12007, 1995. 27. BECQ, F., M. FANJUL, M. MERTEN, C. FIGARELLA, E. HOLLANDE, AND M. GOLA. Possible regulation of CFTR-chloride chan-

January 2000

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.


nels by membrane-bound phosphatases in pancreatic duct cells. FEBS Lett. 327: 337–342, 1993. BECQ, F., T. J. JENSEN, X. B. CHANG, A. SAVOIA, J. M. ROMMENS, L. C. TSUI, M. BUCHWALD, J. R. RIORDAN, AND J. W. HANRAHAN. Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc. Natl. Acad. Sci. USA 91: 9160 –9164, 1994. BECQ, F., B. VERRIER, X. B. CHANG, J. R. RIORDAN, AND J. W. HANRAHAN. cAMP- and Ca21-independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs. J. Biol. Chem. 271: 16171–16179, 1996. BERGER, H. A., S. M. TRAVIS, AND M. J. WELSH. Regulation of the cystic fibrosis transmembrane conductance regulator Cl2 channel by specific protein kinases and protein phosphatases. J. Biol. Chem. 268: 2037–2047, 1993. BERNDT, N., D. G. CAMPBELL, F. B. CAUDWELL, P. COHEN, E. F. DA CRUZ E SILVA, O. B. DA CRUZ E SILVA, AND P. T. W. COHEN. Isolation and sequence analysis of a cDNA clone encoding a type-1 protein phosphatase catalytic subunit: homology with protein phosphatase 2A. FEBS Lett. 223: 340 –346, 1987. BEULLENS, M., W. STALMANS, AND M. BOLLEN. Characterization of a ribosomal inhibitory polypeptide of protein phosphatase-1 from rat liver. Eur. J. Biochem. 239: 183–189, 1996. BEULLENS, M., A. VAN EYNDE, W. STALMANS, AND M. BOLLEN. The isolation of novel inhibitory polypeptides of protein phosphatase 1 from bovine thymus nuclei. J. Biol. Chem. 267: 16538 –16544, 1992. ¨ EGG, AND A. TAKAI. Effects of okadaic acid BIALOJAN, C., J. C. RU on isometric tension and myosin phosphorylation of chemically skinned guinea-pig taenia coli. J. Physiol. (Lond.) 398: 81–95, 1988. BIALOJAN, C., AND A. TAKAI. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem. J. 256: 283–90, 1988. BIELEFELDT, K., AND M. B. JACKSON. Intramolecular and intermolecular enzymatic modulation of ion channels in excised membrane patches. Biophys. J. 66: 1904 –1914, 1994. BLITZER, R. D., T. WONG, R. NOURANIFAR, R. IYENGAR, AND E. M. LANDAU. Postsynaptic cAMP pathway gates early LTP in hippocampal CA1 region. Neuron 15: 1403–1414, 1995. BODDEKE, H. W., I. MEIGEL, P. BOEIJINGA, J. ARBUCKLE, AND R. J. DOCHERTY. Modulation by calcineurin of 5-HT3 receptor function in NG108 –15 neuroblastoma 3 glioma cells. Br. J. Pharmacol. 118: 1836 –1840, 1996. BOE, R., B. T. GJERTSEN, O. K. VINTERMYR, G. HOUGE, M. LANOTTE, AND S. O. DOSKELAND. The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells. Exp. Cell Res. 195: 237–246, 1991. BOKNIK, P., M. FOCKENBROCK, U. KIRCHHEFER, J. KNAPP, B. LINCK, F. U. MU¨LLER, T. MU¨LLER, J. NEUMANN, U. VAHLENSIEK, AND W. SCHMITZ. Protein phosphatases are functionally increased in a model of heart hypertrophy (Abstract). Circulation 96, Suppl. 1: I-744, 1997. BORITZKI, T. J., T. S. WOLFARD, J. A. BESSERER, R. C. JACKSON, AND D. W. FRY. Inhibition of type II topoisomerase by fostriecin. Biochem. Pharmacol. 37: 4063– 4068, 1988. BOURON, A., AND B. F. REBER. Differential modulation of pharmacologically distinct components of Ca21 currents by protein kinase C activators and phosphatase inhibitors in nerve-growthfactor differentiated rat pheochromocytoma (PC12) cells. Pflu¨gers Arch. 427: 510 –516, 1994. BRAUN, A. P., AND H. SCHULMAN. A non-selective cation current activated via the multifunctional Ca21-calmodulin-dependent protein kinase in human epithelial cells. J. Physiol. (Lond.). 488: 37–55, 1995. BREWIS, N. D., A. J. STREET, A. R. PRESCOTT, AND P. T. COHEN. PPX, a novel protein serine/threonine phosphatase localized to centrosomes. EMBO J. 12: 987–996, 1993. BROWN, N. A., AND G. R. SEABROOK. Phosphorylation- and voltage-dependent inhibition of neuronal calcium currents by activation of human D2(short) dopamine receptors. Br. J. Pharmacol. 115: 459 – 466, 1995.

199

46. BUSHFIELD, M., B. E. LAVAN, AND M. D. HOUSLAY. Okadaic acid identifies a phosphorylation/dephosphorylation cycle controlling the inhibitory guanine-nucleotide-binding regulatory protein Gi2. Biochem. J. 274: 317–321, 1991. 47. CARL, A., J. L. KENYON, D. UEMURA, N. FUSETANI, AND K. M. SANDERS. Regulation of Ca21-activated K1 channels by protein kinase A and phosphatase inhibitors. Am. J. Physiol. 261 (Cell Physiol. 30): C387—C392, 1991. 48. CARMICHAEL, W. W. Cyanobacteria secondary metabolites: the cyanotoxins. J. Appl. Bacteriol. 72: 445– 459, 1992. 49. CARMICHAEL, W. W. The toxins of cyanobacteria. Sci. Am. 270: 78 – 86, 1994. 50. CHAD, J. E., AND R. ECKERT. An enzymatic mechanism for calcium current inactivation in dialysed Helix neurones. J. Physiol. (Lond.). 378: 31–51, 1986. 51. CHAHINE, M., A. BIBIKOVA, AND A. SCULPTOREANU. Okadaic acid enhances prepulse facilitation of cardiac a1-subunit but not endogenous calcium channel currents in Xenopus laevis oocytes. Can. J. Physiol. Pharmacol. 74: 1149 –1156, 1996. 52. CHANG, C. D., H. MUKAI, T. KUNO, AND C. TANAKA. DNA cloning of an alternatively spliced isoform of the regulatory subunit of Ca21/calmodulin-dependent protein phosphatase (calcineurin B alpha 2). Biochim. Biophys. Acta 1217: 174 –180, 1994. 53. CHANG, N. T., L. E. HUANG, AND A. Y. LIU. Okadaic acid markedly potentiates the heat-induced hsp 70 promoter activity. J. Biol. Chem. 268: 1436 –1439, 1993. 54. CHARTIER, L., L. L. RANKIN, R. E. ALLEN, Y. KATO, N. FUSETANI, H. KARAKI, S. WATABE, AND D. J. HARTSHORNE. Calyculin-A increases the level of protein phosphorylation and changes the shape of 3T3 fibroblasts. Cell Motil. Cytoskeleton 18: 26 – 40, 1991. 55. CHEN, J., B. L. MARTIN, AND D. L. BRAUTIGAN. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257: 1261–1264, 1992. 56. CHEN, M. S., A. M. SILVERSTEIN, W. B. PRATT, AND M. CHINKERS. The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J. Biol. Chem. 271: 32315– 32320, 1996. 57. CHEN, M. X., AND P. T. W. COHEN. Activation of protein phosphatase 5 by limited proteolysis or the binding of polyunsaturated fatty acids to the TPR domain. FEBS Lett. 400: 136 –140, 1997. 58. CHEN, M. X., A. E. MCPARTLIN, L. BROWN, Y. H. CHEN, H. M. BARKER, AND P. T. W. COHEN. A novel human protein serine/ threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. EMBO J. 13: 4278 – 4290, 1994. 59. CHEN, Q. X., AND R. K. WONG. Suppression of a Ca21 current by NMDA and intracellular Ca21 in acutely isolated hippocampal neurons. J. Neurophysiol. 73: 515–524, 1995. 60. CHEN, Q. X., AND R. K. WONG. Suppression of GABAA receptor responses by NMDA application in hippocampal neurones acutely isolated from the adult guinea-pig. J. Physiol. (Lond.) 482: 353–362, 1995. 61. CHEN, S. C., G. KRAMER, AND B. HARDESTY. Isolation an partial characterization of an Mr 60,000 subunit of a type 2A phosphatase from rabbit reticulocytes. J. Biol. Chem. 264: 7267–7275, 1989. 62. CHEN, T. C., B. LAW, T. KONDRATYUK, AND S. ROSSIE. Identification of soluble protein phosphatases that dephosphorylate voltage-sensitive sodium channels in rat brain. J. Biol. Chem. 270: 7750 –7756, 1995. 63. CHEN, Y. H., M. X. CHEN, D. R. ALESSI, D. G. CAMPBELL, C. SHANAHAN, P. COHEN, AND P. T. W COHEN. Molecular cloning of cDNA encoding the 110 kDa and 21 kDa regulatory subunits of smooth muscle protein phosphatase 1M. FEBS Lett. 356: 51–55, 1994. 64. CHENG, Q., A. K. ERIKSON, Z. X. WANG, AND D. KILLILEA. Stimulation of phosphorylase phosphatase activity of protein phosphatase 2A1 by protamine is ionic strength dependent and involves interaction of protamine with both substrate and enzyme. Biochemistry 35: 15593–15600, 1996.

200


65. CHIANG, C. E., S. A. CHEN, M. S. CHANG, C. I. LIN, AND H. N. LUK. Genistein directly induces cardiac CFTR chloride current by a tyrosine kinase-independent and protein kinase A-independent pathway in guinea pig ventricular myocytes. Biochem. Biophys. Res. Commun. 235: 74 –78, 1997. 66. CHIK, C. L., B. LI, E. KARPINSKI, AND A. K. HO. Regulation of the L-type Ca21 channel current in rat pinealocytes: role of basal phosphorylation. J. Neurochem. 72: 73– 80, 1999. 67. CHINKERS, M. Targeting of a distinctive protein-serine phosphatase to the protein kinase-like domain of the atrial natriuretic peptide receptor. Proc. Natl. Acad. Sci. USA 91: 11075–11079, 1994. 68. CHISHOLM, A. A., AND P. COHEN. The myosin-bound form of protein phosphatase 1 (PP-1M) is the enzyme that dephosphorylates native myosin in skeletal and cardiac muscles. Biochim. Biophys. Acta 971: 163–169, 1988. 69. CHU, G., W. LUO, J. P. SLACK, C. TILGMANN, W. E. SWEET, M. SPINDLER, K. W. SAUPE, G. P. BOIVIN, C. S. MORAVEC, M. A. MATLIB, I. L. GRUPP, J. S. INGWALL, AND E. G. KRANIAS. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ. Res. 79: 1064 – 1076, 1996. 70. CHU, Y., S. E. WILSON, AND K. K. SCHLENDER. A latent form of protein phosphatase 1a associated with bovine heart myofibrils. Biochim. Biophys. Acta 1208: 45–54, 1994. 71. CHUN, Y. S., H. SIMA, T. NAGASAKI, AND M. NAGAO. PP1 g2, a testis-specific serine-threonine-phosphatase type 1 catalytic subunit, is associated with a protein having high sequence homology with the 78-kDa glucose-regulated protein, a member of the 70-kDa heat shock protein family. Proc. Natl. Acad. Sci. USA 91: 3319 – 3323, 1994. 72. CHUNG, S., AND L. K. KACZMAREK. Modulation of the inactivation of voltage-dependent potassium channels by cAMP. J. Neurosci. 15: 3927–3935, 1995. 73. CHUNG, S. K., P. H. REINHART, B. L. MARTIN, D. BRAUTIGAN, AND I. B. LEVITAN. Protein kinase activity closely associated with a reconstituted calcium-activated potassium channel. Science 253: 560 –562, 1991. 74. CLIPSTONE, N. A., D. F. FIORENTINO, AND G. R. CRABTREE. Molecular analysis of the interaction of calcineurin with drugimmunophilin complexes. J. Biol. Chem. 269: 26431–25437, 1994. 75. COGHLAN, V. M., B. A. PERRINO, M. HOWARD, L. K. LANGEBERG, J. B. HICKS, W. M. GALLATIN, AND J. D. SCOTT. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. Science 267: 108 –111, 1995. 76. COHEN, P. The structure and regulation of protein phosphatases. Annu. Rev. Biochem. 58: 453–508, 1989. 77. COHEN, P. The discovery of protein phosphatases: from chaos and confusion to an understanding of their role in cell regulation and human disease. Bioessays 16: 583–588, 1994. 78. COHEN, P. Novel serine/threonine phosphatases: variety is the spice of life. Trends Biochem. Sci. 22: 245–251, 1997. 79. COHEN, P., AND P. T. COHEN. Protein phosphatases come of age. J. Biol. Chem. 264: 21435–21438, 1989. 80. COHEN, P., C. F. HOLMES, AND Y. TSUKITANI. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem. Sci. 15: 98 –102, 1990. 81. COHEN, P., D. L. SCHELLING, AND M. J. STARK. Remarkable similarities between yeast and mammalian protein phosphatases. FEBS Lett. 250: 601– 606, 1989. 82. CRAIG, M., H. A. LUU, T. L. MCCREADY, D. WILLIAMS, R. J. ANDERSEN, AND C. F. B. HOLMES. Molecular mechanisms underlying the interaction of motuporin and microcystins with type-1 and type-2A protein phosphatases. Biochem. Cell. Biol. 74: 569 –578, 1996. 83. CSORTOS, C., S. ZOLNIEROWICS, E. BAKO, S. D. DURBIN, AND A. A. DEPAOLI. High complexity in the expression of the B subunit of protein phosphatase 2A0. Evidence for the existence of at least seven novel isoforms. J. Biol. Chem. 271: 2578 –2588, 1996. 84. DA CRUZ E SILVA, O. B., S. ALEMANY, D. G. CAMPBELL, AND P. T. W. COHEN. Isolation and sequence analysis of a cDNA clone

85.

86.

87.

88. 89. 90.

91.

92.

93.

94.

95.

96.

97.

98.

99.

100.

101.

102.

Volume 80

encoding the entire catalytic subunit of a type-2A protein phosphatase. FEBS Lett. 221: 415– 422, 1987. DA CRUZ E SILVA, O. B., AND P. T. W. COHEN. A second catalytic subunit of type 2A-protein phosphatase from rabbit skeletal muscle. FEBS Lett. 226: 176 –178, 1987. DA CRUZ E SILVA, E. F., C. FOX, C. C. OUIMET, E. GUSTAFSON, S. J. WATSON, AND P. GREENGARD. Differential expression of protein phosphatase 1 isoforms in mammalian brain. J. Neurosci. 15: 3375–3389, 1995. DAS, A. K., N. R. HELPS, P. T. W. COHEN, AND D. BARFORD. Crystal structure of the protein serine/threonine phosphatase 2C at 2.0 Å resolution. EMBO J. 15: 6798 – 6809, 1996. DE JONG, R. S., E. G. E. DE VRIES, AND N. H. MULDER. Fostriecin: a review of the preclinical data. Anticancer Drugs 8: 413– 418, 1997. DELL AQUA, M. L., AND J. D. SCOTT. Protein kinase anchoring. J. Biol. Chem. 272: 12881–12884, 1997. DE LUCA, A., S. PIERNO, D. COCCHI, AND D. CONTE CAMERINO. Effects of chronic growth hormone treatment in aged rats on the biophysical and pharmacological properties of skeletal muscle chloride channels. Br. J. Pharmacol. 121: 369 –374, 1997. DE LUCA, A., S. PIERNO, A. LIANTONIO, C. CAMERINO, AND D. CONTE CAMERINO. Phosphorylation and IGF-1-mediated dephosphorylation pathways control the activity and the pharmacological properties of skeletal muscle chloride channels. Br. J. Pharmacol. 125: 477– 482, 1998. DENNER, L. A., N. L. WEIGEL, B. L. MAXWELL, W. T. SCHRADER, AND B. W. O’MALLEY. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 250: 1740 –1743, 1990. DENT, P., A. LAVINE, S. NAKIELNY, F. B. CAUDWELL, P. WATT, AND P. COHEN. The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348: 302–308, 1990. DENT, P., L. K. MACDOUGALL, C. MACKINTOSH, D. G. CAMPBELL, AND P. COHEN. A myofibrillar protein phosphatase from rabbit skeletal muscle contains the beta isoform of protein phosphatase-1 complexed to a regulatory subunit which greatly enhances the dephosphorylation of myosin. Eur. J. Biochem. 210: 1037–1044, 1992. DEPAOLI-ROACH, A. A., I. K. PARK, V. CEROVSKY, C. CSORTOS, S. D. DURBIN, M. J. KRUNTZ, A. SITIKOV, P. M. TANG, A. VERIN, AND S. ZOLNIEROWICZ. Serine/threonine protein phosphatase in the control of cell function. Adv. Enzyme Regul. 34: 199 –224, 1994. DESDOUITS, F., J. J. CHEETHAM, H. B. HUANG, Y. G. KWON, E. F. DA CRUZ E SILVA, P. DENEFLE, M. E. EHRLICH, A. C. NAIRN, P. GREENGARD, AND J. A. GIRAULT. Mechanism of inhibition of protein phosphatase 1 by DARPP-32: studies with recombinant DARPP-32 and synthetic peptides. Biochem. Biophys. Res. Commun. 206: 652– 658, 1995. DESDOUITS, F., D. COHEN, A. C. NAIRN, P. GREENGARD, AND J. A. GIRAULT. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase I in vitro and in vivo. J. Biol. Chem. 270: 8772– 8778, 1995. DESDOUITS, F., J. C. SICILIANO, P. GREENGARD, AND J. A. GIRAULT. Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. Proc. Natl. Acad. Sci. USA 92: 2682–2685, 1995. DING, B., R. L. PRICE, T. K. BORG, E. O. WEINBERG, P. F. HALLORAN, AND B. H. LORELL. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ. Res. 84: 729 –734, 1999. DINISCHIOTU, A., M. BEULLENS, W. STALMANS, AND M. BOLLEN. Identification of sds22 as inhibitory subunit of phosphatase-1 in rat liver nuclei. FEBS Lett. 402: 141–144, 1997. DOBROWSKY, R. T., C. KAMIBAYASHI, M. C. MUMBY, AND Y. A. HANNUN. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 268: 15523–15530, 1993. DOCHERTY, R. J., J. C. YEATS, S. BEVAN, AND H. W. BODDEKE. Inhibition of calcineurin inhibits the desensitization of capsaicin-

January 2000

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.


evoked currents in cultured dorsal root ganglion neurones from adult rats. Pflu¨gers Arch. 431: 828 – 837, 1996. DOHADWALA, M., E. F. DA CRUZ E SILVA, F. L. HALL, R. T. WILLIAMS, D. A. CARBONARO-HALL, A. C. NAIRN, P. GREENGARD, AND N. BERNDT. Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA 91: 6408 – 6412, 1994. DOHERTY, M. J., G. MOORHEAD, N. MORRICE, P. COHEN, AND P. T. W. COHEN. Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein phosphatase-1. FEBS Lett. 375: 294 –298, 1995. DOHERTY, M. J., P. R. YOUNG, AND P. T. W. COHEN. Amino acid sequence of a novel protein phosphatase 1 binding protein (R5) which is related to the liver- and muscle-specific glycogen binding subunits of protein phosphatase 1. FEBS Lett. 399: 339 –343, 1995. DOLPHIN, A. C. The effect of phosphatase inhibitors and agents increasing cyclic-AMP-dependent phosphorylation on calcium channel currents in cultured rat dorsal root ganglion neurones: interaction with the effect of G protein activation. Pflu¨gers Arch. 421: 138 –145, 1992. DUAN, D., S. COWLEY, B. HOROWITZ, AND J. R. HUME. A serine residue in ClC-3 links phosphorylation-dephosphorylation to chloride channel regulation by cell volume. J. Gen. Physiol. 113: 57–70, 1999. DU BELL, W. H., S. T. GAA, W. J. LEDERER, AND T. B. ROGERS. Independent inhibition of calcineurin and K1 currents by the immunosuppressant FK-506 in rat ventricle. Am. J. Physiol. 275 (Heart Circ. Physiol. 44): H2041—H2052, 1998. DU BELL, W. H., W. J. LEDERER, AND T. B. ROGERS. Dynamic modulation of excitation-contraction coupling by protein phosphatases in rat ventricular myocytes. J. Physiol. (Lond.). 493: 793– 800, 1996. DUCHATEL LE-GOURDON, I., A. A. LAGRUTTA, AND H. C. HARTZELL. Effects of Mg21 on basal and beta-adrenergic-stimulated delayed rectifier potassium current in frog atrial myocytes. J. Physiol. (Lond.). 435: 333–347, 1991. DUERSON, K., R. E. WHITE, F. JIANG, A. SCHONBRUNN, AND D. L. ARMSTRONG. Somatostatin stimulates BKCa channels in rat pituitary tumor cells through lipoxygenase metabolites of arachidonic acid. Neuropharmacology 35: 949 –961, 1996. DURFEE, T. K., K. BECHERER, P. L. CHEN, S. H. YEH, Y. YANG, A. E. KILBURN, W. H. LEE, AND S. J. ELLEDGE. The retinoblastoma protein associates with the protein phosphatase-1. Genes Dev. 7: 555–569, 1993. EGLOFF, M. P., P. T. W. COHEN, P. REINEMER, AND D. BARFORD. Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate. J. Mol. Biol. 254: 942– 959, 1995. EGLOFF, M. P., D. F. JOHNSON, G. MOORHEAD, P. T. W. COHEN, P. COHEN, AND D. BARFORD. Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. EMBO J. 16: 1876 –1887, 1997. EHRLICH, M. E., T. KURIHARA, AND P. GREENGARD. Rat DARPP32: cloning, sequencing, and characterization of the cDNA. J. Mol. Cell. Neurosci. 2: 1–10, 1990. EISFELD, J., G. MIKALA, G. VARADI, A. SCHWARTZ, AND U. KLO¨CKNER. Inhibition of cloned human L-type cardiac calcium channel by 2,3-butanedione monoxime does not require PKA-dependent phosphorylation sites. Biochem. Biophys. Res. Commun. 230: 489 – 492, 1997. ELBRECHT, A., J. DIRENZO, R. G. SMITH, AND S. SHENOLIKAR. Molecular cloning of protein phosphatase inhibitor-1 and its expression in rat and rabbit tissues. J. Biol. Chem. 265: 13415–13418, 1990. ENAN, E., AND F. MATSUMURA. Specific inhibition of calcineurin by type II synthetic pyrethroid insecticides. Biochem. Pharmacol. 43: 1771–1784, 1992. ENDO, S., X. ZHOU, J. CONNOR, B. WANG, AND S. SHENOLIKAR. Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Biochemistry 35: 5220 –5228, 1996. ERDO¨DI, F. C., C. CSORTOS, G. BOT, AND P. GERGELY. Effects of

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

201

acidic and basic macromolecules on the activity of protein phosphatase-1. Biochim. Biophys. Acta 827: 23–29, 1985. ERDO¨DI, F. C., C. CSORTOS, G. BOT, AND P. GERGELY. Separation of rabbit liver latent and spontaneously active phosphorylase phosphatases by chromatography on heparin-sepharose. Biochem. Biophys. Res. Commun. 128: 705–712, 1985. ERDO¨DI, F. C., M. ITO, AND D. J. HARTSHORNE. Biochemistry of Smooth Muscle Contraction. Orlando, FL: Academic, 1996, p. 131– 142. ERIKSSON, J. E., L. GRONBERG, S. NYGARD, J. P. SLOTTE, AND J. A. MERILUOTO. Hepatocellular uptake of 3H-dihydromicrocystin-LR, a cyclic peptide toxin. Biochim. Biophys. Acta 1025: 60 – 66, 1990. ERIKSSON, J. E., D. TOIVOLA, J. A. O. MERILUOTO, H. KARAKI, Y.-G. HAN, AND D. HARTSHORNE. Hepatocyte deformation induced by cyanobacterial toxins reflects inhibition of protein phosphatases. Biochem. Biophys. Res. Commun. 173: 1347–1353, 1990. ETO, M., T. OHMORI, M. SUZUKI, K. FURUJA, AND F. MORITA. A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. J. Biochem. 118: 1104 –1107, 1995. ETO, M., S. SENBA, F. MORITA, AND M. YAZAWA. Molecular cloning of a novel phosphorylation dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: its specific localization in smooth muscle. FEBS Lett. 410: 356 –360, 1997. FAUX, M. C., AND J. D. SCOTT. More on target with protein phosphorylation: conferring specifity by location. Trends Biochem. Sci. 21: 312–315, 1996. FAVRE, B., P. TUROWSKI, AND B. A. HEMMINGS. Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin A, okadaic acid, and tautomycin. J. Biol. Chem. 272: 13856 –13863, 1997. FAVRE, B., S. ZOLNIEROWICZ, P. TUROWSKI, AND B. A. HEMMINGS. The catalytic subunit of protein phosphatase 2A is carboxyl-methylated in vivo. J. Biol. Chem. 269: 16311–16317, 1994. FERNANDEZ-SARABIA, M. J., A. SUTTON, T. ZHONG, AND K. T. ARNDT. SIT4 protein phosphatase is required for the normal accumulation of SWI4, CLN1, CLN2, and HCS26 RNAs during late G1. Genes Dev. 6: 2417–2428, 1992. FIENBERG, A. A., N. HIROI, P. G. MERMELSTEIN, W. SONG, G. L. SNYDER, A. NISHI, A. CHERAMY, J. P. O’CALLAGHAN, D. B. MILLER, D. G. COLE, R. CORBETT, C. N. HAILE, D. C. COOPER, S. P. ONN, A. A. GRACE, C. C. OUIMET, F. J. WHITE, S. E. HYMAN, D. J. SURMEIER, J. GIRAULT, E. J. NESTLER, AND P. GREENGARD. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281: 838 – 842, 1998. FINN, A. L., M. L. GAIDO, AND M. DILLARD. Reconstitution and regulation of an epithelial chloride channel. Mol. Cell. Biochem. 114: 21–26, 1992. FINN, A. L., M. L. GAIDO, M. DILLARD, AND D. L. BRAUTIGAN. Regulation of an epithelial chloride channel by direct phosphorylation and dephosphorylation. Am. J. Physiol. 263 (Cell Physiol. 32): C172—C175, 1992. FISCHER, H., B. ILLEK, AND T. E. MACHEN. The actin filament disrupter cytochalasin D activates the recombinant cystic fibrosis transmembrane conductance regulator Cl2 channel in mouse 3T3 fibroblasts. J. Physiol. (Lond.). 489: 745–754, 1995. FISCHER, H., B. ILLEK, AND T. E. MACHEN. Regulation of CFTR by protein phosphatase 2B and protein kinase C. Pflu¨gers Arch. 436: 175–181, 1998. FLOER, M., AND J. STOCK. Carboxyl methylation of protein phosphatase 2A from Xenopus eggs is stimulated by cAMP and inhibited by okadaic acid. Biochem. Biophys. Res. Commun. 198: 372–379, 1994. FOMINA, A. F., AND E. S. LEVITAN. Control of Ca21 channel current and exocytosis in rat lactotrophs by basally active protein kinase C and calcineurin. Neuroscience 78: 523–531, 1997. FORNEROD, M., J. BOER, S. VAN BAAL, M. JAEGLE, M. VON LINDERN, K. G. MURTI, D. DAVIS, J. BONTEN, A. BUIJS, AND G. GROSVELD. Relocation of the carboxy terminal part of CAN from

202

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153. 154.

155.

156.

157.

STEFAN HERZIG AND JOACHIM NEUMANN the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene 10: 1739 –1748, 1995. FOULKES, J. G., AND P. COHEN. The regulation of glycogen metabolism: purification and properties of protein phosphatase inhibitor-2 from rabbit skeletal muscle. Eur. J. Biochem. 105: 195–203, 1980. FRACE, A. M., AND H. C. HARTZELL. Opposite effects of phosphatase inhibitors on L-type calcium and delayed rectifier currents in frog cardiac myocytes. J. Physiol. (Lond.). 472: 305–326, 1993. FRENCH, P. J., J. BIJMAN, A. G. BOT, W. E. BOOMAARS, B. J. SCHOLTE, AND H. R. DE JONGE. Genistein activates CFTR Cl2 channels via a tyrosine kinase- and protein phosphatase-independent mechanism. Am. J. Physiol. 273 (Cell Physiol. 42): C747— C753, 1997. FRENCH, P. J., J. BIJMAN, M. EDIXHOVEN, A. B. VAANDRAGER, B. J. SCHOLTE, S. M. LOHMANN, A. C. NAIRN, AND H. R. DE JONGE. Isotype-specific activation of cystic fibrosis transmembrane conductance regulator-chloride channels by cGMP-dependent protein kinase II. J. Biol. Chem. 270: 26626 –26631, 1995. FRITSCH, J., AND A. EDELMAN. Osmosensitivity of the hyperpolarization-activated chloride current in human intestinal T84 cells. Am. J. Physiol. 272 (Cell Physiol. 41): C778 —C786, 1997. FRYER, M. W., AND R. S. ZUCKER. Ca21-dependent inactivation of Ca21 current in Aplysia neurons: kinetic studies using photolabile Ca21 chelators. J. Physiol. (Lond.). 464: 501–528, 1993. FUJIKI, H. Is the inhibition of protein phosphatase 1 and 2A activities a general mechanism of tumor promotion in human cancer development? Mol. Carcinogen. 5: 91–94, 1992. FUJIKI, H., AND M. SUGANUMA. Tumor promotion by inhibitors of protein phosphatases 1 and 2A: the okadaic acid class of compounds. Adv. Cancer Res. 61: 143–154, 1993. FUJITA, H., T. MATSUMOTO, H. KAWASHIMA, E. OGATA, T. FUJITA, AND N. YAMASHITA. Activation of Cl2 channels by extracellular Ca21 in freshly isolated rabbit osteoclasts. J. Cell. Physiol. 169: 217–225, 1996. FURUKAWA, K., S. W. BARGER, E. M. BLALOCK, AND M. P. MATTSON. Activation of K1 channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature 379: 74 – 78, 1996. GADSBY, D. C., T. C. HWANG, T. BAUKROWITZ, G. NAGEL, M. HORIE, AND A. C. NAIRN. Regulation of CFTR channel gating. Jpn. J. Physiol. 44, Suppl.: S183—S192, 1994. GADSBY, D. C., AND A. C. NAIRN. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol. Rev. 79, Suppl.: S77—S107, 1999. GALINDO, E., J. ZWILLER, M. F. BADER, AND D. AUNIS. Chromostatin inhibits catecholamine secretion in adrenal chromaffin cells by activating a protein phosphatase. Proc. Natl. Acad. Sci. USA 89: 7398 –7402, 1992. GAO, T., A. YATANI, M. L. DELL’ACQUA, H. SAKO, S. A. GREEN, N. DASCAL, J. D. SCOTT, AND M. M. HOSEY. cAMP-dependent regulation of cardiac L-type Ca21 channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron 19: 185–196, 1997. ¨ DI, AND G. BOT. Heparin inhibits the activGERGELY, P., F. ERDO ity of protein phosphatase-1. FEBS Lett. 169: 45– 48, 1984. GIRI, P. R., S. HIGUCHI, AND R. L. KINCAID. Chromosomal mapping of the human genes for the calmodulin-dependent protein phosphatase (calcineurin) catalytic subunit. Biochem. Biophys. Res. Commun. 181: 252–258, 1991. GOLDBERG, J., H. HUANG, Y. KWON, P. GREENGARD, A. C. NAIRN, AND J. KURIYAN. Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature 376: 745–753, 1995. GOLOWASCH, J., D. PAUPARDIN-TRITSCH, AND H. M. GERSCHENFELD. Enhancement by muscarinic agonists of a high voltage-activated Ca21 current via phosphorylation in a snail neuron. J. Physiol. (Lond.). 485: 21–28, 1995. GOMBOSOVA, I., P. BOKNIK, U. KIRCHHEFER, J. KNAPP, H. LU¨SS, F. U. MU¨LLER, T. MU¨LLER, U. VAHLENSIECK, W. SCHMITZ, G. S. BODOR, AND J. NEUMANN. Postnatal changes in contractile time parameters, calcium regulatory proteins, and phos-

158.

159.

160.

161.

162.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

Volume 80

phatases. Am. J. Physiol. 274 (Heart Circ. Physiol. 43): H2123— H2132, 1998. GONG, M. C., P. COHEN, T. KITAZAWA, M. IKEBE, M. MASUO, A. P. SOMLYO, AND A. V. SOMLYO. Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J. Biol. Chem. 267: 14662–14668, 1992. GONG, M. C., A. FUGLSANG, D. ALESSI, S. KOBAYASHI, P. COHEN, A. V. SOMLYO, AND A. P. SOMLYO. Arachidonic acid inhibits myosin light chain phosphatase and sensitizes smooth muscle to calcium. J. Biol. Chem. 267: 21492–21498, 1992. GORDON, S. E., D. L. BRAUTIGAN, AND A. L. ZIMMERMAN. Protein phosphatases modulate the apparent agonist affinity of the light-regulated ion channel in retinal rods. Neuron 9: 739 –748, 1992. GREEN, D. D., S. I. YANG, AND M. C. MUMBY. Molecular cloning and sequence analysis of the catalytic subunit of bovine type 2A protein phosphatase. Proc. Natl. Acad. Sci. USA 84: 4880 – 4884, 1987. GRIFFITH, J. P., J. L. KIM, E. E. KIM, M. D. SINTCHAK, J. A. THOMSON, M. J. FITZGIBBON, M. A. FLEMING, P. R. CARON, K. HSIAO, AND M. A. NAVIA. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82: 507–522, 1995. GROSCHNER, K., K. SCHUHMANN, W. BAUMGARTNER, V. PASTUSHENKO, H. SCHINDLER, AND C. ROMANIN. Basal dephosphorylation controls slow gating of L-type Ca21 channels in human vascular smooth muscle. FEBS Lett. 373: 30 –34, 1995. GUERINI, D., AND C. B. KLEE. Cloning of human calcineurin A: evidence for two isozymes and identification of a polyproline structural domain. Proc. Natl. Acad. Sci. USA 86: 9183–9187, 1989. GUO, H., AND Z. DAMUNI. Autophosphorylation-activated protein kinase phosphorylates and inactivates protein phosphatase 2A. Proc. Natl. Acad. Sci. USA 90: 2500 –2504, 1993. GUO, H., S. A. REDDY, AND Z. DAMUNI. Purification and characterization of an autophosphorylation-activated protein serine threonine kinase that phosphorylates and inactivates protein phosphatase 2A. J. Biol. Chem. 268: 11193–11198, 1993. GUO, X. W., J. P. H. TH’NG, R. A. SWANK, H. J. ANDERSON, C. TUDAN, E. M. BRADBURY, AND M. ROBERGE. Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J. 14: 976 –985, 1995. GUPTA, R. C., J. NEUMANN, A. M. WATANABE, M. LESCH, AND H. N. SABBAH. Evidence for the existence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocytes. Am. J. Physiol. 270 (Heart Circ. Physiol. 39): H1159 — H1164, 1996. GUPTA, R. C., M. TAIMURA, T. MISHIMA, M. LESCH, AND H. N. SABBAH. Protein phosphatase activity is increased and state of phosphorylation of phospholamban is decreased in myocardium of dogs with chronic heart failure (Abstract). Circulation 96, Suppl. 1: I-361, 1997. GUY, G. R., X. CAO, S. P. CHUA, AND Y. H. TAN. Okadaic acid mimics multiple changes in early protein phosphorylation and gene expression induced by tumor necrosis factor or interleukin-1. J. Biol. Chem. 267: 1846 –1852, 1992. HABY, C., O. LARSSON, M. S. ISLAM, D. AUNIS, P. O. BERGGREN, AND J. ZWILLER. Inhibition of serine/threonine protein phosphatases promotes opening of voltage-activated L-type Ca21 channels in insulin-secreting cells. Biochem. J. 298: 341–346, 1994. HALL, S. K., J. ZHANG, AND M. LIEBERMAN. Cyclic AMP prevents activation of a swelling-induced chloride-sensitive conductance in chick heart cells. J. Physiol. (Lond.). 488: 359 –369, 1995. HARTZELL, H. C., Y. HIRAYAMA, AND J. PETIT-JACQUES. Effects of protein phosphatase and kinase inhibitors on the cardiac L-type Ca current suggest two sites are phosphorylated by protein kinase A and another protein kinase. J. Gen. Physiol. 106: 393– 414, 1995. HEALY, A. M., S. ZOLNIEROWICZ, A. E. STAPLETON, M. GOEBL, A. A. DEPAOLI-ROACH, AND J. R. PRINGLE. CDC55, a Saccharomyces cerevisiae gene involved in cellular morphogenesis: identification,

January 2000

175.

176.

177.

178.

179.

180.

181.

182.

183.

184.

185.

186.

187.

188.

189.

190.

191.

192.

193.


characterization, and homology to the B subunit of mammalian type 2A protein phosphatase. Mol. Cell. Biol. 11: 5767–5780, 1991. HELL, J. W., C. T. YOKOYAMA, S. T. WONG, C. WARNER, T. P. SNUTCH, AND W. A. CATTERALL. Differential phosphorylation of two size forms of the neuronal class C L-type calcium channel a1 subunit. J. Biol. Chem. 268: 19451–19457, 1993. HELPS, N. R., H. M. BARKER, S. J. ELLEDGE, AND P. T. W. COHEN. Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour suppressor p53. FEBS Lett. 377: 195–300, 1995. HEMMINGS, B. A., C. ADAMS-PEARSON, F. MAURER, P. MU¨LLER, J. GORIS, W. MERLEVEDE, J. HOFSTEENGE, AND S. R. STONE. a- and b-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry 29: 3166 –3173, 1990. HEMMINGS, H. C., JR., P. GREENGARD, H. Y. TUNG, AND P. COHEN. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310: 503–505, 1984. HEMMINGS, H. C., JR., AND P. GREENGARD. DARPP-32, a dopamine- and 3,5-cAMP-regulated phosphoprotein. Regional, tissue and phylogenetic distribution. J. Neurosci. 6: 1469 –1481, 1986. HEMMINGS, H. C., JR., A. C. NAIRN, J. I. ELLIOTT, AND P. GREENGARD. Synthetic peptide analogs of DARPP-32 (Mr 32,000 dopamine- and cAMP-regulated phosphoprotein), an inhibitor of protein phosphatase-1. Phosphorylation, dephosphorylation, and inhibitory activity. J. Biol. Chem. 265: 20369 –20376, 1990. HEMMINGS, H. C., JR., A. C. NAIRN, AND P. GREENGARD. DARPP32, a dopamine-adenosine 39:59-monophosphate-regulated neuronal phosphoprotein. J. Biol. Chem. 259: 14491–14497, 1984. HEMMINGS, B. A., W. WERNET, R. MAYER, F. MAURER, J. HOFSTEENGE, AND S. R. STONE. The nucleotide sequence of the cDNA encoding the human lung protein phosphatase 2A beta catalytic subunit. Nucleic Acids Res. 16: 11366, 1988. HENDRIX, P., P. TUROWSKI, R. E. MAYER-JAECKEL, J. GORIS, J. HOFSTEENGE, W. MERLEVEDE, AND B. A. HEMMINGS. Analysis of subunit isoforms in protein phosphatase 2A holoenzymes from rabbit and Xenopus. J. Biol. Chem. 268: 7330 –7337, 1993. HERICHE, J.-K., F. LEBRIN, T. RABILLOUD, D. LEROY, E. M. CHAMBAZ, AND Y. GOLDBERG. Regulation of protein phosphatase 2A by direct interaction with casein kinase 2a. Science 276: 952–955, 1997. HERNANDEZ-SOTOMAYOR, S. M., M. MUMBY, AND G. CARPENTER. Okadaic acid-induced hyperphosphorylation of the epidermal growth factor receptor. Comparison with receptor phosphorylation and functions affected by another tumor promoter, 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem. 266: 21281–21286, 1991. HERZIG, S., A. MEIER, M. PFEIFFER, AND J. NEUMANN. Stimulation of protein phosphatases as a mechanism of the muscarinicreceptor-mediated inhibition of cardiac L-type Ca21 channels. Pflu¨gers Arch. 429: 531–538, 1995. HERZIG, S., P. PATIL, J. NEUMANN, C. M. STASCHEN, AND D. T. YUE. Mechanisms of beta-adrenergic stimulation of cardiac Ca21 channels revealed by discrete-time Markov analysis of slow gating. Biophys. J. 65: 1599 –1612, 1993. HESCHELER, J., M. KAMEYAMA, AND W. TRAUTWEIN. On the mechanism of muscarinic inhibition of the cardiac Ca current. Pflu¨gers Arch. 407: 182–189, 1986. HESCHELER, J., M. KAMEYAMA, W. TRAUTWEIN, G. MIESKES, AND H. D. SOLING. Regulation of the cardiac calcium channel by protein phosphatases. Eur. J. Biochem. 165: 261–266, 1987. ¨ EGG, A. TAKAI, AND W. HESCHELER, J., G. MIESKE, J. C. RU TRAUTWEIN. Effects of a protein phosphatase inhibitor, okadaic acid, on membrane currents of isolated guinea-pig cardiac myocytes. Pflu¨gers Arch. 412: 248 –252, 1988. HILL-VENNING, C., AND G. A. COTTRELL. Modulation of voltagedependent calcium current in Helix aspersa buccal neurones by serotonin and protein kinase C activators. Exp. Physiol. 77: 891– 901, 1992. HIRANO, K., F. ERDO¨DI, J. G. PATTON, AND D. J. HARTSHORNE. Interaction of protein phosphatase type 1 with a splicing factor. FEBS Lett. 389: 191–194, 1996. HIRANO, K., M. ITO, AND D. J. HARTSHORNE. Interaction of the

194.

195.

196.

197.

198.

199.

200.

201.

202.

203.

204.

205.

206.

207.

208.

209.

210.

211.

212.

203

ribosomal protein, L5, with protein phosphatase type 1. J. Biol. Chem. 270: 19786 –19790, 1995. HIRSCH, J., AND E. SCHLATTER. K1 channels in the basolateral membrane of rat cortical collecting duct are regulated by a cGMPdependent protein kinase. Pflu¨gers Arch. 429: 338 –344, 1995. HO, K., C. G. NICHOLS, W. J. LEDERER, J. LYTTON, P. M. VASSILEV, M. V. KANAZIRSKA, AND S. C. HEBERT. Cloning and expression of an inwardly rectifying ATP-regulated potassium channel. Nature 362: 31–38, 1993. HOGER, J. H., A. E. WALTER, D. VANCE, L. YU, H. A. LESTER, AND N. DAVIDSON. Modulation of a cloned mouse brain potassium channel. Neuron 6: 227–236, 1991. HOLM, N. R., P. CHRISTOPHERSEN, S. P. OLESEN, AND S. GAMMELTOFT. Activation of calcium-dependent potassium channels in mouse brain neurons by neurotrophin-3 and nerve growth factor. Proc. Natl. Acad. Sci. USA 94: 1002–1006, 1997. HOLMES, C. F., D. G. CAMPBELL, F. B. CAUDWELL, A. AITKEN, AND P. COHEN. The protein phosphatases involved in cellular regulation. Primary structure of inhibitor-2 from rabbit skeletal muscle. Eur. J. Biochem. 155: 173–182, 1986. HOLMES, C. F., H. A. LUU, F. CARRIER, AND F. J. SCHMITZ. Inhibition of protein phosphatases-1 and -2A with acanthifolicin. Comparison with diarrhetic shellfish toxins and identification of a region on okadaic acid important for phosphatase inhibition. FEBS Lett. 270: 216 –218, 1990. HONKANEN, R. E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 330: 283–286, 1993. HONKANEN, R. E., M. DUKELOW, J. ZIEGLER, R. E. MOORE, B. S. KHATRA, AND A. L. BOLTON. Cyanobacterial nodularin is a potent inhibitor of type 1 and type 2A protein phosphatases. Mol. Pharmacol. 40: 577–583, 1991. HONKANEN, R. E., J. ZIEGLER, R. E. MOORE, S. DAILY, B. S. KHATRA, M. DUKELOW, AND A. L. BOLTON. Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. J. Biol. Chem. 265: 19401–19404, 1990. HONKANEN, R. E., J. ZWILLER, S. L. DAILY, B. S. KHATRA, M. DUKELOW, AND A. L. BOLTON. Identification, purification and characterization of a novel serine/threonine protein phosphatase from bovine brain. J. Biol. Chem. 266: 6614 – 6619, 1991. HOOL, L. C., L. M. MIDDLETON, AND R. D. HARVEY. Genistein increases the sensitivity of cardiac ion channels to b-adrenergic receptor stimulation. Circ. Res. 83: 33– 42, 1998. HORI, M., J. MAGAE, Y. G. HAN, D. J. HARTSHORNE, AND H. KARAKI. A novel protein phosphatase inhibitor, tautomycin. Effect on smooth muscle. FEBS Lett. 285: 145–148, 1991. HUANG, F. L., AND W. H. GLINSMANN. Separation and characterization of two phosphorylase phosphatase inhibitors from rabbit skeletal muscle. Eur. J. Biochem. 70: 419 – 426, 1976. HUANG, F. L., AND W. H. GLINSMANN. Second heat-stable protein inhibitor of phosphorylase phosphatase from rabbit muscle. FEBS Lett. 62: 326 –329, 1976. HUANG, X., AND R. E. HONKANEN. Molecular cloning, expression, and characterization of a novel human serine/threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degeneration C gene product (rdgC). J. Biol. Chem. 273: 1462–1668, 1998. HUANG, B., D. QIN, M. BOUTJIR, AND M. GIDH-JAIN. Diminished basal phosphorylation level of phospholamban in left ventricular myocytes from rats with left coronary infarction. Role of b-adrenergic pathway, Gi, phosphodiesterase and phosphatase (Abstract). Circulation 96, Suppl. 1: I-19, 1997. HUANG, F. L., S. TAO, AND W. H. GLINSMANN. Multiple forms of protein phosphatase inhibitors in mammalian tissues. Biochem. Biophys. Res. Commun. 78: 615– 623, 1977. HUANG, R. Q., AND G. H. DILLON. Maintenance of recombinant type A gamma-aminobutyric acid receptor function: role of protein tyrosine phosphorylation and calcineurin. J. Pharmacol. Exp. Ther. 286: 243–255, 1998. HUANG, X. C., C. SUMNERS, AND E. M. RICHARDS. Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal

204

213.

214.

215.

216.

217.

218.

219.

220.

221.

222.

223.

224.

225.

226.

227.

228.

229.

230.

STEFAN HERZIG AND JOACHIM NEUMANN cells via type 2 receptors in a pertussis toxin sensitive fashion. Adv. Exp. Med. Biol. 396: 209 –215, 1996. HUBBARD, M. J., AND P. COHEN. Regulation of protein phosphatase-1G from rabbit skeletal muscle. 1. Phosphorylation by cAMPdependent protein kinase at site 2 releases catalytic subunit from the glycogen bound holoenzyme. Eur. J. Biochem. 186: 701–709, 1989. HUBBARD, M. J., AND P. COHEN. Regulation of protein phosphatase-1G from rabbit skeletal muscle. 2. Catalytic subunit translocation is a mechanism for reversible inhibition of activity toward glycogen bound substrates. Eur. J. Biochem. 186: 711–716, 1989. HUBBARD, M. J., P. DENT, C. SMYTHE, AND P. COHEN. Targetting of protein phosphatase 1 to the sarcoplasmic reticulum of rabbit skeletal muscle by a protein that is similar or identical to the G subunit that directs the enzyme to glycogen. Eur. J. Biochem. 189: 243–249, 1990. HWANG, T. C., M. HORIE, AND D. C. GADSBY. Functionally distinct phospho-forms underlie incremental activation of protein kinaseregulated Cl2 conductance in mammalian heart. J. Gen. Physiol. 101: 629 – 650, 1993. ICHIKAWA, K., K. HIRANO, M. ITO, J. TANAKA, T. NAKANO, AND D. J. HARTSHORNE. Interactions and properties of smooth muscle myosin phosphatase. Biochemistry 35: 6313– 6320, 1996. ICHIKAWA, K., M. ITO, AND D. J. HARTSHORNE. Phosphorylation of the large subunit of myosin phosphatase and inhibition of phosphatase acitivity. J. Biol. Chem. 271: 4733– 4740, 1996. ILLEK, B., J. R. YANKASKAS, AND T. E. MACHEN. cAMP and genistein stimulate HCO2 3 conductance through CFTR in human airway epithelia. Am. J. Physiol. 272 (Lung Cell. Mol. Physiol. 16): L752—L761, 1997. INGRAM, S. L., AND J. T. WILLIAMS. A non-selective cation current activated via the multifunctional Ca21/calmodulin-dependent protein kinase in human epithelial cells. J. Physiol. (Lond.). 488: 37–55, 1995. INGRAM, S. L., AND J. T. WILLIAMS. Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J. Physiol. (Lond.). 492: 97–106, 1996. INOUE, M., N. FUJISHIRO, AND I. IMANAGA. Mg21-dependent phosphatase as an inhibitory mediator of the nonselective cation current induced by aluminum fluoride in guinea-pig chromaffin cells. Brain Res. 687: 199 –204, 1995. INOUE, M., AND I. IMANAGA. Phosphatase is responsible for run down, and probably G protein-mediated inhibition of inwardly rectifying K1 currents in guinea pig chromaffin cells. J. Gen. Physiol. 105: 249 –266, 1995. INOUE, M., Y. SAKAMOTO, A. YANO, AND I. IMANAGA. Cyanide suppression of inwardly rectifying K1 channels in guinea pig chromaffin cells involves dephosphorylation. Am. J. Physiol. 273 (Cell Physiol. 42): C137—C147, 1997. ISHIHARA, H., B. L. MARTIN, D. L. BRAUTIGAN, H. KARAKI, H. OZAKI, Y. KATO, N. FUSETANI, S. WATABE, K. HASHIMOTO, D. UEMURA, AND D. J. HARTSHORNE. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem. Biophys. Res. Commun. 159: 871– 877, 1989. ISHIHARA, H., H. OZAKI, K. SATO, M. HORI, H. KARAKI, S. WATABE, Y. KATO, N. FUSETANI, K. HASHIMOTO, D. UEMURA, AND D. J. HARTSHORNE. Calcium-independent activation of contractile apparatus in smooth muscle by calyculin-A. J. Pharmacol. Exp. Ther. 250: 388 –396, 1989. JAGIELLO, I., M. BEULLENS, W. STALMANS, AND M. BOLLEN. Subunit structure and regulation of protein phosphatase-1 in rat liver nuclei. J. Biol. Chem. 270: 17257–17263, 1995. JAKAB, M., T. M. WEIGER, AND A. HERMANN. Ethanol activates maxi Ca21-activated K1 channels of clonal pituitary (GH3) cells. J. Membr. Biol. 157: 237–245, 1997. JESSUS, C., J. GORIS, S. STAQUET, X. CAYLA, R. OZON, AND W. MERLEVEDE. Identification of the ATP-Mg-dependent and polycation-stimulated protein phosphatases in the germinal vesicle of the Xenopus oocyte. Biochem. J. 260: 45–51, 1989. JOCHIMSEN, E. M., W. W. CARMICHAEL, J. AN, D. M. CARDO, S. T. COOKSON, C. E. M. HOLMES, M. B. C. ANTUNES, D. A. MELO FILHO, T. M. LYRA, V. S. T. BARRETO, S. M. F. O. AZE-

231.

232.

233.

234.

235.

236.

237.

238.

239.

240.

241.

242.

243.

244.

245.

246.

247.

248.

Volume 80

VEDO, AND W. R. JARVIS. Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil. N. Engl. J. Med. 338: 873– 878, 1998. JOHNSON, D., P. COHEN, Y. H. CHEN, M. X. CHEN, AND P. T. W. COHEN. Identification of the regions on the M110 subunit of protein phosphatase 1M that interact with the M21 subunit and with myosin. Eur. J. Biochem. 244: 931–939, 1997. JOHNSON, D. F., G. MOORHEAD, F. B. CAUDWELL, P. COHEN, Y. H. CHEN, M. X. CHEN, AND P. T. W. COHEN. Identification of protein-phosphatase-1-binding domains on the glycogen and myofibrillar targetting subunits. Eur. J. Biochem. 239: 317–325, 1996. JUREVICIUS, J., AND R. FISCHMEISTER. Acetylcholine inhibits Ca21 current by acting exclusively at a site proximal to adenylyl cyclase in frog cardiac myocytes. J. Physiol. (Lond.). 491: 669 – 675, 1996. KAMIBAYASHI, C., R. ESTES, R. L. LICKTEIG, S.-I. YANG, C. CRAFT, AND M. C. MUMBY. Comparison of heterotrimeric protein phosphatase 2A containing different B subunits. J. Biol. Chem. 269: 20139 –20148, 1994. KAMIBAYASHI, C., R. L. LICKTEIG, R. ESTES, G. WALTER, AND M. C. MUMBY. Expression of the A subunit of protein phosphatase 2A and characterization of its interactions with the catalytic and regulatory subunits. J. Biol. Chem. 267: 21864 –21872, 1992. KAMMERMEIER, P. J., AND S. W. JONES. Facilitation of L-type calcium current in thalamic neurons. J. Neurophysiol. 49: 410 – 417, 1998. KANG, J., P. POSNER, AND C. SUMNERS. Angiotensin II type 2 receptor stimulation of neuronal K1 currents involves an inhibitory GTP binding protein. Am. J. Physiol. 267 (Cell Physiol. 36): C1389 —C1397, 1994. KAWAI, S. Apomorphine is a potent inhibitor of type 2A protein phosphatase in rat brain. Biochem. Biophys. Res. Commun. 176: 737–740, 1991. KIM, D. Beta-adrenergic regulation of the muscarinic-gated K1 channel via cyclic AMP-dependent protein kinase in atrial cells. Circ. Res. 67: 1292–1298, 1990. KIM, D. Modulation of acetylcholine-activated K1 channel function in rat atrial cells by phosphorylation. J. Physiol. (Lond.). 437: 133–155, 1991. KIM, D. Mechanism of rapid desensitization of muscarinic K1 current in adult rat and guinea pig atrial cells. Circ. Res. 73: 89 –97, 1993. KIM, S. J., K. Y. KIM, S. J. TAPSCOTT, T. S. WINOKUR, K. PARK, H. FUJIKI, H. WEINTRAUB, AND A. B. ROBERTS. Inhibition of protein phosphatases blocks myogenesis by first altering MyoD binding activity. J. Biol. Chem. 267: 15140 –15145, 1992. KIM, S. J., R. LAFYATIS, K. Y. KIM, P. ANGEL, H. FUJIKI, M. KARIN, M. B. SPORN, AND A. B. ROBERTS. Regulation of collagenase gene expression by okadaic acid, an inhibitor of protein phosphatases. Cell Regul. 1: 269 –278, 1990. KIM, D., M. WATSON, AND V. INDYK. ATP-dependent regulation of a G-protein-coupled K1 channel (GIRK1/GIRK4) expressed in oocytes. Am. J. Physiol. 272 (Heart Circ. Physiol. 41): H195—H206, 1997. KINCAID, R. L., P. R. GIRIR, S. HIGUCHI, J. TAMURA, S. C. DIXON, C. A. MARIETTA, D. A. AMORESE, AND B. M. MARTIN. Cloning and characterization of molecular isoforms of the catalytic subunit of calcineurin using nonisotopic methods. J. Biol. Chem. 265: 11312– 11319, 1990. KING, B., C. C. CHEN, A. N. AKOPIAN, G. BURNSTOCK, AND J. N. WOOD. A role for calcineurin in the desensitization of the P2X3 receptor. Neuroreport 24: 1099 –1102, 1997. KISSINGER, C. R., H. E. PARGE, D. R. KNIGHTON, C. T. LEWIS, L. A. PELLETIER, A. TEMPCZYK, V. J. KALISH, K. D. TUCKER, R. E. SHOWALTER, E. W. MOOMAW, L. N. GASTINEI, N. HABUKA, X. CHEN, F. MALDONATO, J. E. BARKER, R. BACQUET, AND J. E. VILLAFRANCA. Crystal structure of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378: 641– 644, 1995. KITAGAWA, Y., R. SAKAI, T. TAHIRA, H. TSUDA, N. ITO, T. SUGIMURA, AND M. NAGAO. Molecular cloning of rat phosphoprotein phosphatase 2Ab cDNA and increased expression of phospha-

January 2000

249.

250.

251.

252.

253.

254.

255.

256.

257.

258.

259.

260.

261.

262.

263.

264.

265.

266.

267.


tase 2Aa and 2Ab in rat liver tumors. Biochem. Biophys. Res. Commun. 157: 821– 827, 1988. KITAGAWA, Y., T. TAHIRA, I. IKEDA, K. KIKUCHI, S. TSUIKI, T. SUGIMURA, AND M. NAGAO. Molecular cloning cDNA for the catalytic subunit of rat liver type 2A protein phosphatase, and detection of high levels of expression of the gene in normal and cancer cells. Biochim. Biophys. Acta 951: 123–129, 1988. KNAPP, J., P. BOKNIK, B. LINCK, H. LU¨SS, F. U. MU¨LLER, P. NACKE, J. NEUMANN, W. SCHMITZ, AND U. VAHLENSIECK. The protein phosphatase inhibitor cantharidin attenuates b-adrenoceptor mediated vasorelaxation. Br. J. Pharmacol. 120: 421– 428, 1997. KNAPP, J., P. BOKNIK, S. HUKE, H. LU¨SS, F. U. MU¨LLER, T. MU¨LLER, P. NACKE, W. SCHMITZ, U. VAHLENSIECK, AND J. NEUMANN. On the mechanism of action of cantharidin in smooth muscle. Br. J. Pharmacol. 123: 911–919, 1998. KOLESNICK, R., AND D. W. GOLDE. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77: 325–328, 1994. KONDO, N., I. KODAMA, H. KOTAKE, AND S. SHIBATA. Electrical effects of okadaic acid extracted from black sponge on rabbit sinus node. Br. J. Pharmacol. 101: 241–246, 1990. KONDRATYUK, T., AND S. ROSSIE. Depolarization of rat brain synaptosomes increases phosphorylation of voltage-sensitive sodium channels. J. Biol. Chem. 272: 16978 –16983, 1997. KOPTA, C., AND J. H. STEINBACH. Comparison of mammalian adult and fetal nicotinic acetylcholine receptors stably expressed in fibroblasts. J. Neurosci. 14: 3922–3933, 1994. KOSTYUK, P. G., AND E. A. LUKYANETZ. Mechanisms of antagonistic action of internal Ca21 on serotonin-induced potentiation of Ca21 currents in Helix neurones. Pflu¨gers Arch. 424: 73– 83, 1993. KOUMI, S., J. A. WASSERSTROM, AND R. E. TEN EICK. Betaadrenergic and cholinergic modulation of the inwardly rectifying K1 current in guinea-pig ventricular myocytes. J. Physiol. (Lond.). 486: 647– 659, 1995. KOUMI, S., J. A. WASSERSTROM, AND R. E. TEN EICK. Betaadrenergic and cholinergic modulation of inward rectifier K1 channel function and phosphorylation in guinea-pig ventricle. J. Physiol. (Lond.). 486: 661– 678, 1995. KOWLURU, A., S. E. SEAVEY, M. E. RABAGLIA, R. NESHER, AND S. A. METZ. Carboxymethylation of the catalytic subunit of protein phosphatase 2A in insulin-secreting cells: evidence for functional consequences on enzyme activity and insulin secretion. Endocrinology 137: 2315–2323, 1996. KUBOKAWA, M., C. M. MCNICHOLAS, M. A. HIGGINS, W. WANG, 1 AND G. GIEBISCH. Regulation of ATP-sensitive K channel by membrane-bound protein phosphatases in rat principal tubule cell. Am. J. Physiol. 269 (Renal Fluid Electrolyte Physiol. 38): F355— F362, 1995. KUNO, T., T. TAKEDA, M. HIRAI, A. ITO, H. MUKAI, AND C. TANAKA. Evidence for a second isoform of the catalytic subunit of calmodulin-dependent protein phosphatase (calcineurin A). Biochem. Biophys. Res. Commun. 165: 1352–1358, 1989. KURIHARA, T., R. M. LEWIS, J. EISLER, AND P. GREENGARD. Cloning of complementary DNA for DARPP-32 a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. J. Neurosci. 8: 508 –517, 1988. KWAK, Y. G., S. K. PARK, K. P. CHO, AND S. W. CHAE. Reciprocal modulation of ATP-sensitive K1 channel activity in rat ventricular myocytes by phosphorylation of tyrosine and serine/threonine residues. Life Sci. 58: 897–904, 1996. KWON, Y. G., S. Y. LEE, Y. CHOI, P. GREENGARD, AND A. C. NAIRN. Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. Proc. Natl. Acad. Sci. USA 94: 2168 –2173, 1997. LA, B. Q., S. L. CAROSI, J. VALENTICH, S. SHENOLIKAR, AND S. C. SANSOM. Regulation of epithelial chloride channels by protein phosphatase. Am. J. Physiol. 260 (Cell Physiol. 29): C1217—C1223, 1991. LAI, M. M., P. E. BURNETT, H. WOLOSKER, S. BLACKSHAW, AND S. H. SNYDER. Cain, a novel physiologic protein inhibitor of calcineurin. J. Biol. Chem. 273: 18325–18331, 1998. LAI, Y., B. Z. PETERSON, AND W. A. CATTERALL. Selective de-

268.

269.

270.

271.

272.

273.

274.

275.

276.

277.

278.

279.

280.

281.

282.

283.

284.

285.

286.

205

phosphorylation of the subunits of skeletal muscle calcium channels by purified phosphoprotein phosphatases. J. Neurochem. 61: 1333–1339, 1993. LAIDLEY, C. W., E. COHEN, AND J. E. CASIDA. Protein phosphatase in neuroblastoma cells: [3H]cantharidin binding site in relation to cytotoxicity. J. Pharmacol. Exp. Ther. 280: 1152–1158, 1997. LANSDELL, K. A., J. F. KIDD, S. J. DELANEY, B. J. WAINWRIGHT, AND D. N. SHEPPARD. Regulation of murine cystic fibrosis transmembrane conductance regulator Cl2 channels expressed in Chinese hamster ovary cells. J. Physiol. (Lond.). 512: 751–764, 1998. LANG, R. J., I. Z. OZOLINS, AND R. J. PAUL. Effects of okadaic acid and ATPgS on cell length and Ca21-channel currents recorded in single smooth muscle cells of the guinea-pig taenia caeci. Br. J. Pharmacol. 104: 331–336, 1991. LARSSON, O., C. J. BARKER, A. SJO¨HOLM, H. CARLQVIST, R. H. MICHELL, A. BERTORELLO, T. NILSSON, R. E. HONKANEN, G. W. MAYR, J. ZWILLER, AND P. O. BERGGREN. Inhibition of phosphatases and increased Ca21 channel activity by inositol hexakisphosphate. Science 278: 471– 474, 1997. LEE, M. Y., H. W. BANG, I. J. LIM, D. Y. UHM, AND S. D. RHEE. Modulation of large conductance calcium-activated K1 channel by membrane-delimited protein kinase and phosphatase activities. Pflu¨gers Arch. 429: 150 –152, 1994. LEE, J., Y. CHEN, T. TOLSTYKH, AND J. STOCK. A specific protein carboxyl methyltransferase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc. Natl. Acad. Sci. USA 93: 6043– 6047, 1996. LEE, K., I. C. ROWE, AND M. L. ASHFORD. Characterization of an ATP-modulated large conductance Ca21-activated K1 channel present in rat cortical neurones. J. Physiol. (Lond.). 488: 319 –337, 1995. LEE, L., AND J. STOCK. Protein phosphatase 2A catalytic subunit is methyl-esterified at its carboxyl terminus by a novel methyltranferase. J. Biol. Chem. 268: 19192–19195, 1993. LEGENDRE, P., C. ROSENMUND, AND G. L. WESTBROOK. Inactivation of NMDA channels in cultured hippocampal neurons by intracellular calcium. J. Neurosci. 13: 674 – 684, 1993. LI, M., H. GUO, AND Z. DAMUNI. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34: 1988 –1996, 1995. LI, M., A. MAKKINJE, AND Z. DAMUNI. The myeloid leukemiaassociated protein set is a potent inhibitor of protein phosphatase 2A. J. Biol. Chem. 271: 11059 –11062, 1996. LI, M., A. MAKKINJE, AND Z. DAMUNI. Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry 35: 6998 –7002, 1996. LI, M., J. W. WEST, R. NUMANN, B. J. MURPHY, T. SCHEUER, AND W. A. CATTERALL. Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase. Science 261: 1439 –1443, 1993. LI, Y. M., AND J. E. CASIDA. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc. Natl. Acad. Sci. USA 89: 11867–11870, 1992. LI, Y. M., C. MACKINTOSH, AND J. E. CASIDA. Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site. Biochem. Pharmacol. 46: 1435–1443, 1993. LIEBERMAN, D. N., AND I. MODY. Regulation of NMDA channel function by endogenous Ca21-dependent phosphatase. Nature 369: 235–239, 1994. LIGHT, P. E., B. G. ALLEN, M. P. WALSH, AND R. J. FRENCH. Regulation of adenosine triphosphate-sensitive potassium channels from rabbit ventricular myocytes by protein kinase C and type 2A protein phosphatase. Biochemistry 34: 7252–7257, 1995. LIGHT, P. E., A. A. SABIR, B. G. ALLEN, M. P. WALSH, AND R. J. FRENCH. Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K1 channels. A possible mechanistic link to ischemic preconditioning. Circ. Res. 79: 399 – 406, 1996. LINCK, B., P. BOKNIK, P. KNAPP, F. U. MU¨LLER, J. NEUMANN, W. SCHMITZ, AND U. VAHLENSIECK. Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts. Br. J. Pharmacol. 119: 545–550, 1996.

206


287. LIU, J., J. D. FARMER, JR., W. S. LANE, J. FRIEDMAN, I. WEISSMAN, AND S. L. SCHREIBER. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807– 815, 1991. 288. LOPATIN, A. N., AND C. G. NICHOLS. 2,3-Butanedione monoxime (BDM) inhibition of delayed rectifier DRK1 (Kv2.1) potassium channels expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 265: 1011–1016, 1993. 289. LU, C., R. KUMAR, T. AKITA, AND R. W. JOYNER. Developmental changes in the actions of phosphatase inhibitors on calcium current of rabbit heart. Pflu¨gers Arch. 427: 389 –398, 1994. 290. LUAN, S., W. LI, F. RUSNAK, S. M. ASSMANN, AND S. L. SCHREIBER. Immunosuppressants implicate protein phosphatase regulation of K1 channels in guard cells. Proc. Natl. Acad. Sci. USA 90: 2202–2206, 1993. 291. LUKYANETZ, E. A. Evidence for colocalization of calcineurin and calcium channels in dorsal root ganglion neurons. Neuroscience 78: 625– 628, 1997. 292. LUKYANETZ, E. A., T. P. PIPER, AND T. S. SIHRA. Calcineurin involvement in the regulation of high-threshold Ca21 channels in NG108 –15 (rodent neuroblastoma 3 glioma hybrid) cells. J. Physiol. (Lond.). 510: 371–385, 1998. 293. LUO, J., M. D. PATO, J. R. RIORDAN, AND J. W. HANRAHAN. Differential regulation of single CFTR channels by PP2C, PP2A, and other phosphatases. Am. J. Physiol. 274 (Cell Physiol. 43): C1397—C1410, 1998. 294. MACDOUGALL, L. K., D. G. CAMPBELL, M. J. HUBBARD, AND P. COHEN. Partial structure and hormonal regulation of rabbit liver inhibitor-1: distribution of inhibitor-1 and inhibitor-2 in rabbit and rat tissues. Biochim. Biophys. Acta 1010: 218 –226, 1989. 295. MACKINTOSH, C., D. G. CAMPBELL, A. HIRAGA, AND P. COHEN. Phosphorylation of the glycogen-binding subunit of protein phosphatase-1G in response to adrenalin. FEBS Lett. 234: 189 –194, 1988. 296. MACKINTOSH, C., AND S. KLUMPP. Tautomycin from the bacterium Streptomyces verticillatus. FEBS Lett. 277: 137–140, 1990. 297. MACKINTOSH, C., AND R. W. MACKINTOSH. Inhibitors of eukaryontic protein (serine/threonine) phosphatases: environmental toxins prove useful in the laboratory. Adv. Protein Phosphatases 8: 343–354, 1994. 298. MACKINTOSH, C., K. A. BEATTIE, S. KLUMPP, P. COHEN, AND G. A. CODD. Cyanobacterial microcystin-LR is a potent and specific inhibitor of protein phosphatase 1 and 2A from both mammals and higher plants. FEBS Lett. 264: 187–192, 1990. 299. MACKINTOSH, R. W., K. N. DALBY, D. G. CAMPBELL, P. T. W. COHEN, P. COHEN, AND C. MACKINTOSH. The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1. FEBS Lett. 371: 236 –240, 1995. 300. MAHADEVAN, L. C., A. C. WILLIS, AND M. J. BARRATT. Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors. Cell 65: 775– 783, 1991. 301. MANALAN, A. S., AND D. K. WERTH. Cardiac calmodulin-stimulated protein phosphatase: purification and identification of specific sarcolemmal substrates. Circ. Res. 60: 602– 611, 1987. 302. MANN, D. J., D. G. CAMPBELL, C. H. MCGOWAN, AND P. T. COHEN. Mammalian protein serine/threonine phosphatase 2C: cDNA cloning and comparative analysis of amino acid sequences. Biochim. Biophys. Acta 1130: 100 –104, 1992. 303. MANN, D. J., V. DOMBRADI, AND P. T. COHEN. Drosophila protein phosphatase V functionally complements a SIT4 mutant in Saccharomyces cerevisiae and its amino-terminal region can confer this complementation to a heterologous phosphatase catalytic domain. EMBO J. 12: 4833– 4842, 1993. 304. MARUNAKA, Y., N. NIISATO, AND Y. SHINTANI. Protein phosphatase 2B-dependent pathway of insulin action on single Cl2 channel conductance in renal epithelium. J. Membr. Biol. 161: 235–245, 1998. 305. MATEO, J., E. CASTRO, J. ZWILLER, D. AUNIS, AND M. T. MIRASPORTUGAL. 59-(N-ethylcarboxamido)adenosine inhibits Ca21 influx and activates a protein phosphatase in bovine adrenal chromaffin cells. J. Neurochem. 64: 77– 84, 1995.

Volume 80

306. MATSUDA, S., H. KOSAKO, K. TAKENAKA, K. MORIYAMA, H. SAKAI, T. AKIYAMA, Y. GOTOH, AND E. NISHIDA. Xenopus MAP kinase activator: identification and function as a key intermediate in the phosphorylation cascade. EMBO J. 11: 973–982, 1992. 307. MATSUZAWA, S., T. SUZUKI, M. SUZUKI, A. MATSUDA, T. KAWAMURA, Y. MIZUNO, AND K. KIKUCHI. Thyrsiferyl 23-acetate is a novel specific inhibitor of protein phosphatase PP2A. FEBS Lett. 356: 272–274, 1994. 308. MAYER, R. E., P. HENDRIX, P. CRON, R. MATTHIES, S. R. STONE, J. GORIS, W. MERLEVEDE, J. HOFSTEENGE, AND B. A. HEMMINGS. Structure of the 55-kDa regulatory subunit of protein phosphatase 2A: evidence for a neuronal-specific isoform. Biochemistry 30: 3589 –3597, 1991. 309. MCCRIGHT, B., AND D. M. VIRSHUP. Identification of a new family of protein phosphatase 2A regulatory subunits. J. Biol. Chem. 270: 26123–26128, 1995. 310. MCNICHOLAS, C. M., W. WANG, K. HO, S. C. HEBERT, AND G. GIEBISCH. Regulation of ROMK1 K1 channel activity involves phosphorylation processes. Proc. Natl. Acad. Sci. USA 91: 8077– 8081, 1994. 311. MEDINA, I., N. FILIPPOVA, A. BAKHRAMOV, AND P. BREGESTOVSKI. Calcium-induced inactivation of NMDA receptor-channels evolves independently of run-down in cultured rat brain neurones. J. Physiol. (Lond.). 495: 411– 427, 1996. 312. MEGURO, T., C. HONG, K. ASAI, G. TAGAKI, T. A. MCKINSEY, E. N. OLSON, AND S. F. VATNER. Cyclosporine attenuates pressureoverload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84: 735–740, 1999. 313. MEISTER, B., J. FRYCKSTEDT, M. SCHALLING, R. CORTES, T. HOKFELT, A. APERIA, H. C. HEMMINGS, A. C. NAIRN, M. EHRLICH, AND P. GREENGARD. Dopamine and cAMP-regulated phosphoprotein (DARPP-32) and dopamine DA1 agonist sensitive Na1,K1-ATPase in renal tubule cells. Proc. Natl. Acad. Sci. USA 86: 8068 – 8072, 1989. 314. MILAN, D., J. GRIFFITH, M. SU, E. R. PRICE, AND F. MCKEON. The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation. Cell 79: 437– 447, 1994. 315. MIRONOV, S. L., AND H. D. LUX. Calmodulin antagonists and protein phosphatase inhibitor okadaic acid fasten the “run-up” of high-voltage activated calcium current in rat hippocampal neurones. Neurosci. Lett. 133: 175–178, 1991. 316. MOLKENTIN, J. D., J. R. LU, C. L. ANTOS, B. MARKHAM, J. RICHARDSON, J. ROBBINS, S. R. GRANT, AND E. N. OLSON. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215–228, 1998. 317. MORISHITA, W., AND B. R. SASTRY. Postsynaptic mechanisms underlying long-term depression of GABAergic transmission in neurons of the deep cerebellar nuclei. J. Neurophysiol. 76: 59– 68, 1996. 318. MUMBY, M. C., K. L. RUSSELL, L. J. GARRARD, AND D. D. GREEN. Cardiac contractile protein phosphatases. Purification of two enzyme forms and their characterization with subunit-specific antibodies. J. Biol. Chem. 262: 6257– 6265, 1987. 319. MUMBY, M. C., AND G. WALTER. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol. Rev. 73: 673– 699, 1993. 320. MURAMATSU, T., P. R. GIRI, S. HIGUCHI, AND R. L. KINCAID. Molecular cloning of a calmodulin-dependent phosphatase from murine testis: identification of a developmentally expressed nonneural isoenzyme. Proc. Natl. Acad. Sci. USA 89: 529 –533, 1992. 321. MURPHY, B. J., S. ROSSIE, K. S. DE JONGH, AND W. A. CATTERALL. Identification of the sites of selective phosphorylation and dephosphorylation of the rat brain Na1 channel a subunit by cAMP-dependent protein kinase and phosphoprotein phosphatase. J. Biol. Chem. 268: 27355–27362, 1993. 322. NAGATA, K., H. KAWASE, H. HANDA, K. YANO, M. YAMASAKI, Y. ISHIMI, A. OKUDA, A. KIKUCHI, AND K. MATSUMOTO. Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis. Proc. Natl. Acad. Sci. USA 92: 4279 – 4283, 1995. 323. NAKASHIMA, Y., AND K. ONO. Rate-limiting steps in activation of

January 2000


cardiac Cl2 current revealed by photolytic application of cAMP. Am. J. Physiol. 267 (Heart Circ. Physiol. 36): H1514 —H1522, 1994. 324. NAKIELNY, S., D. G. CAMPBELL, AND P. COHEN. The molecular mechanism by which adrenalin inhibits glycogen synthesis. Eur. J. Biochem. 199: 713–722, 1991. 325. NAM, K. Y., M. HIRO, S. KIMURA, H. FUJIKI, AND Y. IMANISHI. Permeability of a non-TPA-type tumor promoter, okadaic acid, through lipid bilayer membrane. Carcinogenesis 11: 1171–1174, 1990. 326. NEUMANN, J., P. BOKNIK, S. HERZIG, W. SCHMITZ, H. SCHOLZ, R. C. GUPTA, AND A. M. WATANABE. Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid. Am. J. Physiol. 265 (Heart Circ. Physiol. 34): H257— H266, 1993. 327. NEUMANN, J., P. BOKNIK, S. HERZIG, W. SCHMITZ, H. SCHOLZ, K. WIECHEN, AND N. ZIMMERMANN. Biochemical and electrophysiological mechanisms of the positive inotropic effect of calyculin A, a protein phosphatase inhibitor. J. Pharmacol. Exp. Ther. 271: 535–541, 1994. 327a.NEUMANN, J., P. BOKNIK, G. KASPAREIT, S. BARTEL, E.-G. KRAUSE, H. T. PASK, W. SCHMITZ, AND H. SCHOLZ. Effects of the phosphatase inhibitor calyculin A on the phosphorylation of Cprotein in mammalian ventricular cardiomyocytes. Biochem. Pharmacol. 49: 1583–1588, 1995. 328. NEUMANN, J., T. ESCHENHAGEN, L. R. JONES, B. LINCK, W. SCHMITZ, H. SCHOLZ, AND N. ZIMMERMANN. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J. Mol. Cell. Cardiol. 29: 265–272, 1997. 329. NEUMANN, J., R. C. GUPTA, W. SCHMITZ, H. SCHOLZ, A. C. NAIRN, AND A. M. WATANABE. Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ. Res. 69: 1450 –1457, 1991. 330. NEUMANN, J., S. HERZIG, P. BOKNIK, M. APEL, G. KASPAREIT, W. SCHMITZ, H. SCHOLZ, M. TEPEL, AND N. ZIMMERMANN. On the cardiac contractile, biochemical and electrophysiological effects of cantharidin, a phosphatase inhibitor. J. Pharmacol. Exp. Ther. 274: 530 –539, 1995. 332. NEUMANN, J., Y. SUZUKI, L. J. FIELD, AND A. A. DEPAOLIROACH. Targeted overexpression of glycogen/SR-associated protein phosphatase to murine heart (Abstract). Naunyn-Schmiedeberg’s Arch. Pharmacol. 357: R109, 1998. 333. NOMOTO, K., N. SHIBATA, K. KITAMURA, Y. MIZUNO, AND K. KIKUCHI. Molecular cloning and analysis of the 59-flanking region of the rat PP1a gene. Biochim. Biophys. Acta 1309: 221–224, 1996. 334. NORMAN, S. A., AND D. M. MOTT. Molecular cloning and chromosomal localization of human skeletal muscle PP-1g1 cDNA. Mamm. Genome 5: 41– 45, 1994. 335. OBARA, K., AND H. YABU. Dual effect of phosphatase inhibitors on calcium channels in intestinal smooth muscle cells. Am. J. Physiol. 264 (Cell Physiol. 33): C296 —C301, 1993. 336. OBEJERO-PAZ, C. A., M. AUSLENDER, AND A. SCARPA. PKC activity modulates availability and long openings of L-type Ca21 channels in A7r5 cells. Am. J. Physiol. 275 (Cell Physiol. 44): C535—C543, 1998. 337. OCHI, R., AND Y. KAWASHIMA. Modulation of slow gating process of calcium channels by isoprenaline in guinea-pig ventricular cells. J. Physiol. (Lond.). 424: 187–204, 1990. 338. OKUBO, S., M. ITO, Y. TAKASHIBA, K. ICHIKAWA, M. MIYAHARA, H. SHIMIZU, T. KONISHI, H. SHIMA, M. NAGAO, D. J. HARTSHORNE, AND T. NAKANO. A regulatory subunit of smooth muscle myosin bound phosphatase. Biochem. Biophys. Res. Commun. 200: 429 – 434, 1994. 339. ONO, K., AND H. A. FOZZARD. Phosphorylation restores activity of L-type calcium channels after rundown in inside-out patches from rabbit cardiac cells. J. Physiol. (Lond.) 454: 673– 688, 1992. 340. ONO, K., AND H. A. FOZZARD. Two phosphatase sites on the Ca21 channel affecting different kinetic functions. J. Physiol. (Lond.). 470: 73– 84, 1993. 341. PARK, I. K., P. ROACH, J. BONDOR, S. P. FOX AND A. A. DEPAOLIROACH. Molecular mechanism of the synergistic phosphorylation of phosphatase inhibitor-2. Cloning, expression and site directed

342.

343.

344.

345.

346.

347.

348.

349.

350.

351.

352.

353.

354.

355.

356.

357.

358.

359.

360.

207

mutagenesis of phosphatase inhibitor-2. J. Biol. Chem. 269: 944 – 954, 1994. PARSONS, J. N., G. J. WIEDERRECHT, S. SALOWE, J. J. BURBAUM, L. L. ROKOSZ, R. L. KINCAID, AND S. J. O’KEEFE. Regulation of calcineurin phosphatase activity and interaction with the FK-506-FK-506 binding protein complex. J. Biol. Chem. 269: 19610 – 19616, 1994. PELECH, S., AND P. COHEN. The protein phosphatases involved in cellular regulation. 1. Modulation of protein phosphatases-1 and 2A by histone H1, protamine, polylysine and heparin. Eur. J. Biochem. 148: 245–251, 1985. PEREZ-REYES, E., W. YUAN, X. WEI, AND D. M. BERS. Regulation of the cloned L-type cardiac calcium channel by cyclic-AMP-dependent protein kinase. FEBS Lett. 342: 119 –123, 1994. PINTOR, J., J. GUALIX, AND M. T. MIRAS-PORTUGAL. Dinucleotide receptor modulation by protein kinases (protein kinases A and C) and protein phosphatases in rat brain synaptic terminals. J. Neurochem. 68: 2552–2557, 1997. PRICE, D. J., J. R. GROVE, V. CALVO, J. AVRUCH, AND B. E. BIERER. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257: 973–977, 1992. QU, Y., J. ROGERS, T. TANADA, T. SCHEUER, AND W. A. CATTERALL. Modulation of cardiac Na1 channels expressed in a mammalian cell line and in ventricular myocytes by protein kinase C. Proc. Natl. Acad. Sci. USA 91: 3289 –3293, 1994. QUINTON, P. M., AND M. M. REDDY. Regulation of absorption by phosphorylation of CFTR. Jpn. J. Physiol. 44, Suppl. 2: S207— S213, 1994. RAMAN, I. M., G. TONG, AND C. E. JAHR. Beta-adrenergic regulation of synaptic NMDA receptors by cAMP-dependent protein kinase. Neuron 16: 415– 421, 1996. REDDY, M. M., AND P. M. QUINTON. Deactivation of CFTR-Cl conductance by endogenous phosphatases in the native sweat duct. Am. J. Physiol. 270 (Cell Physiol. 39): C474 —C480, 1996. REENSTRA, W. W., K. YURKO-MAURO, A. DAM, S. RAMAN, AND S. SHORTEN. CFTR chloride channel activation by genistein: the role of serine/threonine protein phosphatases. Am. J. Physiol. 271 (Cell Physiol. 40): C650 —C657, 1996. REINHART, P. H., S. CHUNG, B. L. MARTIN, D. L. BRAUTIGAN, AND I. B. LEVITAN. Modulation of calcium-activated potassium channels from rat brain by protein kinase A and phosphatase 2A. J. Neurosci. 11: 1627–1635, 1991. REINHART, P. H., AND I. B. LEVITAN. Kinase and phosphatase activities intimately associated with a reconstituted calcium-dependent potassium channel. J. Neurosci. 15: 4572– 4579, 1995. ROACH, P., P. J. ROACH, AND A. A. DEPAOLI-ROACH. Phosphoprotein phosphatase inhibitor 2. Identification as a species of molecular weight 31,000 in rabbit muscle, liver and other tissues. J. Biol. Chem. 260: 6314 – 6317, 1985. ROBELLO, M., C. AMICO, AND A. CUPELLO. A dual mechanism for impairment of GABAA receptor activity by NMDA receptor activation in rat cerebellum granule cells. Eur. Biophys. J. 25: 181–187, 1997. ROBERGE, M., C. TUDAN, S. M. F. HUANG, K. W. HARDER, F. R. JIRIK, AND H. ANDERSON. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res. 54: 6115– 6121, 1994. ROBINSON, N. A., J. G. PAGE, C. F. MATSON, G. A. MIURA, AND W. B. LAWRENCE. Tissue distribution, excretion and hepatic biotranformation of microcystin-LR in mice. J. Pharmacol. Exp. Ther. 256: 176 –182, 1991. ROEPER, J., C. LORRA, AND O. PONGS. Frequency-dependent inactivation of mammalian A-type K1 channel Kv1.4 regulated by Ca21/calmodulin-dependent protein kinase. J. Neurosci. 17: 3379 – 3391, 1997. ROSENMUND, C., AND G. L. WESTBROOK. Rundown of N-methylD-aspartate channels during whole-cell recording in rat hippocampal neurons: role of Ca21 and ATP. J. Physiol. (Lond.) 470: 705– 729, 1993. RUNNEGAR, M., N. BRANDT, S. M. KONG, E. Y. C. LEE, AND L. ZHANG. In vivo and in vitro binding of microcystin to protein

208

361. 362.

363.

364.

365.

366.

367.

368.

369.

370.

371. 372.

373.

374.

375.

376.

377.

378.

STEFAN HERZIG AND JOACHIM NEUMANN phosphatases 1 and 2A. Biochem. Biophys. Res. Commun. 216: 162–169, 1995. RUPPERSBERG, J. P., AND B. FAKLER. Complexity of the regulation of Kir2.1 K1 channels. Neuropharmacology 35: 887– 893, 1996. SANGUINETTI, M. C., AND N. K. JURKIEWICZ. Two components of cardiac delayed rectifier K1 current. J. Gen. Physiol. 96: 195–215, 1990. SANSOM, S. C., J. D. STOCKAND, D. HALL, AND B. WILLIAMS. Regulation of large calcium-activated potassium channels by protein phosphatase 2A. J. Biol. Chem. 272: 9902–9906, 1997. SASAKI, K., H. SHIMA, Y. KITAGAWA, S. IRINO, T. SUGIMURA, AND M. NAGAO. Identification of members of the protein phosphatase 1 gene family in the rat and enhanced expression of protein phosphatase 1a gene in rat hepatocellular carcinomas. Jpn. J. Cancer Res. 81: 1272–1280, 1990. SATO, Y., P. MARIOT, P. DETIMARY, P. GILON, AND J. C. HENQUIN. Okadaic acid-induced decrease in the magnitude and efficacy of the Ca21 signal in pancreatic beta cells and inhibition of insulin secretion. Br. J. Pharmacol. 123: 97–105, 1998. SCHIFFMANN, S. N., F. DESDOUITS, R. MENU, P. GREENGARD, J. D. VINCENT, J. J. VANDERHAEGHEN, AND J. A. GIRAULT. Modulation of the voltage-gated sodium current in rat striatal neurons by DARPP-32, an inhibitor of protein phosphatase. Eur. J. Neurosci. 10: 1312–1320, 1998. SCHLICHTER, L. C., P. A. PAHAPILL, AND I. CHUNG. Dual action of 2,3-butanedione monoxime (BDM) on K1 current in human T lymphocytes. J. Pharmacol. Exp. Ther. 261: 438 – 446, 1992. SCHRO¨DER, F., R. HANDROCK, D. J. BEUCKELMANN, S. HIRT, R. HULLIN, L. PRIEBE, R. H. G. SCHWINGER, J. WEIL, AND S. HERZIG. Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation 98: 969 –976, 1998. SCHUBERT, R., V. N. SEREBRYAKOV, H. ENGEL, AND H. H. HOPP. Iloprost activates KCa channels of vascular smooth muscle cells: role of cAMP-dependent protein kinase. Am. J. Physiol. 271 (Cell Physiol. 40): C1203—C1211, 1996. SCHUHMANN, K., C. ROMANIN, W. BAUMGARTNER, AND K. GROSCHNER. Intracellular Ca21 inhibits smooth muscle L-type Ca21 channels by activation of protein phosphatase type 2B and by direct interaction with the channel. J. Gen. Physiol. 110: 503–513, 1997. SCOTT, J. D. Dissection of protein kinase and phosphatase targeting interactions. Soc. Gen. Physiol. Ser. 52: 227–239, 1997. SCULPTOREANU, A., E. ROTMAN, M. TAKAHASHI, T. SCHEUER, AND W. A. CATTERALL. Voltage-dependent potentiation of the activity of cardiac L-type calcium channel a1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA 90: 10135–101359, 1993. SCULPTOREANU, A., T. SCHEUER, AND W. A. CATTERALL. Voltage-dependent potentiation of L-type Ca21 channels due to phosphorylation by cAMP-dependent protein kinase. Nature 364: 240 – 243, 1993. SIHRA, T. S., A. C. NAIRN, P. KLOPPENBURG, Z. LIN, AND C. POUZAT. A role for calcineurin (protein phosphatase-2B) in the regulation of glutamate release. Biochem. Biophys. Res. Commun. 212: 609 – 616, 1995. SHENOLIKAR, S., AND A. C. NAIRN. Protein phosphatases: recent progress. Adv. Second Messenger Phosphoprotein Res. 23: 1–121, 1991. SHIBATA, S., Y. ISHIDA, H. KITANO, Y. OHIZUMI, J. HABON, Y. TSUKITANI, AND H. KIKUCHI. Contractile effects of okadaic acid, a novel ionophore-like substance from black sponge, on isolated smooth muscles under the condition of Ca deficiency. J. Pharmacol. Exp. Ther. 223: 135–143, 1982. SHIMA, H., T. HANEJI, Y. HATANO, I. KASUGAI, T. SUGIMURA, AND M. NAGAO. Protein phosphatase 1 gamma 2 is associated with nuclei of meiotic cells in rat testis. Biochem. Biophys. Res. Commun. 194: 930 –937, 1993. SHIMA, H., Y. HATANO, Y. S. CHUN, T. SUGIMURA, Z. ZHANG, E. Y. LEE, AND M. NAGAO. Identification of PP1 catalytic subunit isotypes PP1 gamma 1, PP1 delta and PP1 alpha in various rat tissues. Biochem. Biophys. Res. Commun. 192: 1289 –1296, 1993.

Volume 80

379. SHIMIZU, H., M. ITO, M. MIYAHARA, K. ICHIKAWA, S. OKUBO, T. KONISHI, N. NAKA, T. TANAKA, K. HIRANO, D. J. HARTSHORNE, AND T. NAKANO. Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase. J. Biol. Chem. 269: 30407– 30411, 1994. 380. SHIRAKAWA, S., H. MOCHIZUKI, S. KOBAYASHI, T. TAKEHARA, H. SHIMA, M. NAGAO, AND T. HANEJI. Immunohistochemical and immunoblotting identification of protein phosphatase 1g1 in rat salivary glands. FEBS Lett. 393: 57–59, 1996. 381. SIK, A., N. HAJOS, A. GULASKI, I. MODY, AND T. F. FREUND. The absence of a major Ca21 signalling pathway in GABAergic neurons of the hippocampus. Proc. Natl. Acad. Sci. USA 95: 3245–3250, 1998. 382. SILBERBERG, S. D., A. LAGRUTTA, J. P. ADELMAN, AND K. L. MAGLEBY. Wanderlust kinetics and variable Ca21 sensitivity of Drosophila, a large conductance Ca21-activated K1 channel, expressed in oocytes. Biophys. J. 70: 2640 –2651, 1996. 383. SINGER-LAHAT, D., I. LOTAN, M. BIEL, V. FLOCKERZI, F. HOFMANN, AND N. DASCAL. Cardiac calcium channels expressed in Xenopus oocytes are modulated by dephosphorylation but not by cAMPdependent phosphorylation. Receptors Channels 2: 215–226, 1994. 384. SMITH, P. A., B. A. WILLIAMS, AND F. M. ASHCROFT. Block of ATP-sensitive K1 channels in isolated mouse pancreatic beta-cells by 2,3-butanedione monoxime. Br. J. Pharmacol. 112: 143–149, 1994. 385. SMITH, R. D., AND A. L. GOLDIN. Protein kinase A phosphorylation enhances sodium channel currents in Xenopus oocytes. Am. J. Physiol. 263 (Cell Physiol. 32): C660 —C666, 1992. 386. SONTAG, E., S. FEDOROV, C. KAMIBAYASHI, D. ROBBINS, M. COBB, AND M. MUMBY. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the MAP kinase pathway and induces cell proliferation. Cell 75: 887– 897, 1993. 387. SONTAG, E., V. NUNBDAKDI-CRAIG, G. LEE, G. S. BLOOM, AND M. C. MUMBY. Regulation of the phosphorylation state and microtubule-binding activity of tau by protein phosphatase 2A. Neuron 17: 1201–1207, 1996. 388. STELZER, A., AND H. SHI. Impairment of GABAA receptor function by N-methyl-D-aspartate-mediated calcium influx in isolated CA1 pyramidal cells. Neuroscience 62: 813– 828, 1994. 389. STOCKAND, J. D., AND S. C. SANSOM. Mechanism of activation by cGMP-dependent protein kinase of large Ca21-activated K1 channels in mesangial cells. Am. J. Physiol. 271 (Cell Physiol. 40): C1669 —C1677, 1996. 390. STOCKAND, J. D., AND S. C. SANSOM. Glomerular mesangial cells: electrophysiology and regulation of contraction. Physiol. Rev. 78: 723–744, 1998. 391. STOCKAND, J. D., M. SILVERMAN, D. HALL, T. DERR, B. KUBACAK, AND S. C. SANSOM. Arachidonic acid potentiates the feedback response of mesangial BKCa channels to angiotensin II. Am. J. Physiol. 274 (Renal Physiol. 43): F658 —F664, 1998. 392. STONE, S. R., J. HOFSTEENGE, AND B. A. HEMMINGS. Molecular cloning of cDNAs coding two isoforms of the catalytic subunit of protein phosphatase 2A. Biochemistry 26: 7215–7220, 1987. 393. STONE, S. R., R. MAYER, W. WERNET, F. MAURER, J. HOFSTEENGE, AND B. A. HEMMINGS. The nucleotide sequence of the cDNA encoding the human lung protein phosphatase 2A alpha catalytic subunit. Nucleic Acids Res. 16: 11365, 1988. 394. STRALFORS, P., A. HIRAGA, AND P. COHEN. The protein phosphatases involved in cellular regulation. Purification and characterisation of the glycogen-bound form of protein phosphatase-1 from rabbit skeletal muscle. Eur. J. Biochem. 149: 295–303, 1985. 395. STURGILL, T. W., L. B. RAY, E. ERIKSON, AND J. L. MALLER. Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature 334: 715–718, 1988. 396. SUGANUMA, M., H. FUJIKI, H. SUGURI, S. YOSHIZAWA, M. HIROTA, M. NAKAYASU, M. OJIKA, K. WAKAMATSU, K. YAMADA, AND T. SUGIMURA. Okadaic acid: an additional non-phorbol-12tetradecanoate-13-acetate-type tumor promoter. Proc. Natl. Acad. Sci. USA 85: 1768 –1771, 1988. 397. SURMEIER, D. J., J. BARGAS, H. C. HEMMINGS, JR., A. C. NAIRN, AND P. GREENGARD. Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron 14: 385–397, 1995.

January 2000


398. SUSSMANN, M. A., H. W. LIM, N. GUDE, T. TAIGEN, E. N. OLSON, J. ROBBINS, M. C. COLBERT, A. GUALBERTO, D. F. WIECZOREK, AND J. D. MOLTENKIN. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281: 1690 –1693, 1998. 399. SUTHERLAND, C., I. A. LEIGHTON, AND P. COHEN. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296: 15–19, 1993. 400. TAKAI, A., C. BIALOJAN, M. TROSCHKA, AND J. C. RU¨EGG. Smooth muscle myosin phosphatase inhibition and force enhancement by black sponge toxin. FEBS Lett. 217: 81– 84, 1987. 401. TAKAI, A., K. SASAKI, H. NAGAI, G. MIESKES, M. ISOBE, K. ISONO, AND T. YASUMOTO. Inhibition of specific binding of okadaic acid to protein phosphatase 2A by microcystin-LR, calyculin-A and tautomycin: method of analysis of interactions of tight-binding ligands with target protein. Biochem. J. 306: 657– 665, 1995. 402. TAKANO, K., P. R. STANFIELD, S. NAKAJIMA, AND Y. NAKAJIMA. Protein kinase C-mediated inhibition of an inward rectifier potassium channel by substance P in nucleus basalis neurons. Neuron 14: 999 –1008, 1995. 403. TAKANO, K., T. TAKEI, A. TERAMOTO, AND N. YAMASHITA. GHRH activates a nonselective cation current in human GH-secreting adenoma cells. Am. J. Physiol. 270 (Endocrinol. Metab. 33): E1050 —E1057, 1996. 404. TAMURA, S., K. R. LYNCH, J. LARNER, J. FOX, A. YASUI, K. KIKUCHI, Y. SUZUKI, AND S. TSUIKI. Molecular cloning of rat type 2C (IA) protein phosphatase mRNA. Proc. Natl. Acad. Sci. USA 86: 1796 –1800, 1989. 405. TANG, P. M., J. A. BONDOR, K. M. SWIDEREK, AND A. A. DEPAOLI-ROACH. Molecular cloning and expression of the regulatory (RGL) subunit of glycogen-associated protein phosphatase. J. Biol. Chem. 266: 15782–15789, 1991. 406. TEHRANI, M. H., AND E. M., BARNES, JR. GABAA receptors in mouse cortical homogenates are phosphorylated by endogenous protein kinase A. Brain Res. 24: 55– 64, 1994. 407. TEHRANI, M. H., M. C. MUMBY, AND C. KAMIBAYASHI. Identification of a novel protein phosphatase 2A regulatory subunit highly expressed in muscle. J. Biol. Chem. 271: 5164 –5170, 1996. 408. TERASAWA, T., T. KOBAYASHI, T. MURAKAMI, M. OHNISHI, S. KATO, O. TANAKA, H. KONDO, H. YAMAMOTO, T. TAKEUCHI, 21 AND S. TAMURA. Molecular cloning of a novel isotype of Mg dependent protein phosphatase beta (type 2C beta) enriched in brain and heart. Arch. Biochem. Biophys. 307: 342–349, 1993. 409. TERASHIMA, A., M. NAKAI, T. HASHIMOTO, T. KAWAMATA, T. TANIGUCHI, M. YASUDA, K. MAEDA K, AND C. TANAKA. Singlechannel activity of the Ca21-dependent K1 channel is modulated by FK506 and rapamycin. Brain Res. 786: 255–258, 1998. 410. THEVENIN, C., S. J. KIM, AND J. H. KEHRL. Inhibition of protein phosphatases by okadaic acid induces AP1 in human T cells. J. Biol. Chem. 266: 9363–9366, 1991. 411. THOMAS, G. D., B. O’ROURKE, R. SIKKINK, F. RUSNAK, E. MARBAN, AND R. G. VICTOR. Differential modulation of cortical synaptic activity by calcineurin (phosphatase 2B) versus phosphatases 1 and 2A. Brain Res. 749: 101–108, 1997. 412. TIAN, L., H. G. KNAUS, AND M. J. SHIPSTON. Glucocorticoid regulation of calcium-activated potassium channels mediated by serine/threonine protein phosphatase. J. Biol. Chem. 273: 13531– 13536, 1998. 413. TOKUI, T., F. BROZOVICH, S. ANDO, AND M. IKEBE. Enhancement of smooth muscle contraction with protein phosphatase inhibitor 1: activation of inhibitor 1 by cGMP dependent protein kinase. Biochem. Biophys. Res. Commun. 220: 777–783, 1996. 414. TONG, G., AND C. E. JAHR. Regulation of glycine-insensitive desensitization of the NMDA receptor in outside-out patches. J. Neurophysiol. 72: 754 –761, 1994. 415. TONG, G., D. SHEPHERD, AND C. E. JAHR. Synaptic desensitization of NMDA receptors by calcineurin. Science 267: 1510 –1512, 1995. 416. TRINKLE-MULCAHY, L., K. ICHIKAWA, D. J. HARTSHORNE, M. J. SIEGMAN, AND T. M. BUTLER. Thiophosphorylation of the 130-kDa subunit is associated with a decreased activity of myosin light

417.

418.

419.

420.

421.

422.

423.

424.

425.

426.

427.

428.

429.

430.

431.

432. 433.

434.

209

chain phosphatase in a-toxin-permeablized smooth muscle. J. Biol. Chem. 270: 18191–18194, 1995. TRIPATHI, O., AND N. SPERELAKIS. Calcineurin trapped in liposomes inhibits the action potentials of isolated 3-days-old embryonic chick ventricle. J. Dev. Physiol. 18: 121–124, 1992. TUROWSKI, P., A. FERNENDEZ, B. FAVRE, N. J. C. LAMB, AND B. A. HEMMINGS. Differential methylation and altered conformation of cytoplasmic and nuclear forms of protein phosphatase 2A during cell cycle progression. J. Cell Biol. 129: 397– 410, 1995. UEKI, K., T. MURAMATSU, AND R. L. KINCAID. Structure and expression of two isoforms of the murine calmodulin-dependent protein phosphatase regulatory subunit (calcineurin B). Biochem. Biophys. Res. Commun. 187: 537–543, 1992. USUKI, T., K. OBARA, T. SOMEYA, H. OZAKI, H. KARAKI, N. FUSETANI, AND H. YABU. Calyculin A increases voltage-dependent inward current in smooth muscle cells isolated from guinea pig taenia coli. Experientia 47: 939 –941, 1991. VAESEN, M., S. BARNIKOL-WATANABE, H. GO¨TZ, L. A. AWNI, T. COLE, B. ZIMMERMANN, H. D. KRATZIN, AND N. HILSCHMANN. Purification and characterization of two putative HLA class II associated proteins: PHAPI and PHAPII. Biol. Chem. Hoppe-Seyler 375: 113–126, 1994. VAN EYNDE, A., M. BEULLENS, W. STALMANS, AND M. BOLLEN. Full activation of a nuclear species of protein phosphatase-1 by phosphorylation with protein kinase A and casein kinase-2. Biochem. J. 297: 447– 449, 1994. VAN EYNDE, A., S. WERA, M. BEULLENS, S. TORREKENS, F. VAN LEUVEN, W. STALMANS, AND M. BOLLEN. Molecular cloning of NIPP-1, a nuclear inhibitor of protein phosphatase-1, reveals homology with polypeptides involved in RNA processing. J. Biol. Chem. 270: 28068 –28074, 1995. VICTOR, R. G., F. RUSNAK, R. SIKKINK, E. MARBAN, AND B. O’ROURKE. Mechanism of Ca21-dependent inactivation of L-type Ca21 channels in GH3 cells: direct evidence against dephosphorylation by calcineurin. J. Membr. Biol. 156: 53– 61, 1997. VICTOR, R. G., G. D. THOMAS, E. MARBAN, AND B. O’ROURKE. Presynaptic modulation of cortical synaptic activity by calcineurin. Proc. Natl. Acad. Sci. USA 92: 6269 – 6273, 1995. VON LINDERN, M., M. FORNEROD, S. VAN BAAL, M. JAEGLE, T. DE WIT, A. BUIJS, AND G. GROSVELD. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol. Cell. Biol. 12: 1687–1697, 1992. VON LINDERN, M., S. VAN BAAL, J. WIEGANT, A. RAAP, A. HAGEMEIJER, AND G. GROSVELD. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 39 half to different genes: characterization of the set gene. Mol. Cell. Biol. 12: 3346 –3355, 1992. VULSTEKE, V., M. BEULLENS, E. WAELKENS, W. STALMANS, AND M. BOLLEN. Properties and phosphorylation sites of baculovirus-expressed nuclear inhibitor of protein phosphatase-1 (NIPP1). J. Biol. Chem. 272: 32972–32978, 1997. VYKLICKY, L., JR. Calcium-mediated modulation of N-methyl-Daspartate (NMDA) responses in cultured rat hippocampal neurones. J. Physiol. (Lond.). 470: 575– 600, 1993. WALTER, G., F. FERRE, O. ESPIRITU, AND A. CARBONE-WILEY. Molecular cloning and sequence of cDNA encoding polyoma medium tumor antigen-associated 61-kDa protein. Proc. Natl. Acad. Sci. USA 86: 8669 – 8672, 1989. WALSH, H., A. CHENG, AND R. E. HONKANEN. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases type 1 (PP1) and 2A (PP2A) is highly selective for PP2A. FEBS Lett. 416: 230 –234, 1997. WALTON, K. M., AND J. E. DIXON. Protein tyrosine phosphatases. Annu. Rev. Biochem. 62: 101–120, 1993. WANG, F., S. ZELTWANGER, I. C. YANG, A. C. NAIRN, AND T. C. HWANG. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J. Gen. Physiol. 111: 477– 490, 1998. WANG, L. Y., B. A. ORSER, D. L. BRAUTIGAN, AND J. F. MACDONALD.

210

435.

436.

437.

438. 439.

440.

441.

442.

443.

444.

445.

446.

447.

448.

449.

450.

451.

452.

453.

STEFAN HERZIG AND JOACHIM NEUMANN Regulation of NMDA receptors in cultured hippocampal neurons by protein phosphatases 1 and 2A. Nature 369: 230 –232, 1994. WANG, Y., C. TOWNSEND, AND R. L. ROSENBERG. Regulation of cardiac L-type Ca channels in planar lipid bilayers by G proteins and protein phosphorylation. Am. J. Physiol. 264 (Cell Physiol. 33): C1473—C1479, 1993. WARD, S. M., F. VOGALIS, D. P. BLONDFIELD, H. OZAKI, N. FUSETANI, D. UEMURA, N. G. PUBLICOVER, AND K. M. SANDERS. Inhibition of electrical slow waves and Ca21 currents of gastric and colonic smooth muscle by phosphatase inhibitors. Am. J. Physiol. 261 (Cell Physiol. 30): C64 —C70, 1991. WENK, J., H. I. TROMPETER, K. G. PETTRICH, P. T. COHEN, D. G. CAMPBELL, AND G. MIESKES. Molecular cloning and primary structure of a protein phosphatase 2C isoform. FEBS Lett. 297: 135–138, 1992. WERA, S., AND B. A. HEMMINGS. Serine/threonine protein phosphatases. Biochem. J. 311: 17–29, 1995. WERTH, D. K., J. R. HAEBERLE, AND D. R. HATHAWAY. Purification of a myosin phosphatase from bovine aortic smooth muscle. J. Biol. Chem. 257: 7306 –7309, 1982. WERZ, M. A., K. S. ELMSLIE, AND S. W. JONES. Phosphorylation enhances inactivation of N-type calcium channel current in bullfrog sympathetic neurons. Pflu¨gers Arch. 424: 538 –545, 1993. WHITE, R. E., A. B. LEE, A. D. SHCHERBATKO, T. M. LINCOLN, A. SCHONBRUNN, AND D. L. ARMSTRONG. Potassium channel stimulation by natriuretic peptides through cGMP-dependent dephosphorylation. Nature 361: 263–266, 1993. WHITE, R. E., A. SCHONBRUNN, AND D. L. ARMSTRONG. Somatostatin stimulates Ca21-activated K1 channels through protein dephosphorylation. Nature 351: 570 –573, 1991. WIECHEN, K., D. T. YUE, AND S. HERZIG. Two distinct functional effects of protein phosphatase inhibitors on guinea-pig cardiac L-type Ca21 channels. J. Physiol. (Lond.) 484: 583–592, 1995. WILLIAMS, K. R., H. C. HEMMINGS, M. B. LOPRESTI, W. H. KONIGSBERG, AND P. GREENGARD. DARPP-32 a dopamine- and cyclic AMP regulated neuronal phosphoprotein. Primary structure and homology with protein phosphatase inhibitor 1. J. Biol. Chem. 261: 1890 –1903, 1986. WILSON, G. F., N. S. MAGOSKI, AND L. K. KACZMAREK. Modulation of a calcium-sensitive nonspecific cation channel by closely associated protein kinase and phosphatase activities. Proc. Natl. Acad. Sci. USA 95: 10938 –10943, 1998. WYLLIE, D. J., AND R. A. NICOLL. A role for protein kinases and phosphatases in the Ca21-induced enhancement of hippocampal AMPA receptor-mediated synaptic responses. Neuron 13: 635– 643, 1995. XIAO, M. Y., M. KARPEFORS, B. GUSTAFSSON, AND H. WIGSTROM. On the linkage between AMPA and NMDA receptor-mediated EPSPs in homosynaptic long-term depression in the hippocampal CA1 region of young rats. J. Neurosci. 15: 4496 – 4506, 1995. XIAO, Y. F., AND J. J. MCARDLE. Activation of protein kinase A partially reverses the effects of 2,3-butanedione monoxime on the transient outward K1 current of rat ventricular myocytes. Life Sci. 57: 335–343, 1995. XIE, H., AND S. CLARKE. An enzymatic activity in bovine brain that catalyzes the reversal of the C-terminal methyl esterification of protein phosphatase 2A. Biochem. Biophys. Res. Commun. 203: 1710 –1715, 1994. XIE, W., K. R. H. SOLOMONS, S. FREEMAN, M. A. KAETZEL, K. S. BRUZIK, D. J. NELSON, AND S. B. SHEARS. Regulation of Ca21dependent Cl2 conductance in a human colonic epithelial cell line (T84): cross-talk between Ins(3,4,5,6)P4 and protein phosphatases. J. Physiol. (Lond.) 510: 66 – 673, 1998. YAKEL, J. L. Inactivation of the Ba21 current in dissociated Helix neurons: voltage dependence and the role of phosphorylation. Pflu¨gers Arch. 420: 470 – 478, 1992. YANG, I. C., T. H. CHENG, F. WANG, E. M. PRICE, AND T. C. HWANG. Modulation of CFTR chloride channels by calyculin A and genistein. Am. J. Physiol. 272 (Cell Physiol. 41): C142—C155, 1997. YANG, S., R. L. LICKTEIG, R. C. ESTES, K. RUNDELL, G. WALTER,

M. C. MUMBY. Control of protein phosphatase 2A by simian virus 40 small t antigen. Mol. Cell. Biol. 64: 1988 –1995, 1991. YATSUNAMI, J., A. KOMORI, T. OHTA, M. SUGANUMA, S. H. YUSPA, AND H. FUJIKI. Hyperphosphorylation of cytokeratins by okadaic acid class tumor promoters in primary human keratinocytes. Cancer Res. 53: 992–996, 1993. YU, H., F. CHANG, AND I. S. COHEN. Pacemaker current if in adult canine cardiac ventricular myocytes. J. Physiol. (Lond.) 485: 469 – 483, 1995. ZHANG, J., Z. ZHANG, K. BREW, AND E. Y. C. LEE. Mutational analysis of the catalytic subunit of muscle protein phosphatase-1. Biochemistry 35: 6276 – 6282, 1996. ZHANG, L., A. D. BONEV, G. M. MAWE, AND M. T. NELSON. Protein kinase A mediates activation of ATP-sensitive K1 currents by CGRP in gallbladder smooth muscle. Am. J. Physiol. 267 (Gastrointest. Liver Physiol. 30): G494 —G499, 1994. ZHANG, L., Z. ZHANG, F. LONG, AND E. Y. C. LEE. Tyrosine-272 is involved in the inhibition of protein phosphatase-1 by multiple toxins. Biochemistry 35: 1606 –1611, 1996. ZHANG, W., R. C. KOWAL, F. RUSNAK, R. A. SIKKING, E. N. OLSON, AND R. G. VICTOR. Failure of calcineurin inhibitors to prevent pressure-overload hypertrophy in rats. Circ. Res. 84: 722– 728, 1999. ZHANG, Z., S. ZHAO, F. LONG, L. ZHANG, G. BAI, H. SHIMA, M. NAGAO, AND E. Y. C. LEE. A mutant of protein phosphatase-1 that exhibits altered toxin sensitivity. J. Biol. Chem. 269: 16997–17000, 1994. ZHAO, X. L., L. M. GUTIERREZ, C. F. CHANG, AND M. M. HOSEY. The a1-subunit of skeletal muscle L-type Ca channels is the key target for regulation by A-kinase and protein phosphatase-1C. Biochem. Biophys. Res. Commun. 198: 166 –173, 1994. ZHOU, S. S., A. TAKAI, M. TOMINAGA, AND Y. OKADA. Phosphatase-mediated enhancement of cardiac cAMP-activated Cl2 conductance by a Cl2 channel blocker, anthracene-9-carboxylate. Circ. Res. 81: 219 –228, 1997. ZHOU, X. B., P. RUTH, J. SCHLOSSMANN, F. HOFMANN, AND M. KORTH. Protein phosphatase 2A is essential for the activation of Ca21-activated K1 currents by cGMP-dependent protein kinase in tracheal smooth muscle and Chinese hamster ovary cells. J. Biol. Chem. 271: 19760 –19767, 1996. ZHOU, X. B., J. SCHLOSSMANN, F. HOFMANN, P. RUTH, AND M. KORTH. Regulation of stably expressed and native BK channels from human myometrium by cGMP- and cAMP-dependent protein kinase. Pflu¨gers Arch. 436: 725–734, 1998. ZHU, Y., AND S. R. IKEDA. 2,3-Butanedione monoxime blockade of Ca21 currents in adult rat symphathetic neurons does not involve “chemical phosphatase” activity. Neurosci. Lett. 155: 24 –28, 1993. ZHU, Y., AND S. R. IKEDA. Modulation of Ca21-channel currents by protein kinase C in adult rat sympathetic neurons. J. Neurophysiol. 72: 1549 –1560, 1994. ZHU, Y., AND J. L. YAKEL. Calcineurin modulates G protein-mediated inhibition of N-type calcium channels in rat sympathetic neurons. J. Neurophysiol. 78: 1161–1165, 1997. ZIMMERMANN, N., P. BOKNIK, E. GAMS, S. GSELL, L. R. JONES, R. MAAS, J. NEUMANN, AND H. SCHOLZ. Mechanism of the contractile effects of 2,3-butanedione-monoxime in the mammalian heart. Naunyn-Schmiedeberg’s Arch. Pharmacol. 354: 431–436, 1996. ZOLNIEROWICS, S., C. CSORTOS, J. BONDOR, A. VERIN, M. C. MUMBY, AND A. A. DEPAOLI-ROACH. Diversity in the regulatory B-subunits of protein phosphatase 2A: identification of a novel isoform highly expressed in brain. Biochemistry 33: 11858–11867, 1994. ZONG, X., J. SCHREIECK, G. MEHRKE, A. WELLING, A. SCHUSTER, E. BOSSE, V. FLOCKERZI, AND F. HOFMANN. On the regulation of the expressed L-type calcium channel by cAMP-dependent phosphorylation. Pflu¨gers Arch. 430: 340 –347, 1995. ZWILLER, J., E. M. OGASAWARA, S. S. NAKAMOTO, AND A. L. BOYNTON. Stimulation by inositol trisphosphate and tetrakisphosphate of a protein phosphatase. Biochem. Biophys. Res. Commun. 155: 767–772, 1988. AND

454.

455.

456.

457.

458.

459.

460.

461.

462.

463.

464.

465.

466.

467.

468.

469.

470.

471.

Volume 80